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Abstract
Drug-induced hepatotoxicity is a major cause of failure of drug candidates during
development and of drug withdrawal post-marketing. Exposure of individuals to
many different classes of drugs, including several anti-cancer agents, can result in
liver toxicity. In oncology, the aim of treatment with cytotoxic drugs is to selectively
target and kill all cancerous cells, whilst leaving the healthy tissue unharmed. In
practice, anti-cancer drugs induce cytotoxic effects in all proliferating cells and, to a
certain extent, non-dividing cells. For some anti-cancer drugs this manifests as liver-
related dose-limiting toxicity. If this occurs in early phase clinical trials, it may stop
clinical development of that drug. Unfortunately, current pre-clinical models poorly
predict a potentially hepatotoxic anti-cancer agent.
Therefore, the aim of the studies included in this thesis is to evaluate in vitro models
in which anti-cancer drug-induced hepatotoxicity may be detected, to decrease the
likelihood of hepatotoxic anticancer agents entering clinical development. In vitro
models that represent hepatocytes, the major cell type in the liver, were selected, and
were all of human origin. Murine models were not considered as there are
significant inter-species differences that may impact on drug metabolism and
therefore on drug-induced liver toxicity. The selected models comprised fresh and
cryopreserved hepatocytes (from 24 and 3 individuals respectively), an immortalised
hepatocyte cell line (THLE-2) and hepatoma cell lines (Flep 3B2.1-7, Hep G2, Huh-
7D12, PLC/PRF/5, and SK-HEP-1). These cells were characterised, and then
assessed in terms of their sensitivity to a known hepatotoxic drug (mithramycin),
drugs used in clinical practice in colorectal cancer (oxaliplatin, 5-FU) and novel
agents in preclinical development (ruthenium compounds).
In order to characterise the cell models, morphology, growth parameters, and
viability were considered. Fresh and cryopreserved hepatocytes did not proliferate in
culture, whereas the cell lines had doubling times ranging from 33 to 54 hours.
Hepatocyte viability varied between donors at isolation and after transport. The
impact of transporting fresh hepatocytes in different cold-storage media, and the
duration between isolation and plating, on hepatocyte viability was investigated.
IV
Gene expression was also studied by quantitative reverse-transcription polymerase
chain reaction (qRT-PCR). The genes evaluated were involved in drug transport
(ABCB1), drug metabolism (CYP450s, UGTs), or were liver specific genes
(albumin, transthyretin, a-1-antitrypsin). mRNA expression of all liver-specific
genes except CYP1A1 was higher in fresh hepatocytes than in any of the other
models investigated. None of the in vitro models mimic the gene expression profile
of hepatocytes but the hepatoma cell lines express some liver-specific genes. Stress-
induced genes (p21, heat-shock protein 70 and hypoxia-inducible factor-la) were
evaluated to identify the impact of hepatocyte plating on stress gene expression.
mRNA expression of all stress-induced genes increased following plating in the
majority of donors. The impact on gene expression of the duration of transport, the
transport media, and plating, was assessed to improve the use of fresh human cells in
hepatotoxicity assessment.
To identify the most appropriate in vitro model on the basis of the identification of
hepatocyte-toxic drugs, cytotoxicity assays were carried out following exposure of
each of the cell models to increasing concentrations of the selected drugs. DNA
damaging agents induce cytotoxic effects; therefore cell death was considered as the
endpoint for evaluating drug-induced hepatotoxicity. The sulforhodamine B and
MTT cytotoxicity assays were carried out, followed by determination of IC50 values
from the data obtained. Instead of aiming for an absence of toxicity, it is more
interesting to determine the difference between an active concentration killing
tumour cells and achievable in the clinic, and a toxic concentration, killing
hepatocytes. This "in vitro therapeutic index" may be able to discriminate which
drug is likely to induce significant liver toxicity, at predicted therapeutic doses.
Colon cancer lines were used to determine the active concentrations for mithramycin,
oxaliplatin and 5-FU. The effect of these drugs was then determined in the
hepatocyte models. The "in vitro therapeutic index" was able to discriminate
between known hepatotoxin mithramycin. and oxaliplatin and 5-FU which both had
a higher therapeutic index in fresh hepatocytes. Flepatoma cell lines gave lower
therapeutic indices but the ranking of the compounds was similar as with the fresh
hepatocytes. Finally, using this approach, the hepatotoxicity of two ruthenium
compounds in pre-clinical development (RM175 & HC11) was identified, using
fresh hepatocytes and hepatoma cell lines.
A subset of in vitro models (fresh and cryopreserved hepatocytes, Hep3B2.1-7,
HepG2, Huh-7D12 and PLC/PRF/5), which appeared to be the most promising based
on gene expression and cytotoxicity data, were then selected to study the contribution
of oncosis and/or apoptosis to cytotoxicity, and to see whether a hepatotoxic drug
could be detected earlier during drug exposure. Assays to measure ATP levels and
capsase-3/7 activation in drug-treated cells were optimised and used for
mithramycin-, oxaliplatin- and 5-FU-treated cells. ATP levels and caspase-3/7
activation varied between cell lines and hepatocytes in response to all three drugs
investigated, and was detectable immediately following drug treatment.
These data suggest that fresh hepatocytes are a suitable in vitro model in which to
accurately identify hepatotoxicity associated with anti-cancer drugs. They express
liver-specific genes, and are more sensitive to the hepatotoxic drug mithramycin,
than to oxaliplatin and 5-FU. A cytotoxicity assay using hepatoma cell lines
(Hep3B2.1-7 and Huh-7D12) could also be used, despite their low expression of
liver-related genes. These results should help select the most appropriate in vitro
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The liver is the largest organ in the body, and it performs a wide range of
physiologically essential functions. In order to understand the significance of
damage to the liver, it is first necessary to consider the unique structure and functions
of this organ. Common tests that are used to assess liver function and/or detect liver
damage will also be considered.
1.1.1 Structure of the liver
Anatomically, the liver is divided into four lobes that are visible macroscopically: the
left-, right-, quadrate- and caudate- lobes. The liver is functionally divided into eight
segments based on the distribution of the portal and hepatic veins: each segment
receives a branch of the portal vein and is an independent functional unit. At a
microscopic level, the liver consists ofmany individual functional units, traditionally
called lobules. Each lobule is bounded by four to five portal triads (supplied from
the portal vein and hepatic artery) and has a central terminal hepatic venule (central
vein) (Thomson and Shaffer, 2000). It is also possible to consider liver structure in
terms of multiple acini, and this is considered to be a more physiologically sound
concept than that of the liver lobule (Thomson and Shaffer, 2000). At the centre of
the acinus is the portal triad (branches of the hepatic portal vein, hepatic artery and
bile duct bound together), and the terminal hepatic venules are at the periphery. The
acinus is divided into 3 zones based upon the distance from the blood vessels.
The acini are comprised of several cell types that include hepatocytes,
cholangiocytes, Kupffer cells, stellate cells and Pit cells. Hepatocytes are arranged in
interconnected sheets and cords that are one or two cells thick (see figure 1.1), with
blood-filled spaces called sinusoids running between them (Thomson and Shaffer,
2000). Hepatocytes are in contact with the sinusoidal blood as it passes from the
portal tracts to enter the terminal hepatic venules (Farrell. 1994). They are separated
from the bloodstream by a single layer of sinusoidal endothelial cells with
interspersed Kupffer cells (the liver's resident macrophages), stellate (fat-storing or
Ito) cells and Pit cells (Thomson and Shaffer, 2000). The sinusoidal lining is
fenestrated, allowing the exchange of molecules and small particles between
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hepatocytes and the blood stream. The Kupffer cells form part of the
reticuloendothelial system and phagocytose particulate matter in circulating blood
(particularly spent erythrocytes), endotoxins and other noxious substances (Thomson
and Shaffer, 2000). Stellate cells store vitamin A and produce extracellular matrix
proteins such as collagens; they are also distributed among the sinusoidal endothelial
cells like the Kupffer cells (Thomson and Shaffer, 2000). Pit cells are large, granular
lymphocytes, which function as natural killer cells. The extracellular matrix of the
liver includes its reticulin framework and several molecular forms of collagen,
laminin, fibronectin and other extracellular glycoproteins.
Figure 1.1: Schematic representation of the fine structure of the human liver
(Source: Alberts et al, 2002: Adaptation of figure 22-21)
Unlike most organs, which have a single blood supply, the liver receives blood from
two sources. Oxygenated blood comes from the hepatic artery (25%), and oxygen-
depleted blood comes from the intestinal tract via the hepatic portal vein (75%)
(Thomson and Shaffer, 2000). Small branches of each blood vessel (the terminal
portal venule and the terminal hepatic arteriole) enter the acinus at the portal triad
(zone 1). Blood from the portal venules and hepatic arterioles then mixes and flows
through the hepatic sinusoids between plates of hepatocytes (see figure 1.1), towards
the terminal hepatic venule (zone 3) where blood from several acini merges (Farrell,
1994). This double vascularisation allows the absorption of substances from the
fenestrated
endothelial cell




blood by sinusoids. The terminal hepatic venules then merge to form the hepatic
vein, which carries the efferent blood to the inferior vena cava.
The hepatocytes also form a system of bile canaliculi into which they secrete waste
products of their metabolism and bile, which is ultimately discharged into the gut via
bile ducts (Thomson and Shaffer, 2000). The canaliculi are formed by grooves on
the contact surface of adjacent hepatocytes. The biliary system forms another
important feature of the liver. Secretion of bile salts, other organic anions and
electrolytes occurs through the canalicular region of the plasma membrane of
hepatocytes (see figure 1.1). Bile passes out of the canaliculi and into the bile
ductules, which are composed of bile duct epithelial cells (cholangiocytes). Bile
ductules pass to the portal and interlobular bile ducts, which then drain into the large
intra-hepatic bile ducts, which eventually leave the liver via the porta hepatis
(Thomson and Shaffer, 2000). There they unite to form the common hepatic duct.
The cystic duct connects the gall bladder to the common hepatic duct, below which
point the common bile duct descends to enter the duodenum (Farrell, 1994).
1.1.1.1 Hepatocytes
Hepatocytes are the predominant cell type in the liver and represent 60-80% of the
number of cells, occupying approximately 80% of the liver volume (Bayliss & Skett,
1996). There are approximately 2.6 x 1011 hepatocytes in the normal adult liver
(Yamashita et al, 2000), which are arranged in plates that radiate out from each
portal triad toward adjacent central veins.
Hepatocytes are polarised cells which possess well defined basolateral (sinusoidal)
and apical (canalicular) plasma membrane domains (Simons and Fuller, 1985).
Membrane proteins are first transported to the basolateral surface and if necessary
migrate to the apical side (Wessels et al, 1989). This is important since during in
vitro culture basal proteins relocate to the apical side.
The nuclei in hepatocytes are round with dispersed chromatin and prominent
nucleoli. The nuclei of hepatocytes vary in size more so than in many other cell
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types, and reflects polyploidy. Over fifty percent of hepatocytes have a polyploid
nucleus (Alberts et al., 2002). Binucleate cells are also common. Hepatocytes
contain many mitochondria, and large amounts of rough endoplasmic reticulum and
free ribosomes.
The liver is normally quiescent, and hepatocytes normally live for a year or more and
are renewed at a slow rate (Alberts et al., 2002). Another capability of the liver,
which is not common among other organs, is its ability to regenerate under specific
conditions. After partial hepatectomy, infection, or exposure to chemical toxicants
(alcohol, certain drugs), the liver has the capability to regenerate, whereby
hepatocyte proliferation occurs. Problems may arise when regeneration of
hepatocytes lost by apoptotic or oncotic cell death mask the detection of liver injury
(Jaeschke et al, 2002). The liver is capable of rapidly increasing or decreasing its
size by cell proliferation or cell death, when the need arises.
1.1.1.2 Cholangiocytes
Cholangiocytes are the epithelial cells that line the bile duct. They participate in bile
formation and secretion, and are actively involved in the absorption and secretion of
water, chloride, bile acids and glucose (Tietz and LaRusso, 2002). One enzyme that
is present in cholangiocytes, and is used as a marker of liver function is gamma
glautamyl transpeptidase (GGT). GGT activity in hepatocytes is prominent in fetal
liver but disappears after birth. In cholangiocytes, GGT is involved in the synthesis
of glutathione, playing a crucial role in maintaining both glutathione and cysteine
levels: GGT breaks down glutathione to generate gamma-glutamyl compounds and
cysteinylglycine, which is further cleaved by membrane-bound dipeptidases. The
constituent amino acids are then taken up and used by cells for intracellular
resynthesis of glutathione (Zhang et al, 2005).
1.1.1.3 Kupffer Cells
Kupffer cells are the macrophages of the liver, and form part of the
reticuloendothelial system. Their primary function is to recycle old red blood cells
that are no longer functional. However, they can also be involved in the liver's acute
or chronic response to toxic compounds. Kupffer cells are able to transverse the
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sinusoidal barrier and enter the space of Disse, facilitating their signalling function.
Central to this signalling role is the ability of Kupffer cells to respond to local
changes by the release of cytokines and other signalling molecules such as reactive
oxygen species. Kupffer cell activation results in the release of an array of
inflammatory mediators, growth factors and reactive oxygen species (Roberts et al,
2007). This activation appears to modulate acute hepatocyte injury as well as
chronic liver responses. KC can be seen as the first responder to toxicants that release
inflammatory mediators inducing subsequent hepatic damage. However, in some
cases, cytokines released from KC appear to protect the liver from further damage.
KC act also as antigen presenting cells and play in this respect an essential role in
idiosyncratic liver toxicity (Uetrecht, 2007). Therefore Kupffer cells can act as
either protector or as a mediator of damage, depending on the toxic agent.
1.1.2 Functions of the liver
The liver performs several functions, for which its intricate structure and variety of
cell types is necessary. However, the majority of the functions of the liver are
carried out by hepatocytes. The principal functions of the liver fall into two
categories: functions of synthesis (proteins, carbohydrates, cholesterol, bile, lipids,
urea); and functions of metabolism and excretion of endogenous and exogenous
compounds (either via the biliary system or back into the blood stream).
Hepatocytes are dependant on ATP for many functions, including ureagenesis,
gluconeogenesis and fatty acid metabolism among multiple other metabolic
processes (Jaeschke et al, 2002).
1.1.2.1 Protein Synthesis
One of the main roles of hepatocytes is the synthesis and secretion of the majority of
proteins that circulate in the plasma: albumin, and most of the globulins other than
gamma globulins. Globulins include the clotting factors: fibrinogen, prothrombin
(factor II), and factors V, VII, IX and X. They also produce several structural
proteins and enzymes. As one of the functions of the liver is to synthesise albumin, a
change in the synthetic functions of the liver can alter the disposition of drugs that
are tightly bound to albumin (DeLeve, 2003). Albumin and clotting factors can be
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used as markers of liver injury. However, the half-life of albumin is approximately
20 days and its detection is more useful in chronic rather than acute liver disease.
Because of its abundance, a decrease in albumin levels corresponds to a reduction in
liver capacity.
1.1.2.2 Carbohydrate and Lipid Metabolism
The liver also plays a central role in energy status as the major store of glycogen and
as the site of gluconeogenesis (forming glucose from non-carbohydrate sources such
as amino acids) (Bayliss & Skett, 1996). The liver forms fatty acids from
carbohydrates and synthesises triglycerides from fatty acids and glycerol. The liver
packages triglycerides with cholesterol, phospholipids and an apoprotein into a
lipoprotein. The lipoprotein enters blood for utilisation or storage in adipocytes.
Most cholesterol synthesis also takes place in the liver, and bile salts are the major
product of cholesterol catabolism. The liver is the sole site of bile salt formation.
A large number of enzymes are involved various pathways of metabolism in the
liver, but two are often used to assess liver function or liver damage: Alanine
aminotransferase (ALT) and aspartate aminotransferase (AST). AST is present in
various tissues while ALT is predominantly expressed in liver and kidneys.
1.1.2.3 Drug Metabolism and Transport
Xenobiotic metabolism and transport (uptake and excretion) is an important function
of the liver. Several steps are involved in drug handling by the liver: uptake from the
blood by diffusion or by carrier-mediated transport at the sinusoidal pole of the
hepatocyte, metabolism by phase I and phase II reactions within the hepatocyte;
active transport across the canalicular pole into bile; and excretion via the bile into
the intestine (DeLeve, 2003). Examples of drug metabolising enzymes involved in
anti-cancer drug metabolism are provided in table 1.1. The liver is the principal
organ involved in drug metabolism; other sites of drug metabolism include epithelial
cells of the gastrointestinal tract, lungs, kidneys and the skin. The metabolic
functions of the liver are performed by the hepatocytes and therefore transport of
drugs and their metabolites into and out of hepatocytes is also important.
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Drugs administered orally which are then absorbed from the stomach and the
intestine must pass through the liver before being transported throughout the body
(and to its target) by the circulation. These compounds are subjected to 'first pass'
metabolism in the liver (and the small intestine where some CYP enzymes are
present). A drug that escapes first pass metabolism maintains its biological activity,
and other routes of administration that avoid first-pass metabolism include
intravenous and intramuscular.
It should be noted that while drug metabolism is required to efficiently eliminate
these compounds from the body, certain chemicals are metabolically activated to
reactive derivatives that cause cell toxicity and cancer. Among these, the CYP450s
that metabolically activate toxicants and carcinogens are limited to a few forms
including CYP1A1, CYP1A2, CYP1B1, CYP2A6, and CYP2E1. CYP1A1 and
CYP IB 1 metabolically activate polycyclic aromatic hydrocarbons such as
benzo[a]pyrene. CYP1A2 carries out the N-oxidation of arylamines and heterocyclic
amine food mutagens and CYP2E1 metabolises numerous low-molecular-weight
toxicants and suspected carcinogenic agents (Gonzalez, 2005).
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Table 1.1: Drug metabolising enzymes and examples of their anti-cancer





CYP1A1 Dacarbazine, docetaxel, erlotinib, tamoxifen
CYP1A2 Dacarbazine, erlotinib, etoposide, flutamide,
imatinib, tamoxifen
CYP2A6 Cyclophosphamide, ifosfamide, letrozole, tegafur
CYP2B6 Cyclophosphamide ifosfamide, tamoxifen
CYP2C8 Cyclophosphamide, docetaxel, ifosfamide,
paclitaxel, tegafur, tretinoin
CYP2C9 Cyclophosphamide, ifosfamide, imatinib,
tamoxifen, tegafur, tretinoin
Phase 1 CYP2C19 Cyclophosphamide, ifosfamide, imatinib,
tamoxifen, thalidomide
CYP2D6 Imatinib, tamoxifen, vinorelbine




cytarabine, docetaxel, doxorubicin, erlotonib,
etoposide, flutamide, fulvestrant, gefitinib,
ifosfamide, imatinib, irinotecan, letrozole,
mitoxantrone, paclitaxel, tamoxifen, teniposide,
topotecan, tretinoin, vinblastine, vincristine,
vindesine, vinorelbine
Phase II
UGT* Doxorubicin, epirubicin, etoposide, irinotecan,
topotecan, tamoxifen
SULT* Tamoxifen
GST* Busulfan, chlorambucil, cyclophosphamide,
doxorubicin, ifosfamide, melphalan, nitrosurea
1.1.2.3.1 Phase I Reactions
Phase I drug metabolism includes oxidation, reduction, hydrolysis and hydration
reactions (Gibson and Skett, 2001). In most cases, the final product of these
reactions contains a chemically reactive functional group and is prepared for phase II
(conjugation) reactions. If the metabolites of phase I reactions are sufficiently polar,
they may be readily excreted following phase I metabolism. Phase I enzymes
include Cytochrome P450s, flavin-containing mono-oxygenases, and epoxide
hydrolases. Oxidation reactions performed by the microsomal mixed-function
oxidase system (cytochrome P450-dependent) are arguably the most studied family
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of drug metabolising enzymes, and this enzyme system carries out a wide diversity
of reactions and has a wide variety of substrates.
The most widely studied drug-metabolising enzymes are the cytochrome P450-
dependent mixed-function oxidases. Cloning and sequencing of CYP450 cDNAs
and. more recently, total genome sequencing have revealed the existence of 57
putatively functional genes and 58 pseudogenes in humans (Nelson, 2006). These
genes are grouped, based on amino acid sequence similarity, into a large number of
families and are found embedded in the membrane of the endoplasmic reticulum.
CYP P450s are principally expressed in hepatocytes. However, some P450s are also
expressed at lower levels in gut. lung, kidney and haematopoietic tissue (Gonzalez,
2005). CYP450s are complex and diverse in their regulation and catalytic activities.
1.1.2.3.1.1 Cytochrome P450s activity
A limited number of CYP450s (15 in humans) are primarily involved in xenobiotic
metabolism: CYP450 families 1 to 3. Oxidation reactions involve the addition of
oxygen or removal of a hydrogen, catalysed by mixed function oxidases and mono-
oxygenases in the liver. These oxidative reactions typically involve a CYP450
haemoprotein, NADPH and oxygen. CYP450 can also catalyse reduction and
peroxidation reactions.
The central features of the cytochrome P450 catalytic cycle are the ability of the
haem iron to undergo cyclic oxidation/reduction in conjunction with substrate (drug)
binding and oxygen activation, as shown in figure 1.2. Step 1 involves drug binding
to the oxidised (ferric Fe3+) form of CYP450. Step 2 involves the first electron
reduction of substrate-bound ferric CYP450 to the ferrous (Fe2+) form of the
haemoprotein, and requires NADPH H+ and NADPH-CYP450 reductase. Step 3
involves binding of molecular oxygen to the binary ferrous CYP450-substrate
complex. Steps 4, 5, and 6 involve putative electron rearrangement, introduction of
the second and subsequent oxygen insertion into the drug substrate and hydoxylated
metabolite release. Step 5 involves NADPH CYP450 reductase or cytochrome bs
and its associated flavoprotein reductase.
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CYP3A4 is the most abundant P450 in the liver and plays a role in the metabolism of
approximately half of all the drugs on the market and in development. CYP3A4
exhibits considerable inter-individual variation in expression in the human
population by one to two orders of magnitude (Gibson and Skett, 2001). The
CYP3A family metabolises many drugs, and several anticancer agents including
docetaxel, etoposide, gefitinib, imatinib, irinotecan, tamoxifen, vinblastine and
















Figure 1.2: Catalytic cycle of Cytochrome P450
RH represents the drug substrate and ROH the corresponding hydroxylated
metabolite.
1.1.2.3.1.2 Cytochrome P450 Regulation
The metabolism of drugs is substantially influenced by the passive or deliberate
intake of many chemical substances. Exposure to these substances may be either in
the environment, for medical reasons or as a result of lifestyle. These chemical
substances come from a variety of sources including pharmaceutical products,
cosmetics, food additives and industrial chemicals.
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The duration and intensity of the pharmacological action ofmany drugs is influenced
by their rate of metabolism. Therefore inducers and inhibitors of drug metabolism
play a key role in the pharmacological effect of many drugs, as they can alter the
expression and activity of many drug metabolising enzymes. Inducers of drug
metabolism have the potential to decrease the duration and intensity of drug action,
whereas the opposite is true for inhibitors. Consideration is given here to the
CYP450 families of enzymes, however these principles of gene induction and
inhibition hold true for several of the other drug metabolising enzymes. Many drugs
are known to induce either their own metabolism or the biotransformation of other
drugs. The induction of specific liver enzymes, particularly the CYP450s, plays a
role and has implications in clinical pharmacology and toxicology. One example of
this is the antibiotic rifampicin, which is a CYP3A4 inducer. Rifampicin-induction
of CYP3A4 can cause increased clearance of co-administered drugs such as warfarin,
and verapamil.
The mechanisms underlying induction of drug metabolising enzymes, and
particularly that of the CYP450s have been extensively studied. Induction of drug
metabolism may arise as a consequence of increased synthesis, decreased
degradation, activation of pre-existing components or a combination of the three.
However, the majority of CYP450s are transcriptionally regulated, and induction
involves ligand-dependent nuclear receptors (NR) (Nakata et al, 2006).
The mechanism of induction of many of the CYP450s that are involved in drug
metabolism has been investigated and include CYP1A1, and CYP2B*, CYP3A*.
CYP1A1 is of interest because of its ability to activate environmental compounds,
such as polyaromatic hydrocarbons (PAH), to biologically reactive metabolites that
interact with DNA, resulting in chemical carcinogenesis. CYP1A1 is present in low
amounts in non-induced liver (approximately 2-5% of the total CYP450 content) but
increases approx 8-16 fold upon induction. CYP1Al is induced by a wide variety of
environmental chemicals including PAHs (e.g. benzo[a]pyrene, P-naphthoflavone),
and is associated with a specific cytosolic receptor; the aryl hydrocarbon receptor
(AhR) (Whitlock, 1999). As shown in figure 1.3A, PAHs enter the cell and combine
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with cytosolic AhR. Inducer-free Ahr exists in combination with at least two other
proteins (heat shock protein 90 [Hsp90] and AhR-interacting protein [AIP]), the
function of which is not entirely clear but they are though to maintain the AhR in a
receptive configuration for induced binding. The inducer-receptor complex
translocates to the nucleus where it heterodimerises with the AhR nuclear
translocator protein (Arnt). This complex (probably in conjunction with other
transcription factors) targets several genes in the nucleus including CYP1A1. An
initiation complex forms at the CYP1A1 promoter and increases the rate of mRNA
synthesis. Large amounts of newly translated CYP1A1 protein are then incorporated
into the membrane of the endomplasmic reticulum (along with haem insertion)
resulting in CYP1A1 induction (Whitlock, 1999). The AhR/Arnt system is not
solely dedicated to transcriptional activation of CYP1A1. but is involved in the
activation of several other genes including other xenobiotic metabolising enzymes.
CYP3A4 is the predominantly expressed CYP isoform in the liver, and is critical in
the metabolism of many clinically used drugs: it is estimated that CYP3A4 is
responsible for approximately 60% of the cytochrome P450-mediated metabolism of
pharmaceuticals in therapeutic use, in addition to metabolising a number of
endogenous compounds (e.g. testosterone) and environmental xenobiotics (e.g.
aflotoxins) (Gibson and Skett, 2000). This isoform is highly inducible in man by
synthetic/natural steroids (e.g. dexamethasone), and drugs such as rifampicin and
phenobarbitone. Regulation of CYP3A* genes (CYP3A4, CYP3A5, CYP3A7) is
complex, mainly due to the number of regulatory elements found in both the distal
enhancer and the proximal promoter. Similar to CYP1A1 induction, cellular
receptors play a critical role in regulation of CYP3A* gene expression, the most
important of which is pregnane X receptor (PXR) (Pascussi et al 2001). Several
cellular receptors are involved in CYP3A* induction (figure 1.3B), and inducers may
show preferential specificity for one receptor or interact with more than one receptor.
PXR is a member of the nuclear receptor family and plays an important role in
CYP3A4 gene regulation for several xenobiotic and endogenous steroid inducers.
PXR possesses a ligand-(inducer)-binding domain and a DNA binding domain.
PXR/RXR heterodimer formation is essential for the activation of CYP3A4 reporter
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gene constructs by xenobiotics and naturally occurring pregnane steroids. In
addition, two further receptors mediate induction of the CYP3As, namely the
glucocorticoid receptor and the constitutive androstane receptor (CAR), the latter
also forming a heterodimer complex with the RXR (Pascussi et al 2001). CAR has
been shown to bind inducers, followed by binding of the inducer-receptor complex to
the corresponding response element in CYP3A* promoters, however the precise role
of the GR is unknown.
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B Xenobiotic or steroid inducer
Figure 1.3: Receptor-dependent CYP induction in hepatocytes
A) CYP1A1 induction: Polyaromatic hydrocarbons (PAHs) act as a CYP1A1-
inducer, binding to Aryl hydrocarbon receptor |AhR] (that was previously bound in
cytosol to Ahr-interacting protein [AIP] and heat shock protein 90 [Hso90]). The
inducer-AhR complex translocates to the nucleus where it heterodimerises with AhR
nuclear translocator (Arnt) and targets the CYP1A1 gene. It binds at the promoter,
increases mRNA synthesis and results in induced CYP1A1. B) CYP3A4 induction:
In the nucleus of hepatocytes, xenobiotics or steroid inducers bind to nuclear
receptors (pregnane X receptor [PXR], retinoid X receptor [RXR], glucocorticoid
receptor [GR], constitutive androstane receptor [CAR] and inducer-receptor
complexes bind response elements in CYP3A4 promoter, increasing mRNA
synthesis and results in induced CYP3A4. (Adapted from Gibson and Skett, 2001)
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These two examples demonstrate CYP450 induction in hepatocytes, however similar
nuclear-receptor mediated induction occurs for several drug-metabolising enzymes
(phase I and phase II) and drug transporters. The different NRs along with their
target genes are shown in table 1.2. Despite the large numbers of ligands that can
interact with each nuclear receptor, the sets of genes activated by these ligands are
very different. With the example of PXR, this is due to a change in conformation
after ligand binding (Poso and Honkakoski, 2006). PXR and CAR have one of the
broadest spectrums of gene regulation as they regulate note only CYPs but also other
proteins such as drug transporters (Timsit and Negishi, 2007).







































Conversely to the induction of drug metabolising enzymes discussed above,
inhibition can also occur. Several cases of inhibition of CYP450 enzymes have been
well defined. Many xenobiotics of diverse chemical structure can act through a
variety of mechanisms to decrease the biotransformation of drugs. The inhibition of
drug metabolism by xenobiotics can take place in several ways, including the
destruction of pre-existing enzymes, inhibition of enzyme synthesis or by binding to
and thus inactivating the drug metabolising enzyme. Inhibition of a particular drug
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metabolising enzyme can occur when there are co-substrates; two (or more) drugs
can compete for the same drug metabolising enzyme and dependent on their relative
affinities and inhibitory potencies can result in inhibition of metabolism of one of the
drugs, which leads to accumulation of one substance, and can induce toxic effects
(drug-drug interaction). One example of this phenomenon is in the inhibition of
CYP3A4 by clotrimazole and saquinavir. Another cause of inhibition of drug
metabolism is destruction of functional CYP450s in the liver. Xenobiotics
containing an olefinic (C=C) or acetylinic (C=C) function are activated by CYP450s,
resulting in metabolites that cause CYP450 haem destruction. Examples of
compounds that undergo suicidal activation by CYP450s include the olefinic
compounds ethylene and vinyl chloride, and the acetylenic compound acetylene.
Metal ions are also capable of inhibiting functional oxidase activity by a variety of
mechanisms (dependant on the metal in question). One example of this is the metal
ion cobalt that exerts its inhibitory effect on drug metabolism by modulating the
synthesis and degradation of the haem prosthetic group of CYP450. In addition to
modulating the synthesis and/or degradation of CYP450s, some xenobiotics can
inhibit drug metabolism by forming inactive complexes with CYP450s. These
compounds are substrates of CYP450 and require metabolism to exert their full
inhibitory effect. Inhibitors forming complexes are metabolised by CYP450,
forming a metabolic product that binds tightly to the haemoprotein that originally
formed it, thus preventing its further participation in drug metabolism. Examples of
drugs which can act in this way include amphetamine, cimetidine, isoniazid and
methadone.
1.1.2.3.2 Phase II Reactions
Many products of phase I drug metabolism are not eliminated rapidly and undergo a
phase II reaction, generally considered to be detoxification reactions. These
reactions involve an endogenous substrate combining with the newly incorporated
functional group on the drug molecule to form a highly polar conjugate. The result is
therefore a water-soluble metabolite that can be excreted in urine or bile. Phase II
reactions are also known as conjugation reactions and enzymes that carry out these
reactions include UDP-glucuronosyltransferases (UGT), sulfotransferases (SULT),
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Glutathione S-transferases (GSTs), and N-acetyltransferases. The phase II reactions
are usually faster than phase I reactions and therefore the rate-limiting step in the
metabolism of a compound is usually the phase I reaction.
Glucuronidation is quantitively the most important of all the conjugation reactions,
and involves conjugation of drugs and endogenous compounds to glucuronic acid.
Many functional groups (hydroxyl, carboxyl, amino, sulfhydryl) present in phase-I
metabolised drug molecules have the potential to be glucuronidated, and certain
drugs can be directly conjugated with glucuronic acid without the need for phase I
metabolism. The enzyme that catalyses the conjugation of drugs with glucuronic
acid is UDP_glucuronosyl transferase (UGT). UGT exists as a family of structurally
related, although catalytically distinct, multiple forms and approximately 16 have
been detected in man (Gibson and Skett, 2001). UGTs 1A1, 1A3, 1A4, 1A6, 2B4,
2B7, 2B10, 2B11 and 2B15 are all expressed in the human liver. The isoforms are
divided into families based on their amino acid sequence similarity, similar to the
CYP450s. The resulting drug-glucuronide conjugate is either excreted in the urine or
faeces and the molecular weight of the conjugate is a critical determinant of the route
of excretion. For example glucuronide conjugates with molecular weight greater
than 400 daltons (i.e. drugs with molecular weight greater than 200 daltons) are
excreted predominantly in the bile primarily, whereas lower molecular weight
conjugates primarily undergo urinary excretion. Therefore high molecular weight
drugs such as morphine and chloramphenicol are excreted in the bile and hence into
the intestine. The intestinal flora contains significant amounts of the enzyme P-
glucuronidase, an enzyme that catalyses the hydrolysis of the glucuronide conjugate,
resulting in the re-formation of free drug (parent compound or phase I metabolite),
which can then be reabsorbed from the intestine, transported to the liver and then
undergoes re-conjugation and re-excretion. This loop is called the entero-hepatic
circulation and may make a contribution to prolonging the half-life of the drug in the
body, potentiating the pharmacological action of the drug, providing that sufficiently
high blood levels of the drug are achieved. This would show in a pharmacokinetic
profile as a return of free metabolite and has been reported for the anti-cancer
topoisomerase inhibitor irinotecan and its metabolite SN-38 (Canal et al, 1996).
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The glutathione-S-transferase (GST) family of enzymes are widely distributed
through the body, particularly in the cytosol of hepatocytes. They catalyse the
conjugation of a variety of compounds with the endogenous tripeptide (Gly-Cys-Glu)
glutathione (glutamylcysteinylglycine, GSH), as follows:
R-CH -X Glutathione-S-transferase ( r-CH -SG2"
GSH " 2"
where R-CH2-X represents hundreds of electrophilic drugs and xenobiotics, and R-
CH2-SG represents the drug-glutathione adduct. Glutathione is recognised as a
protective compound within the body for the removal of potentially toxic
electrophilic compounds. Many drugs are, or are metabolised by phase I metabolism
to, strong electrophiles, and these can generally be conjugated to glutathione to form
(usually) non-toxic conjugates. Glutathione conjugates can be excreted in urine, or
more usually in bile, but more often further metabolism of the conjugates takes place.
Once glutathione is conjugated to the drug, it can be attacked by y-
glutamyltranspeptidase, which removes the glutamate, and a peptidase which
removes the glycine, to yield the cysteine conjugate. N-acetylation of the cysteine
pathway can then occur to yield the N-acetylcysteine conjugate or mercapturic acid.
The glycyl-cysteine and cysteine conjugates and the mercapturic acids are all found
as excretion products depending on the substrate and species under study. Substrates
for GSTs include epoxides, alkanes, alkenes, and aromatic halo- and nitro¬
compounds. In addition to their ability to catalyse the above conjugation reaction
(e.g. paracetamol), GSTs have the ability to bind a variety of endogenous and
exogenous substrates without metabolism (e.g. oestradiol, tetracycline, penicillin).
1.1.2.3.3 Drug uptake and excretion
Membrane transporters are present in several organs throughout the body, and play a
vital role in the liver where they are involved in the uptake and excretion of drugs,
and can influence their safety profile. Membrane transporters play such an important
role in the liver in the disposition of drugs that they are sometimes referred to as
phase III detoxification systems (Nakata et al, 2006). In the liver, membrane
transporters are primarily expressed in hepatocytes and cholangiocytes.
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Lipophilic molecules may move from plasma to hepatic cytosol by simple or
facilitated diffusion (Chandra and Brouwer, 2004). However, numerous transport
proteins are present in the basolateral plasma membrane of hepatocytes to mediate
uptake of amphipathic and polar organic compounds, as well as some lipophilic
molecules, from sinusoidal plasma to hepatic cytosol (Chandra and Brouwer, 2004).
Transport proteins in hepatocytes also play an important role in the excretion of
drugs and metabolites, with uni- or bi-directional basolateral transport systems
transporting polar molecules from hepatic cytosol in to the sinusoidal blood. Active
transport proteins in the canalicular plasma membrane of hepatocytes are responsible
for the biliary excretion of drugs and metabolites.
The sinusoidal, basolateral transport proteins, belong to the gene superfamily of
solute carriers, and mediate the movement of compounds to and from the sinusoidal
blood. They comprise the organic anion transporting polypeptides (OATPs), Na+-
taurochlorate co-transporting polypeptide (NTCP), multi-drug resistance-associated
proteins (MRPs), and organic anion and cation transporters (OATs and OCTs)
(Chandra and Brouwer, 2004). OATPs play an important role in the hepatic
clearance of many drugs, transporting a large variety of organic cations as well as
some cations, and neutral steroids. Within this family OATP1A2, 1B1, 1B3 and 2B1
are the proteins predominantly expressed in the human liver, and these are sodium
independent and bi-directional. The Na+ -taurochlorate co-transporting polypeptide
(NTCP) is a sodium dependent transporter responsible for bile salt uptake. OATs are
organic anion transporters, and OAT2, OAT4 and OAT5 are expressed in the human
liver. The MRPs are ATP-dependent, and belong to the ATP binding cassette (ABC)
family of transporters. They transport organic anions (e.g. drugs conjugated to
glutathione, glucuronate or sulphate) out of hepatocytes (Borst et al, 2000).
Bile is an important route for the elimination of drugs, particularly those that have
been biotransformed by the liver (Farrell, 1994). The biliary excretion of xenobiotics
and metabolites occurs predominantly by unidirectional ATP-dependent export
pumps that transport substrates across the canalicular membrane of hepatocytes into
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bile (Chandra and Brouwer, 2004). These canalicular transport proteins belong to
the ABC superfamily of transporters (Hyde et al. 1990). MDR1 (ABCB1) is the
most extensively studied canalicular transporter and it produces p-glycoprotein. It
primarily transports hydrophobic cations, and typical MDR1 substrates include many
anticancer agents (see table 1.3) and several other xenobiotics (e.g. digoxin,
methadone, cyclosporin A) (Ambudkar et al, 1999). MDR1 expression is highly
regulated by the nuclear receptor PXR (Geick et al, 2001; Nakata et al, 2006). Bile
salt export pump (BSEP) transports bile salts. Although not playing a major role in
drug excretion, if its action is inhibited by a drug (e.g. Bosentan) intracellular bile
salts can accumulate which can lead to hepatotoxicity (Fattinger et al, 2001). MRP2
excretes divalent bile salts, and glutathione- glucuronide- and sulphate- conjugates
into bile (Konig et al, 1999). Breast cancer resistance protein (BCRP) may play an
important role in the biliary excretion of sulphated conjugates of steroids and
xenobiotics, and can confer resistance to anti-cancer compounds such as
mitoxantrone and daunorubicin (Chandra and Brouwer, 2004).
Table 1.3 presents commonly identified anti-cancer drug substrates for the human




Table 1.3: Drug transporters and examples of their anti-cancer drug









paclitaxel, teniposide, vinblastine, vincristine
MRP2
Camptothecin, cisplatin, irinotecan,
doxorubicin, etoposide, methotrexate, SN-
38, vinblastine, vincristine












MRP4 Cyclic nucleotide anologues, methotrexate
MRP5 Doxorubicin, methotrexate, nucleotide
anologues, topotecan
MRP6 Doxorubicin, etoposide, teniposide
MRP8 5-Fluorouracil and its metabolites
1.1.2.3.4 Factors affecting drug metabolism and
excretion
There are several factors that can affect drug metabolism in an individual. These
include: inherent factors such as species and genetic differences, age, sex, hormones
and diseases; and external factors such as dietary and environmental factors, and can
alter the host's drug response. The contribution of these components may differ
between different drugs and may also influence the susceptibility of an individual to
drug-induced hepatotoxicity (Ingelman-Sundberg, 2001).
There are species differences in drug metabolising enzymes and transporters between
humans and rodents. This can cause problems when a drug is tested pre-clinically in
animal models and is then administered to humans. One example is the formation of
toxic metabolites that are produced in humans but not in animals due to lack of
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metabolic pathway. The genes regulated by PXR differ between mouse, rat and
human, making it difficult to predict interactions in humans based on data from
rodents (Hartley et al, 2004).
Genetic variations and polymorphisms between human individuals can also affect
drug metabolism, and accounts for some of the variability in the effect of drugs.
Members of the CYP450s enzyme family are highly polymorphic such as CYP2C19
and CYP2D6, and can influence drug disposition. Historically, drugs were tested in
a relatively small population of patients and following approval of a drug, a much
larger population is exposed to the drug and the effects of rare polymorphisms may
then appear. For example CYP2C19 and CYP2D6 are highly polymorphic, which
can result in 'ultrarapid' and 'poor' metabolisers, and the anti-cancer agents that they
metabolise can be found in table 1.1. For CYP2C19 at least 15 variant alleles have
been discovered of which seven encode no enzyme activity, and for CYP2D6 over
40 variant alleles have been described (van Schaik, 2005). Several CYP3A4 single
nucleotide polymorphisms have been reported, and 18 alleles encoding amino acid
changes are known (van Schaik. 2005). The impact of these polymorphisms on CYP
activity is yet to be established. Phase II enzymes also have genetic polymorphisms
influencing their activity. UGT1A1 is polymorphic which can influence the toxicity
of the irinotecan (Iyer et al, 1998). The MDR1 gene is polymorphic and can impact
in some cases on the disposition of drugs that are MDR1 substrates, and may have
consequences for treatment efficacy (Marzolini et al, 2004).
External influences including dietary and environmental factors also have the
potential to impact on drug metabolism. Dietary factors including protein, fat,
carbohydrate, vitamin and alcohol intake as well as intake of tobacco smoke can
influence drug metabolism. Whilst it is of interest that environmental exposure to
petroleum products, heavy metals, pesticides and industrial pollutants can influence
drug metabolism, little can be done to control these.
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1.1.3 Liver Function Tests
To determine the function of, and damage to, the liver in humans, a series of
biochemical markers may be measured. In a blood sample from the patient, levels of
serum alanine transaminase (ALT), aspartate transaminase (AST), y-glutamyl
transferase (GGT), alkaline phosphatase (ALP), bilirubin, albumin and clotting
factors may be measured. Prothrombin time may also be measured. Despite their
name, liver function tests (LFTs) do not directly determine the function of the liver.
These markers can be spilt into two groups: those that determine function; and those
that indicate toxicity. Serum albumin, bilirubin and prothrombin time are true LFTs
for assessment of hepatic function, whereas enzymes (AST, ALT, ALP and GGT)
are markers allowing detection of liver injury.
There are commonly accepted 'normal' limits for levels of each of these markers in
blood, and the defined normal limits for LFTs can vary depending on factors such as
body mass index, race, age and sex. For example, for the aminotransferases AST
and ALT upper reference limits do not change for individuals aged 25 to 60, however
those aged <25 or >60 will require age-adjusted reference limits when determing
acceptable levels of AST and ALT (Dufour et al, 2000). However a guideline of
normal limits can be seen in table 1.4. Changes in these in the same individual over
a period of time, or levels above the upper reference limits may indicate that the liver
is not functioning as normal. LFTs may be abnormal for a variety of reasons, and
could indicate the presence of many kinds of liver disease or a toxic compound. A
wide variety of mechanisms could result in abnormal LFTs, and include decreased
hepatocyte function, hepatocyte transport defects, cell membrane damage or
disruption of bile flow.
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Table 1.4: Normal values of LFTs
(Source: Limdi and Hyde, 2003). IU= international units







Prothrombin time 10.9-12.5 seconds
Whilst these tests are routinely used, it should be noted that they provide clues as to
the condition of the liver but do not always allow diagnosis of particular liver disease
states. In certain cases there may be a disconnect between enzyme levels and
function of the liver for example in cirrhosis where there is ongoing damage to the
liver but patients will normally have normal or only slightly elevated AST and ALT.
In this case AST and ALT lack sensitivity in detecting a chronic liver disease. Also
worthy of mention is the fact that not all of the LFTs determined will be altered
immediately following liver damage. For example, the half-life of albumin in
plasma is approximately 20 days and therefore serum albumin levels change slowly
in response to alterations in albumin synthesis (Johnston, 1999).
AST is expressed in several tissues throughout the body while ALT is primarily
expressed in the liver and kidney. Changes in ALT levels are therefore more specific
for liver damage that AST, and liver injury generally induces a greater increase in
ALT than AST. The half-life of both AST and ALT are short: 17±5 and 47±10 hours
respectively (Dufour et al, 2000). ALP is a membrane-bound enzyme markedly
expressed at the canalicular pole of hepatocytes and cholangiocytes and is secreted in
bile (Alvaro et al. 2000). It is involved in the transport of metabolites across cell
membranes and is found in several other tissues at higher levels than in the liver.
The half life of the liver isoenzyme is approximately 3 days (Dufour et al, 2000). Its
increase in plasma during liver injury is due to retrograde reflux of biliary ALP,
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enhanced hepatic synthesis and release into the serum, and induction of the intestinal
AP form (Poelstra, 1997). Cholestasis stimulates synthesis of ALP by hepatocytes,
and bile salts facilitate release of ALP from cell membranes into the plasma (Moss,
1997). In patients with cholestatic liver disease it is likely that jaundice may be
present.
GGT is another membrane-bound enzyme that is present in the liver and has a
similar localisation to ALP. GGT activity in serum comes primarily from the liver
and the half-life of GGT is approximately 7 to 10 days (increases up to 28 days in
alcohol-related liver disease) (Dufour et al, 2000). Bilirubin is rapidly conjugated by
UGT and conjugated bilirubin is excreted in the bile, therefore being essentially
absent from the blood. It is rapidly bound to albumin to form 5-bilirubin. Presence
of 5-bilirubin corresponds to jaundice, and its half life is approximately equal to that
of albumin. Total protein and albumin are not very informative during acute liver
injury as they have relatively long half-lives. Similarly, prothrombin time is
relatively insensitive as it does not increase unless each clotting factor is <10% of
normal.
Prior to treatment with anti-cancer cytotoxic drugs, patients require careful
assessment of liver function (King and Perry, 2001). LFTs are routinely performed
prior to the onset of every cycle of chemotherapy. LFTs performed before treatment
begins allow baseline readings for each patient and indication of any pre-existing
liver disease. Furthermore, these tests are routinely performed before every cycle of
chemotherapy and are used to detect hepatotoxicity in patients. Chemotherapeutic
agents commonly cause transient LFT abnormalities with elevations in liver
enzymes, without clinical evidence of liver impairment. Mild or moderate transient
elevations of LFTs without clinical toxicity may often be ignored, depending on the
previous experience with a particular drug. The National Cancer Institute (NCI)
Cancer Therapy Evaluation Program has published criteria specifically for reporting
adverse effects, including adverse hepatic events, caused by anti-cancer agents.
These criteria can be seen in table 1.5 and describe corresponding levels of LFTs
with varying grades of toxicity.
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Table 1.5: Grades of liver test abnormalities
Common Toxicity Criteria, Version 2.0, from NCI Cancer Therapy Evaluation
Program. ULN= upper limit of normal; WNL= within normal limits LLN= lower
limit of normal

















































Acute liver injury may be detected by elevation of ALT and AST usually below 10
times the upper reference limit (ULN) with an associated increase of ALP no more
than 3 times the ULN (Dufour et al, 2000). The extent of enzymes elevation likely to
be predictive of serious hepatotoxicity has been described by Zimmerman and
Temple. Hy Zimmerman's rule is based on his observation that drug-induced
jaundice caused by severe hepatocellular injury, without a significant obstructive
component, has a high rate of bad outcomes, from 10-50% mortality (or transplant)
(Zimmerman, 1999). Temple (2006) of the FDA extended this observation from
describing jaundice (imprecise) to stating that elevated bilirubin must be to levels of
at least 2mg/dl. Therefore the 2 revised requirements for Hy's law are i) evidence
that a drug can cause hepatocellular-type injury, generally shown by a higher rate
than control of people with 3 x and greater transaminase elevations over the ULN,
and ii) cases of increased bilirubin (to at least 2 x ULN) in people with concominant
transaminase elevation to at least 3 x ULN and no evidence of intra- or extra-hepatic
bilirubin obstruction (Temple, 2006).
Prothrombin time (PT) is the most important predictor of prognosis in comparison to
the liver enzyme test; PT cut off times of greater than 4 seconds beyond control or
greater than 20 seconds or an international normalised ratio of >6.5 identify patients
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at high risk of death. After toxic liver injury, PT values peak by 24-36 hrs after
injury and then rapidly return to normal. In paracetamol injury, a persistent increase
in PT 4 days after drug ingestions is indicative of liver failure (Dufour, 2000).
In summary, the LFTs as outlined above are routinely used to provide an indication
of the condition of the liver in patients with liver disease or suspected hepatotoxicity.
Whilst the drawbacks of these tests have been described. LFTs are relied upon in the
treatment of patients throughout the world, and can be performed in conjunction with
other clinical investigations if further investigation is required. Other investigations
include performing other biochemical tests, liver ultrasound scans, computerised
tomography scans (CT), magnetic resonance imaging (MRI) scans, or taking a liver
biopsy.
1.2 HEPATOTOXICITY
There are several causes of hepatotoxicity which include drugs, environmental
chemicals, herbal remedies, and dietary supplements. Drug-induced hepatotoxicity
is seen frequently with significant medical, economic, legal, and regulatory
implications, and represents a major challenge for clinicians, the pharmaceutical
industry and regulatory agencies (Gunawan and Kaplowitz, 2004). Drug-induced
hepatotoxicity is the leading cause of failures in drug development (Kaplowitz, 2005)
and is the most frequent reason reported for the withdrawal of an approved drug from
the market (Lee, 2003). Therefore pre-clinical testing and pre-approval clinical trials
do not always detect the hepatotoxic potential of a drug.
The liver is prone to toxicity because it is the first organ perfused by substances
absorbed through the gastro-intestinal tract and is actively involved in metabolism of
many substances. Several adverse hepatic reactions require metabolism of the
compound to reactive metabolites before toxicity occurs (Park et al, 2005). The liver
also carries out many detoxifying metabolism reactions and therefore damage to the
liver can result in impaired metabolism and accumulation of toxic compounds
(Jaeschke et al, 2002). The manifestations of hepatotoxicity, specific mechanisms by
which drugs can cause toxicity to liver, factors which affect the susceptibility of an
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individual to toxicity, and ways in which hepatotoxicity is screened for during
clinical development, will be considered.
1.2.1 Types of Liver Damage Caused by Drugs
Drug-induced liver injury can present as any of the spectrum of acute and chronic
liver diseases. A brief outline of the most common forms of liver disease is provided
below, and includes hepatitis, steatosis, cirrhosis, cholestasis, and hepatocellular
carcinoma (Ishak and Zimmerman, 1995; Kaplowitz, 2005). Hepatitis is defined as
inflammation of the liver, and is characterised by jaundice, fever, liver enlargement
and abdominal pain (Kaplowitz, 2005). Liver inflammation may result in liver cell
damage and destruction, and presence of inflammatory cells in the liver. Acute
hepatitis may show up in LFTs as a marked increase in aminotransferases, coinciding
with hepatocellular necrosis (Holt and Ju. 2006). Steatosis refers to the accumulation
of fat in the liver, and may be accompanied by inflammation and fibrosis. Cirrhosis
is a type of chronic, progressive liver disease in which healthy liver tissue is
destroyed and results in fibrotic scar tissue. The scar tissue that forms is not able to
function and results in non-functioning scar tissue surrounded by functioning liver
tissue, therefore the number of functional hepatocytes is reduced, and can obstruct
the flow of blood through the portal vein (Gibson and Skett, 2001 pg 140).
Cholestasis may be caused by impairment of bile secretion, an obstruction of bile
flow, or a combination of the two. As a result of the stoppage of bile flow, bilirubin
can enter into the blood and accumulate. Intra-hepatic accumulation of bile acids
and excretion products may also occur promoting further hepatic injury (Jaeschke et
al, 2002). Drug-induced cholestasis can be subdivided into pure 'bland' cholestasis
as described, or 'cholestatic hepatitis' in which liver injury and inflammation cause
significant ALT elevations as well as cholestasis and the type of injury that occurs
depends on the agent in question. Cholestasis is characterised by jaundice along with
an elevation in ALP, conjugated bilirubin, and GGT (Holt and Ju, 2006). Cancer of
the liver may be either primary or secondary as metastases from primary cancer.
Hepatocellular carcinoma (hepatoma) is the most common form of primary liver
cancer, and arises from hepatocytes. Toxicologists have proved extremely efficient
in eliminating drug candidates that are carcinogenic from clinical development and
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consequently drug-induced hepato-carcinogenesis is not common. It should be noted
that these disease states do not always exist in isolation, and the presence of one form
of liver disease may lead to another.
Experimental and clinical observations have reached general agreement that there are
two main categories of substances that cause hepatic injury: agents that are
intrinsically hepatotoxic and cause toxicity to which most exposed individuals are
susceptible; and agents that cause hepatotoxicity only in unusually susceptible
individuals, which is termed idiosyncratic hepatotoxicity (Zimmerman, 1999).
Further consideration will be given to hepatotoxicity caused by pharmaceuticals,
subdivided into dose-dependent or idiosyncratic hepatotoxicity.
1.2.1.1 Dose-dependent
Dose-dependent hepatotoxicity, as its name implies, describes an intrinsic property
of the drug and as dose increases so too does toxicity in a high incidence of patients
(Zimmerman, 1999). Predictable dose-response curves are produced, and there is
usually a short interval between drug exposure and observed toxicity. No drug is
safe at all doses, a concept first invoked by Paracelsus, stating that 'solely the dose
determines that a thing is not a poison' (discussed in Borzelleca, 2000). This concept
is illustrated with paracetamol (acetaminophen), which is safely tolerated in the
majority of people who use it at recommended doses and is still responsible for half
of the cases of liver failure in the US due to overdose (Navarro and Senior, 2006).
Metabolism of paracetamol by cytochrome P450s, and extensive depletion of
glutathione is required before hepatotoxicity occurs. Thereafter, the reactive
metabolite of paracetamol can bind to cellular macromolecules and can eventually
result in lethal damage to hepatocytes.
1.2.1.2 Idiosyncratic
By definition, idiosyncratic drug hepatotoxicity occurs in only a small proportion of
individuals exposed to the drug, and is therefore harder to predict than dose-
dependent (reviewed in Kaplowitz, 2005). Idiosyncratic hepatotoxicity may occur in
between 1 in 1000 and 100000 patients exposed to a drug and whilst rare can be
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severe and often fatal (Lee, 2003). Adverse reactions that involve the known
pharmacological mechanism of the drug (on-target effect) are not considered to be
idiosyncratic (Uetrecht, 2007). Idiosyncratic reactions are not dose-related and can
be further divided into immune-mediated allergic, or non-allergic reactions.
Non-allergic idiosyncratic reactions are characterised by the absence of the features
of hypersensitivity, and there may be a long latency period between drug
administration and indication of hepatotoxicity (e.g. six months). Examples of drugs
causing non-allergic idiosyncratic hepatotoxicity include troglitazone, and valproic
acid.
Characteristics of allergic hepatotoxicity include the presence of rash, fever,
eosinophilia, a relatively short latency (one month or less), the presence of
autoantibodies, and rapid recurrence of hepatotoxicity on re-exposure to the drug
(Gunawan and Kaplowitz 2004). Examples of drugs causing allergic idiosyncratic
hepatotoxicity include diclofenac, halothane, and phenytoin resulting in
hepatocellular injury, and amoxicillin-clavulanic acid and erythromycin causing
cholestatic injury.
There is a deficiency in the availability of approaches to reliably predict idiosyncratic
reactions. Whilst several models are being investigated for the study of idiosyncratic
hepatotoxicity there is no ideal model (Uetrech, 2007) and it is unlikely that a system
will be found that can detect a toxicity occurring at such a low rate in the population.
The low incidence of idiosyncratic hepatotoxic reactions explains why these
reactions are not usually detected during preclinical studies or clinical trials and are
only detected after the drug is approved and hundreds of thousands of patients are
being treated.
1.2.2 Mechanisms of Liver Damage Caused by Drugs
Manifestation of drug-induced liver injury can range from an asymptomatic increase
in liver enzymes to fulminant hepatic failure. The pathological conditions occur
from cellular damage in some way, as a result of drug exposure. Each drug
31
Introduction
associated with hepatotoxicity tends to have characteristic latency, and pattern of
injury, and the mechanism may either be related to the chemical properties of the
parent drug, or be metabolism-dependent (Kaplowitz, 2005). There are several
diverse mechanisms resulting in hepatotoxicity of pharmaceuticals, and an overview
of these and the cell death that can occur as a result of damage to cells will be given.
In general terms, drug reactions can be classified as either hepatocellular, cholestatic,
or mixed (Lee, 1995). Further consideration to hepatocyte damage and cholestasis is
given below. If sinusoidal, endothelial or fat-storing Ito cells are targeted veno-
occlusive disease or fibrosis may occur.
As previously mentioned, the hepatocyte is the most abundant cell type in the liver,
and many hepatotoxic drugs first result in damage to hepatocytes (Lee, 1995). Injury
to hepatocytes can result either directly from the disruption of intracellular function
or membrane integrity, or indirectly, from immune-mediated membrane damage. At
least six mechanisms that primarily involve hepatocytes result in liver injury, and the
manner in which intracellular organelles are affected defines the pattern of the
disease (Lee, 2003).
Drugs may cause hepatotoxicity by disruption of intracellular calcium homeostasis or
metabolism of drugs by CYP450s may lead to reactive metabolites capable of
covalently binding to intracellular proteins. These insults can lead to intracellular
dysfunction, loss of ionic gradients, decline in ATP levels, disassembly of actin
fibrils at the hepatocyte surface, blebbing of the cell membrane, cell swelling and cell
lysis (figure 1.4 A) (Lee, 2003).
Other drugs may affect the biliary system and can result in jaundice. Bile secretion
depends on the function ofmembrane transporters in hepatocytes and cholangiocytes
and on the structural and functional integrity of the bile-secretory systems (Trauner
et al, 1998). Disruption of the transport proteins at the hepatocyte canalicular
membrane (figure 1.4 B) by binding to and disabling of membrane transporters
involved in the export of bile from hepatocytes into bile ductules can therefore
interrupt bile flow, resulting in cholestasis (Lee, 2003). Disruption of actin filaments
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may occur next to the canaliculus, the specialized portion of the cell responsible for
bile excretion (Trauner et al. 1998) and the loss of villous processes combined with
the interruption of transport pumps such as multidrug-resistance-associated protein 3
(MRP3) prevent the excretion of bilirubin and other organic compounds (Trauner et
al, 1998). Damage to bile ducts or canaliculi can result in cholestasis without
marked damage of hepatocytes (Lee, 1995). If cholangiocytes are injured, a likely
outcome is prolonged or permanent cholestasis (Lee, 2003). In mixed forms of
hepatic injury, combined failure of canalicular pumps and other intracellular
processes allow toxic bile acids to accumulate, resulting in secondary injury to














Figure 1.4: Mechanisms of Liver Injury (reproduced from Lee, 2005)
Injury to liver cells occurs in patterns specific to the intracellular organelles affected.
The normal hepatocyte shown in the centre of the figure may be affected in at least
six ways, labeled A to F. DD denotes death domain.
Drugs are relatively small molecules and therefore are unlikely to evoke an immune
response (Lee, 2003). As discussed earlier, the metabolic capability of the liver can
result in the production of toxic and non-toxic metabolites, and many hepatocellular
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reactions involve the CYP450 system (figure 1.4 C). CYP450-mediated metabolism
can lead to the covalent binding of drug to enzyme, thus creating new,
nonfunctioning adducts. These enzyme-drug adducts migrate to the cell surface
(figure 1.4 D) in vesicles to serve as target immunogens for cytolytic attack by T
cells, stimulating an immune response involving both cytolytic T cells and cytokines
(Lee, 2003).
In several cases, injury caused by drugs is initiated by bioactivation of drugs in
hepatocytes to chemically reactive metabolites. Bioactivation reactions involving
CYP450-mediated metabolism leads to reactive metabolites that can deplete reduced
glutathione, and become covalently bound to protein and other cellular
macromolecules, such as lipids and nucleic acids, with consequent protein
dysfunction, lipid peroxidation, DNA damage, or oxidative stress (Kaplowitz, 2001;
Holt and Ju, 2006). These chemical consequences can directly affect organelles,
including mitochondria, cytoskeleton, endoplasmic reticulum, microtubules, or
nucleus, or indirectly influence these organelles through activation or inhibition of
signalling kinases, transcription factors, and gene expression profiles (Kaplowitz,
2001). Covalent binding to proteins has been implicated in hepatic toxicity caused
with several drugs, such as paracetamol, halothane and diclofenac (Pumford and
Halmes, 1997).
Apoptosis can be involved in immune-mediated injury, with the involvement of
tumor necrosis factor a (TNFa ) and Fas pathways resulting in the cascade of
intercellular caspases (figure 1.4 E) and controlled hepatocyte death (Lee, 2003).
Further consideration is given to the process of apoptosis below as apoptosis can
occur as a result of several cellular insults and is also the mechanism of action by
which many anticancer agents are cytotoxic.
A further mechanism of drug-induced liver injury involves damage to mitochondria
resulting in disruption of fatty-acid oxidation and/or energy production (Lee, 2003;
Holt and Ju, 2006). Certain drugs inhibit mitochondrial functions including /?-
oxidation (affecting energy production by inhibition of the synthesis of nicotinamide
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adenine dinucleotide and flavin adenine dinucleotide, resulting in decreased ATP
production) and the respiratory-chain enzymes (figure 1.4 F). Free fatty acids cannot
be metabolized, and the lack of aerobic respiration results in the accumulation of
lactate and reactive oxygen species. This pattern of injury is characteristic of a
variety of agents, including nucleoside reverse-transcriptase inhibitors, which bind
directly to mitochondrial DNA, as well as valproic acid, and tetracycline (Lee, 2003).
The outcome of hepatic cell dysfunction may be either triggering of necrotic or
apoptotic processes, or initiation of innate or adaptive immunological reactions
which may ultimately result in apoptosis (Holt and Ju, 2006). Although the causes of
cell death are distinct from one another, apoptosis and oncosis participate in the
pathogenesis of the majority of liver diseases, and may be triggered by a number of
insults, arising either intra-cellularly or extra-cellularly (Kaplowitz, 2001). The first
leads to a pathological pattern of necrosis in vivo, with evidence of inflammatory
response. Conversely, apoptosis follows a specific pattern of protein activation
leading to an orderly cell death and minimising inflammatory response. There is
increasing evidence that apoptosis and oncosis are not separate entities but can be
initiated by similar initiating signals, the mechanisms of cell death being ultimately
related to the level of injury and extent of ATP depletion (Lemasters, 1999). Some
drugs may cause cell death by more than one mechanism: for example paracetamol-
induced hepatocyte cell death has been linked to both oncosis and apoptosis (Kon et
al, 2004).
Despite being morphologically distinct, apoptosis and necrosis can share similar
initiating events (death receptor ligation, chemicals, drug-induced hypoxia, oxidative
stress), and usually involve the participation of mitochondria (Kaplowitz, 2001). The
pattern of cell death depends on the extent of mitochondrial damage, which either
leads to rapid ATP depletion, swelling and lysis (oncosis), or a more selective release
of cytochrome c in the presence of sufficient ATP to activate executioner caspases




Apoptosis is a cell-suicide mechanism, which eliminates individual cells when they
are no longer needed or have become seriously damaged (Ashkenazi and Dixit,
1999). It was first described by Kerr et al in 1972, and is characterised by particular
morphological and biochemical changes within the cell. Morphological changes
include chromatin aggregation, nuclear and cytoplasmic condensation and partition
of cytoplasm and nucleus into membrane bound vesicles called apoptotic bodies.
Biochemical changes include phosphatidylserine externalisation, loss of
mitochondrial membrane potential, and intranucleosomal cleavage. Cell death by
apoptosis does not result in an inflammatory response because the cells do not
rupture and are phagocytosed by macrophages.
Apoptosis does not result from a single signal transduction pathway, but from a
complex cascade of multi-branching pathways, and can be triggered by both extra¬
cellular and intracellular signals (see figure 1.5). Two broad apoptosis pathways
have been defined: the extrinsic (receptor dependent) and intrinsic (receptor
independent) pathways, and both pathways can involve the mitochondria. During the
death-receptor dependent pathway, ligand binding to a death receptor (e.g. Fas, TNF-
Rl, DR3, DR4, DR5 or DR6) recruits downstream effectors such as FADD and
TRADD. activating caspase-8 which in turn can activate Bid and the mitochondrial-
dependent apoptotic pathway, and caspases 3, 6 and 7 (Petak et al, 2001).
Mitochondrial-dependent caspase-9 activation increases caspases 3, 6, 7 activation
(Petak et al, 2001). TNF-R1 and FasR are the predominant death receptors expressed
in hepatocytes (Faubion and Gores, 1999; Jones and Czaja, 1998; Pinkoski et al,
2000), and Fas is expressed in hepatocytes, cholangiocytes, sinusoidal endothelial
cells, stellate cells and Kupffer cells (Pinkoski et al, 2000).
Both the intrinsic and extrinsic pathways of apoptosis result in ATP-dependant
activation of cysteine-dependent aspartate specific proteases (caspases). Caspases
are constitutively expressed in cells (Weil et al. 1996), and active caspases are
generated after proteolytic cleavage of the pro-caspase at specific aspartic acid
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residues. Two families of caspases exist that are initiator caspases (-2, -8, -9 and -
10) and effector caspases (-3, -6 and -7).
Apoptosis, in contrast to oncosis, is an energy-driven process that requires adenosine
triphosphate (ATP) (Tsujimoto, 1997). All cells have an absolute requirement for
energy in the form of ATP for many biological reactions to maintain cell viability
(Crouch et al, 1993). ATP is generated in cells by glycolysis (in the cytosol) and/or
oxidative phosphorylation (in the mitochondria). The balance between ATP
production and consumption determines cell fate (Leist et al, 1997; Nicotera et al,
1998). Drugs can interfere with ATP production or cause uncontrolled ATP
consumption.
Drug-induced liver injury caused by apoptosis of hepatocytes, seems to be mediated
in part via the activation of other cells, activated or recruited to the site of damage via
inflammatory signals (Holt and Ju, 2006). The liver contains large numbers of both
innate and adaptive immune cells, including the largest populations of tissue
macrophages (Kupffer cells), natural killer (NK) cells and NK cells with T cell
receptors (Holt and Ju, 2006). Kupffer cells are a major source of TNFa which can
trigger apoptosis via TNFR1 signalling (Bradham et al, 1998). Paracetamol- and
melphalan-induced liver toxicity can result from production of TNFa, interacting
with hepatocytes, either via its soluble form (paracetamol) or membrane-bound
(melphalan) (Kresse et ah 2005; Laskin et al, 1995). Binding of TNFa to TNFR1 or
TNFR2 recruites FADD via the adapter TRADD. TNF receptors also interact with
TRAF1 and TRAF2 activating JNK and NF-kB (Bradham et al, 1998). Caspase
activation via FADD induces caspase-dependent apoptosis. NF-kB activation
upregulates the transcription of both pro and anti apoptotic proteins which modulate
cell death. Cytotoxic T lymphocytes and natural killer cells secrete FasL and induce
apoptosis in Fas-expressing hepatocytes (Pinkoski et al, 2000). NK cells also induce
cell death via oxidative stress (Jaeschke and Hasegawa, 2006). Activation of Fas
recruits the death-inducing signalling complex (DISC), comprised of FADD. FAS
and pro-caspase 8. Caspase 8 cleaves Bid, inducing cytochrome c release from the
mitochondria. Formation of the apoptosome (cytochrome c, APAF-1 and pro-
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caspase 9) activates caspase 9 activating mitochondrial-independent caspases (3,6
and 6). Bile acids can activate Fas-signalling to induce cholestatic-related liver
injury.
Anticancer drugs may induce both pathways of apoptosis as their therapeutic
mechanism of action, and it is known that the apoptotic pathways of anti cancer
drug-induced cell death involve mitochondria-dependent activation through Bax and
mitochondria-independent activation through Fas (Kim et ah, 2002). Cell-type
specific triggering of death receptor and/ or mitochondrial pathways upon drug
treatment has been reported (Fulda et al, 2001). The death receptors (e.g. Fas, TNF-
R1 DR3, DR4, DR5, and DR6) trigger apoptosis upon engagement by their
corresponding death ligands (Petak et al, 2001). Activation of signalling pathways


















Figure 1.5: Death-receptor-dependent and -independent pathways in anti¬




Oncosis represents a distinctly different pattern of cell death from apoptosis.
Necrosis has become an umbrella term for all non-apoptotic accidental cell death
(Fink and Cookson, 2005). Flowever the term necrosis is used by pathologists to
describe the presence of dead tissue or cells and is actually the sum of changes that
have already occurred in cells (Levin, 1998). The term oncosis, however, has been
accepted by many investigators as a counterpoint to apoptosis, and is used to
describe cells that die by cellular and organelle swelling, blebbing and increased
membrane permeability, and is often the consequence of profound ATP depletion
(Majno and Joris, 1995; Rosser et al 1995).
1.2.3 Risk Factors for Hepatotoxicity
1.2.3.1 General Risk Factors
A variety of risk factors may impact on the susceptibility of humans to drug-induced
hepatotoxicity. These may impact on drug metabolism (see section 1.1.2.3.4) and
therefore predispose to toxicity and include age, race, gender, alcohol consumption,
pre-existing liver disease, genetic polymorphisms, co-medication, and nutritional
status. These factors may be investigated in experiments involving liver tissue from
various donor livers. The effect of these factors on host susceptibility to
hepatotoxicity appears to depend, at least partly, on the relevance of metabolism of
the respective agent to its toxicity (Zimmerman, 1999).
Age can have an important effect on drug metabolism, and therefore alter host
susceptibility to hepatotoxicity. Some individuals may show no detectable changes;
however most people sustain some decline in liver function with aging. With
increasing chronological age liver blood-flow, liver mass and CYP P450-mediated
metabolism may decrease. Decreased renal function, increased body fat,
polypharmacy, multiple medical problems, and increased likelihood of previous
exposure to a particular drug also occur with age and can result in an increased
susceptibility to hepatotoxicity (DeLeve, 2003).
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Race has an influence on genetic polymorphisms in several drug metabolising
enzymes. For example, differences in the phase I drug-metabolising enzyme
CYP2D6 between Caucasians and South Pacific Polynesians have been discovered,
with poor metabolizer status being higher in Caucasian populations (Wanwimolruk
et al. 1998). Another example is the differences in glucuronidation of paracetamol
between Caucasians and Chinese that have also been reported (Osborne et al, 1991).
Response of males and females to the same drug can vary. Pharmacokinetics, drug
response, and incidence of adverse reactions are not the same between men and
women, and drug use is thought to be more frequent in females than males. There
are also differences in body composition and size between males and females. One
example of this phenomenon is with that anti-cancer agent 5-FU where females are at
increased risk of toxicity with 5-FU as drug clearance is slower than in males
(Zalcberg et al, 1998).
Genetic polymorphisms of drug metabolising enzymes involved in the metabolism of
certain drugs can result in increased hepatotoxicity (Eichelbaum et al, 1992). One
example is in the use of irinotecan in patients with Gilbert's syndrome. Irinotecan is
excreted in bile as glucuroconjugated SN-38, but in patients with Gilbert's syndrome
who have a genetic polymorphism leading to deficiency in UGT1A1 enzyme,
irinotecan induces greater toxicity (Floyd et al, 2006). Troglitazone-induced
hepatotoxicity has been associated with CYP2C19 but not CYP2D6 polymorphism
in the Japanese population, with liver injury occurring more frequently in CYP2C19
mutation carriers (Kumashiro et al, 2003). A further example of genetic
polymorphisms that are associated with adverse events is in the use of methotrexate
in childhood acute lymphoblastic leukaemia and malignant lymphoma where
glutathione-S transferase Ml polymorphism was found to be linked with
methotrexate hepatotoxicity (Imanishi et al, 2007).
Any form of pre-existing liver disease can impact on the body's handling of drugs
(Andreasen, 1978). For example cirrhosis of the liver, cholestatic jaundice, and liver
carcinoma have all been reported to decrease the liver's ability to metabolise drugs.
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possibly by decreasing the enzyme activity in the liver, altering hepatic blood flow,
or hypoalbuminaemia which leads to lower plasma binding of drugs (Gibson and
Skett, 2001 pg 144).
When a patient is treated with more than one drug at the same time, the workload of
the liver is increased, and can result in hepatotoxicity. The incidence of adverse drug
reactions increases exponentially with the number of drugs prescribed, and drug
interactions contribute to this phenomenon. Drug interactions that affect hepatic
metabolism may cause toxicity by inhibiting detoxification, inducing activation, or
inhibiting biliary excretion (DeLeve, 2003). The use of anticancer drugs in
combination regimens and supportive drugs administered during chemotherapy is an
example of co-medication and is clinically very relevant.
Excessive alcohol consumption can have a damaging effect on the liver and make it
less able to cope with certain drugs. Acute ethanol exposure can decrease drug
metabolism (Gibson and Skett, 2001 pg 141). Chronic ethanol exposure can lead to
a condition similar to cirrhosis, but firstly can enhance drug metabolism (Gibson and
Skett, 2001 pg 142).
Several manipulations of the diet affect the metabolism and toxicity of xenobiotics
(Zimmerman, 1999). Intake of protein, dietary fat, and dietary carbohydrate may
have an effect. Malnutrition may lead to depletion of tissue-protective molecules
such as glutathione. In fasted individuals who have a low hepatic glycogen content,
hepatocellular necrosis can result from hypoxia, mitochondrial inhibition and
damage to mitochondrial DNA (Jaeschke et al, 2002). Vitamin (retinol [A],
riboflavin [B2], thiamine [Bl], ascorbic acid [C], and E) and mineral intake may also
have an influence. Grapefruit juice is a known CYP3A4 inhibitor, therefore
consumption of grapefruit may decrease CYP3A4 metabolism of drugs
1.2.3.2 Risk Factors for Hepatotoxicity in Patients with Cancer
In addition to the risk factors for hepatotoxicity described above, additional factors in
some patients with cancer may increase the likelihood of a hepatotoxic reaction, or
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make it more difficult to detect. The selection of a chemotherapeutic regimen for
treating cancer is based on a thorough assessment of potential hazards regarding the
patient's clinical condition and the toxicity of chemotherapy (Sachs et al, 2002).
Several factors can increase the risk of drug-induced liver toxicity in patients with
cancer, and examples of these are considered below. They include: the presence of
liver metastases; pre-existing liver disease (e.g. viral hepatitis); immunosuppression;
and drug combinations. Anticancer drugs are routinely administered in combination
regimens, potentially increasing the chance of toxicity caused by drug interactions.
Furthermore, anti-cancer chemotherapy is almost always administered in conjunction
with other supportive agents. A further complication in attributing hepatotoxicity to
a particular anticancer drug is that many of the drugs are given cyclically rather than
continuously.
The presence of cancer in the liver can increase the risk of hepatotoxicity with
certain drugs. The hepatotoxic potential of platinum derivative oxaliplatin in
combination with topoisomerase I inhibitor irinotecan is increased in patients with
colorectal cancer treated with neoadjuvant chemotherapy prior to liver surgery.
Steatosis is typically reported for both compounds (Zorzi et al, 2007).
Cells of the immune system are rapidly dividing cells, and therefore are targeted by
several anti-cancer agents. In patients with underlying hepatitis B and C viruses,
chemotherapeutic immunosuppression has resulted in reactivation of hepatitis viruses
(Hoofnagle et al, 1982). As a consequence of reactivation of hepatitis B virus
infection, fulminant hepatitis has been reported following discontinuation of low-
dose methotrexate therapy (Flowers et al, 1990).
There are several treatment-regimes used in the management of cancer, which
include a combination of two or more anticancer agents administered concurrently.
These regimes are intended to produce a greater cytotoxic effect, but with this comes
the increased risk of toxicity and a higher work-load for the liver. Combination
regimens can affect toxicity, as each anticancer drug has its own mechanism of
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action and toxicity profile, and furthermore these may interact. Examples of
combinations that result in increased toxicity compared to administration of the
agents in isolation include methotrexate with 6-MP (Floyd et al, 2006), gefitinib with
anastrozole (Carlini et al, 2006), and cyclophosphamide with methotrexate and 5-FU
(Floyd et al, 2006).
Co-administration of anticancer agents with other therapeutics to treat or prevent the
common side effects associated with a particular drug or drug combination is
extremely common. Examples include steroids (e.g. dexamethasone), antiemetics
(e.g. domperidone, ondansetron, grandisteron), antibiotics (e.g. co-amoxiclav,
clarythromycin), anti-fungal agents (e.g. fluconazole, ketoconazole). There have
been rare case reports of hepatotoxicity following these drugs, such as jaundice with
ondansetron (Vermill and Judson, 1994). If hepatotoxicity is detected following
chemotherapy consideration should be given to the co-administered drugs when
determining the cause and possible interactions.
1.2.4 Testing for Drug-Induced Hepatotoxicity
Before a drug is approved for use in humans it must go through several years of
testing. The Medicines and Flealthcare products Regulatory Agency (MHRA) is the
government agency in Britain who are responsible for ensuring that drugs meet
acceptable standards of safety, quality and efficacy following their development
before a licence is granted for use in humans. The Food and Drug Administration
(FDA) in America carries out a similar role. There are several factors that may halt
the development of a drug at any stage of the drug development process, and prevent
the granting of a license for its use in humans. Drug hepatotoxicity is a leading cause
of failures in drug development at the clinical phases of investigation (Kaplowitz,
2005). Pre-clinically, there may be indication of hepatotoxic potential of a drug,
detected either via in vitro tests or in the animal toxicology studies required before a
drug is approved for trial in humans. During the various stages of clinical
development in patients, liver toxicity may be detected, and can manifest as any of
the spectrum of asymptomatic abnormalities in liver enzymes through to life-
threatening liver failure. If severe hepatotoxicity occurs in early phase clinical trials,
it may stop the clinical development of a drug. Determination of the cause of
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toxicity is important, as once the offending article has been identified and withdrawn,
liver injury may resolve. An overview of the drug development process and ways in
which hepatotoxicity can be detected throughout this process is given below.
Models used to represent the liver in pre-clinical studies include isolated perfused
livers, tissue slices, isolated cells or cell organelles, membranes or enzymes, each
offering their own advantages and disadvantages (Jaeschke, 2003; Wang et al. 2002;
Olinga et al, 1997; Li et al, 1999; Holownia and Brasko, 2004; Li et al, 1999; Stoff-
Khalili et al, 2006; Davila et al, 1998, Hewitt et al, 2001; Butterworth et al, 1989;
Gomez-Lechon et al, 2003; Ulrich et al, 1995; Anderson et al, 1996; Biagini et al,
2006; Kikkawa et al, 2006; O'Brien et al, 2006; Xu et al, 2004). Whilst these models
are often used for studies of drug metabolism, it is not a requirement to perform
toxicity testing using these models routinely. An isolated liver preparation for in
vitro experiments is an extremely useful research tool, and all of these models (with
the exception of whole organ) can be obtained from humans and from a variety of
animal species. The majority of human liver made available for research is in the
form of surgical biopsies, which are usually obtained from patients undergoing
partial hepatectomy or from the surgical resection of adult livers prepared for
paediatric recipients (Bayliss & Skett, 1996). Models used to predict for toxicity in
human liver during the preclinical development of compounds will be given greater
consideration below, as they form an important part of the studies presented in this
thesis. In silico models may be used even before testing in cells or in addition to, to
predict hepatotoxic potential of drugs from predefined parameters including
structural features. When comparing the models in terms of advantages and
disadvantages, factors to be considered include cost, ease of use, ethics, and
predictive value of the model. Several of these models have been used previously for
assessment of the hepatotoxic potential of many classes of drugs, however a direct
comparison of the benefit of these models in predicting anticancer drug induced
hepatotoxicity has not previously been made.
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1.2.4.1 Isolated enzymes, organelles, and subcellular
fractions
It is possible to isolate fractions from the liver for preclinical drug metabolism and
hepatotoxicity evaluation, as described below. Liver microsomes may be used to
study drug metabolism, and plasma membrane vesicles used to study xenobiotic
transport. The metabolic reactions of drugs studied in microsomes are restricted to
phase I metabolism and glucuronidation reactions and may provide misleading
results with respect to metabolism of a drug.
1.2.4.2 Isolated cells in vitro
Cell preparations may be made from a piece of liver tissue isolated from either
humans or animals. Isolated human hepatocytes appear to be a suitable experimental
model for the study of liver toxicity (Bayliss & Skett, 1996; Gomez-Lechon et al,
2003; Butterworth et al, 1989). Primary cultures of hepatocytes are widely used for
studying drug metabolism and toxicity, with a wide variety of in vitro assay
techniques used to detect the experimental endpoint.
Enzymatic hepatocyte isolation from animal liver was first introduced in 1967
(Bayliss & Skett, 1996). The preparation of isolated hepatocytes from heterogeneous
liver tissue involves several steps. Initially the cells must be dissociated from the
fibroconnective skeleton. Tissue dispersion requires the disruption of reticulin fibrils
along with adhesion proteins, such as fibronectin and laminin, which constitute the
framework of the liver lobule. Hepatocyte isolation also requires the disruption of
cell-cell adhesion, i.e. the junctional complexes and finally the recovery of the
hepatocyte preparation for culture (Bayliss & Skett, 1996).
Human hepatocytes in culture have been shown to maintain plasma protein
production, glycolysis, and urea synthesis for periods of several days (Chen et al.
1998). Conversely, drug metabolising enzymes (particularly the cytochrome P450s)
decline with time (Bayliss & Skett, 1996). Hepatocyte survival can be extended
considerably when cells are maintained in monolayer culture conditions in the
presence of an extra-cellular matrix and/or supplemented media. This is necessary as
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hepatocytes in suspension, with no attachment to any form of extra-cellular matrix,
are viable for only a few hours (Bayliss & Skett, 1996). Therefore, a number of
factors, including the extra-cellular matrix, seeding densities, culture media and
media supplements need to be considered when culturing human hepatocytes. There
are several limitations to the use of fresh hepatocytes, including inability to
proliferate, and the eventual loss of some liver functions in culture (Anderson et al,
1996). Many functions such as drug-metabolising enzyme activities decline within
the first 24-48hours (Paine et al, 2004). Changes in hepatocyte gene expression are
initiated very early into the well-established hepatocyte isolation procedure with
collagenase (Paine et al, 2004). Another problem encountered when working with
human liver is the limited and irregular availability of material for research purposes.
Another major consideration when using human liver to prepare hepatocytes is the
variation in the functional activity between cell preparations (Bayliss & Skett, 1996).
This variability may be the result of the length of time taken in obtaining the sample,
sample storage conditions, or the sample history, as well as the genetic and
environmental factors affecting the donor (Olinga et al, 1998). Information
regarding the patient history, dietary habits, and genetic polymorphism is valuable
when interpreting results (Bayliss & Skett, 1996).
Cryopreservation of hepatocytes may help to overcome some of the issues relating to
supply of hepatocytes for research. It allows cells from one donor to be used over a
period of time and to be used for testing more than one compound. It also ensures
that this valuable and finite resource is not wasted if all of the cells isolated are not
needed immediately. The conditions necessary for successful cryopreservation
continue to be improved on (Ilan, 2002) helping to ensure viable and plateable cells
after thawing. They therefore offer practical advantages, however their limitations
should not be forgotten. Reports mainly focus on drug metabolism studies as
opposed to hepatotoxicity studies following freezing.
In addition to the use of isolated hepatocytes on their own, these cells may be co-
cultured with other different cell types e.g. Kupffer cells.
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As well as isolated hepatocytes, which are a limited resource, there are several cell
lines that are immortalised and therefore able to replicate in vitro that are used to
study the liver. Immortalised, stable, differentiated liver cell lines, capable of
proliferation, and possessing liver-specific function are of great value for the in vitro
study of the human liver. These cell lines have been developed to overcome some of
the problems encountered with normal tissues in vitro, and offer the advantages of
replication in vitro, ready availability, and no concerns about inter-individual
variability that are observed in patient samples (Stacey et al, 2001). These fall into
two categories: those that have specifically been immortalised by addition of a viral
vector, and those that are derived from liver cancer and naturally proliferate.
A replicative culture of engineered immortalised adult human liver epithelial cells
(hepatocytes) have been produced by Pfeifer et al (1993) by transfection of
hepatocytes with recombinant simian large T antigen virus 40 (SV40) DNA, and are
called THLE-2 and THLE-3. These cells have been shown to undergo over 100
population doublings, express several hepatocyte markers including cytokeratin 18
and albumin, and have functional phase 1 and II drug metabolising enzymes, such as
cytochrome P450s and glutathine-S-transferase (Pfeifer et al, 1993). Screening for
hepatotoxicity by Bristol-Myers Squibb Pharmaceutical Research Institute (Dambach
et al. 2005) incorporated studies of immortalised hepatocytes established by Pfeifer
et al.
Hepatocellular carcinoma (hepatoma) cell lines are established from cancers that
develop from hepatocytes. Hepatocellular carcinoma is the most common type of
primary liver cancer, accounting for over 85% of all liver cancers (CancerHelp UK).
Examples of human hepatoma cell lines, which were established from primary
hepatomas, include HepG2, Huh-7 D12, Hep3B, PLC/PRF/5, and SK-HEP-1 and are
available from the American Type Culture Collection (ATCC). These cell lines were
shown to retain some of the specialised functions of the liver that are normally lost
by primary hepatocytes in culture, such as secretion of some major plasma proteins,
and expression of a wide range of phase I and II drug metabolising enzymes
(Mersch-Sundermann et al, 2004; Wilkening et al, 2003). However, these cells are
tumorigenic, have lost their contact inhibition, and therefore differ from fresh
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hepatocytes and immortalised hepatocytes. Many studies of the hepatotoxic potential
of drugs have included Hep G2 cells (Brandon et al, 2005; Burczynski et al, 2000;
Harris et al, 2004; Miret et al, 2006; O'Brien et al, 2000; Samali et al, 1999;
Tirmentstein et al, 2000; Yang et al, 2004), and there are also studies including Huh-
7, Hep3B and PLC/PRF/5 cell lines.
As mentioned, several in vitro assays are available to measure different aspects of
cell death and are compatible with the cell types described above. Miret et al (2006)
compared different methods to assess cytotoxicity in HepG2 cells and concluded that
a selection of assays (ATP, necrosis, and caspase-3/7 activation) used to detect
different aspects of cells death is needed to evaluate drug-induced liver injury.
Measurement of cellular ATP content was used by Lloyd et al (2002) to detect
troglitazone cytotoxicity in human hepatocytes. The measurement of ADP and ATP
in cells and calculation of ADP:ATP ratio has been used to distinguish oncosis from
apoptosis (Bradbury et al, 2000).
1.2.4.3 Liver slices
Human liver slices are the ex-vivo model with the highest structural integrity in
which to study the effects of drugs pre-clinically. Liver slices can also be made from
the liver of several species of animal. Liver slices retain the intact structure of the
organ, maintaining cellular heterogeneity, and can be as thin as 100pm, however the
optimal thickness for slices found to retain their viability during culture is 200-
250pm. Therefore, when used as a model, it must be remembered that the drug must
penetrate through layers of cells. Endpoint toxicity measurements such as potassium
retention, ATP content, enzyme leakage, protein synthesis and MTT reduction have
all been used in this system. Cultured, precision-cut rat liver slices were used by
Moronvalle-Halley et al 2005) to evaluate drug-induced apoptosis. Liver slices from
rat and guinea pig have been used to study the hepatotoxicity of drugs including
hepatotoxic compounds such as carbon tetrachloride and halothane respectively, and
were found to be predictive of toxicity (Olinga et al, 1997). It is also of interest that
liver slices can be cryopreserved, however these are not readily used due to similar
problems as with the isolated cells. It is not apparent whether the extra technical, and
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therefore cost considerations are justified when compared to testing with fresh
hepatocytes.
1.2.4.4 Isolated perfused liver
The liver may be removed following sacrifice of an animal, and perfused so that a
compound can be administered to the isolated organ. Isolated perfused liver has
been used to study rat liver, but has not been employed for this purpose in humans
due to the large size of the organ, limited availability, and ethical considerations
(Olinga et al, 1997).
1.2.4.5 Liver in vivo
Whole animals are frequently used to study the liver in vivo, and may include rodent
and non-rodent species. Signs of liver toxicity in the animals should be documented
following the administration of the test compound, and if the animals are sacrificed
at the end of the experiment, the liver may be removed and examined for signs of
liver damage. Advantages of using the whole animals include maintenance of liver
structure and drug metabolising capabilities, and the possibility for pharmacokinetic
analysis. Disadvantages include the cost, influence from other organs, and endpoint
analysis is more complicated. There is also the potential for interspecies differences
in drug metabolism to confound the results, although transgenic mice expressing
human CYP450 have been developed to try to overcome this (Gonzalez and Yu,
2006).
1.2.4.6 Clinical Trials
Before a drug is granted approval for clinical trials in humans, pre-clinical drug
development to examine efficacy and toxicity must take place. This involves testing
efficacy and toxicity both in vitro and in vivo. Investigations into a drug's
absorption and metabolism, toxicity of drug metabolites, and excretion as well as
genotoxicity studies are carried out. Acute and long-term toxicology studies are
usually required in one rodent and one non-rodent animal species. This stage helps
plan clinical development strategies and ensures adequate knowledge and safety
considerations before trials in humans.
50
Introduction
After a drug has met all the necessary requirements to gain approval for use in
humans, clinical trials may begin. Phase I clinical trials involve administering the
drug to a small number of healthy male volunteers and assessing safety, determining
a safe dosage range and determining side effects. Following successful phase I
development the drug will enter phase II trials during which it will be administered
to patients suffering from the condition the drug is intended to treat, and will
examine efficacy and safety. Phase III trials follow on from successful phase II trials
and extend into a much larger patient population looking to confirm efficacy,
monitor side effects, and compare with other treatments. At all stages adverse drug
reactions, including hepatotoxicity will be closely monitored for, and LFTs may be
performed during any phase of clinical trials to assess if the new compound is having
adverse effects on the liver. A drug will be reported as hepatotoxic if it causes
significant changes in LFTs.
Following successful clinical trials, in terms of efficacy and lack of toxicity, a drug
will be granted approval for use in patients. Phase IV trials, also known as post¬
marketing surveillance, describe the process of monitoring a drug once it has been
licensed. The occurrence of hepatotoxicity of drugs post-marketing can result in
drug withdrawals, modifications of use, and warnings (Kaplowitz, 2005; Ballet,
1997). Several drugs do make it through the full development process, which lasts
on average 12 years, and are then withdrawn or their use restricted following
marketing. This is not only extremely costly for the pharmaceutical company, but is
as a result of serious or fatal adverse events. Any steps towards reducing this are
therefore worthwhile.
1.2.4.7 Testing for Drug-Induced Hepatotoxicity in Oncology
An overview of the drug development process for other classes of drugs is given
above. There are several key differences in the way the pre-clinical and clinical




Preclinical testing strategies may involve any of the in vitro and in vivo models
described above, and in addition testing will be performed in cancer cell lines and
implanted tumours in animals. A summary of the regulatory considerations for pre¬
clinical development of anticancer drugs in the US is provided by DeGeorge et al
(1997). In the UK, preclinical in vivo safety testing of anticancer agents need only be
carried out in rodents. Following an evaluation of rodent-only toxicology studies by
Newell et al (1999), Cancer Research UK in conjunction with the European
Organisation for the Research and Treatment of Cancer (EORTC) promote minimum
preclinical toxicology assessment, using no non-rodent species (Cancer Research UK
website).
For ethical reasons, phase I first-in-human trials of novel anti-cancer agents are
undertaken in patients with cancer who are generally highly pre-treated and
unresponsive to all other treatments for their type of cancer. Therefore they are
assumingly resistant to other anti-cancer therapies. Phase I trials can be conducted in
patients with any kind of cancer. Following successful phase I trials, the compound
will progress into phase II trials in a particular cancer type, and phase III studies
follow successful phase II studies in the same way as for other classes of agents.
1.3 HEPATOTOXICITY INDUCED BY ANTICANCER AGENTS
As mentioned previously, the exposure of individuals to many different classes of
drugs, including several anti-cancer agents, can result in liver toxicity. Traditionally
anti-cancer drugs are administered at the maximum tolerated dose and have a narrow
therapeutic index (Colombo et al, 2001), increasing the potential for toxicity. In
oncology, the aim of treatment with cytotoxic drugs is to selectively target and kill
all cancerous cells, whilst leaving the healthy tissue unharmed. In practice, anti¬
cancer drugs induce cytotoxic effects in all proliferating cells and, to a certain extent,
non-dividing cells. For some anti-cancer drugs this manifests as liver-related dose-
limiting toxicity. Serious hepatotoxic reactions following chemotherapy are
fortunately infrequent; however some compounds do make it through preclinical
safety testing and cause toxicity during clinical trials. Drug-induced liver injury is a
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major reason for failure of novel anticancer agents in clinical development (Spicker
et al. 2007). Therefore, further research into the detection and understanding of
which anti-cancer drugs are likely to cause hepatotoxicity is required.
1.3.1 Chemotherapy-induced hepatotoxicity
There are numerous case reports, papers, and review articles that have been
published documenting clinical signs of liver toxicity following administration of
anti-cancer agents to humans. The chemical properties and mechanism of action of
these agents may aid understanding of the hepatotoxicity caused; however route of
administration and risk factors (discussed in section 1.2.3) may also alter risk of
hepatotoxicity.
1.3.1.1 Type of chemotherapy (single-agents)
Drugs from most of the classes of anticancer agents have been reported to cause
hepatotoxicity and include DNA damaging agents, antimetabolites, topoisomerase
inhibitors, microtubule-targeting drugs, and antitumour antibiotics. Table 1.6 reports
hepatotoxicity resulting from drugs administered as single agents. Dose-dependent
toxicity and off-target effects play a significant role in liver injury. Hepatotoxicity is
reported when there are significant alterations in LFTs. However, cytotoxic agents
commonly cause transient LFT abnormalities, without clinical evidence of liver
impairment. Mild or moderate transient elevations of LFTs without other signs of
liver toxicity could often be ignored. However, when irreversible hepatotoxicity
occurs, early detection of this and withdrawal of the offending drug is imperative
(DeLeve, 2003).
Anticancer agents are reported to cause cell death in cancer cells by induction of
apoptosis. It is known that the apoptotic pathways of anti cancer drug-induced cell
death involve mitochondria-dependent activation through Bax and mitochondria-
independent activation through Fas (Kim et al, 2002). A cell-type specific triggering
of death receptor and/or mitochondrial pathways upon drug treatment has been
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reported (Fulda et al., 1998, 2001). This may be of interest when examining the way
in which an anticancer agent causes hepatotoxicity or induces liver cell death.
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1.3.1.2 Route of administration
The hepatotoxic potential of a drug can be modified depending on the route of drug
administration. A change in the route of administration, by changing the
pharmacokinetic profile of the drug, can increase the incidence of liver toxicity. An
example of this phenomenon is in the hepatic intra-arterial administration of a drug.
The primary aim of hepatic intra-arterial infusion is to ensure that a higher drug
concentration reaches the liver than would occur than if the drug were administered
systemically. When 5-FU is administered for the treatment of non-resectable liver
metastases from colorectal cancer by delivery into the hepatic artery, a significant
advantage in terms of tumour response and median survival time was observed, when
compared with systemic administration (intra-venous). The downside of
administration of intra-arterial 5-FU is the increased observation of hepatotoxicity
(Link et al, 1999). Similarly, intra-arterial floxuridine (FudR) following complete
resection of liver metastases caused biliary toxicity (persistently elevated serum
bilirubin and alkaline phosphatase) in approximately 35% of cases and one patient
developed cirrhosis and died of progressive liver failure associated with this toxicity
(Onaitis et al, 2003). One further example is that melphalan infusion has been
associated with grade 3^4 hepatotoxicity in 19% of treatments in humans in one
phase I trial (Pingpank et al, 2005). As previously discussed, melphalan has been
shown to induce liver injury via the expression of membrane-bound TNF in Kupffer
cells (Kresse et al, 2005). All of these examples are likely to be caused by a dose




When a patient is treated with more than one drug at the same time the workload of
the liver is increased, and can result in hepatotoxicity. The incidence of adverse drug
reactions increases exponentially with the number of drugs prescribed, and drug
interaction contribute to this phenomenon (Blower et al 2005). Drug interactions that
affect hepatic metabolism may cause toxicity by inhibiting detoxification, including
activation, or inhibiting biliary excretion (DeLeve, 2003). The use of anticancer
drugs in combination regimens and supportive drugs administered during
chemotherapy is an example of co-medication. Co-administration of anti-cancer
agents with other therapeutics to treat or prevent the common side effects associated
with a particular drug or drug combination is extremely common. Examples include
steroids (e.g. dexamethasone), antiemetics (e.g. domperidone, ondansetron,
grandisteron), antibiotics (e.g. co-amoxiclav, clarythromycin), anti-fungal agents
(e.g. fluconazole, ketoconazole). There have been case reports of hepatotoxicity
following some of these drugs, such as jaundice with ondansetron (Vermill and
Judson. 1994). If hepatotoxicity is detected following chemotherapy, consideration
should be given to the co-administered drugs when determining the cause and
possible interactions.
1.3.2 Hepatotoxicity during clinical development of novel anti
cancer agents
The drugs listed in table 1.6 have all been licensed for the treatment of various types
of cancer, and much of the evidence of their hepatotoxic potential has arisen during
late-phase clinical trials or after licensing. There are also reports of newer anti¬
cancer agents that have passed pre-clinical testing and demonstrated hepatotoxicity,
which may be dose-limiting, during phase one clinical trials. Examples of these can
be seen in table 1.7.
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Table 1.7: New anti-cancer agents that have had effects on LFTs and/or
caused liver injury during clinical trials
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The purpose of the studies presented in this thesis is to detect hepatotoxicity at an
earlier stage of drug development.
Key issues in predictive toxicology are (i) whether in vivo responses can be predicted




1.4 AIMS AND OBJECTIVES OF THIS STUDY
There are several examples of anti-cancer agents that were not anticipated to cause
hepatotoxicity following pre-clinical testing, but have caused hepatotoxicity in
humans during clinical trials. More toxicity is accepted with anticancer agents than
with other classes of drugs. However, as the number of drugs available to treat the
wide range of cancers is increasing, tolerance of severe toxicities should not be
necessary. Early detection of hepatotoxicity caused by chemotherapy would be
beneficial, and potentially allow unsuitable drugs to be eliminated at an earlier stage
of drug development. This would not only benefit patients, but also help to reduce
the cost of the expensive drug development process.
The primary aim of this project is therefore to improve early detection of drug-
induced hepatocyte toxicity caused by anti-cancer agents, using in vitro models
including human hepatocytes, immortalised hepatocytes and hepatoma cell lines.
The main objectives are:
i) to determine the most appropriate in vitro model by considering cell
phenotype (morphology, proliferation) and genotype (mRNA
expression);
ii) to optimise the most promising model;
iii) to determine the most appropriate in vitro model by comparing the
response of each cell line to selected anti-cancer agents;
This thesis will examine several in vitro models and will first address the intrinsic
parameters of the selected models. Hepatocytes have been used for investigation of
the hepatotoxic potential of other classes of drugs; however their usefulness in
oncology has not yet been fully evaluated. Anti-cancer agents with a known
hepatotoxic or non-hepatotoxic profile have been selected for drug treatment of the
cells and determination of cytotoxicity. There are numerous assays available to
detect cell death in vitro, and it is likely that liver cell death induced by anticancer
agents will be detected with some of them. DNA damaging agents induce cytotoxic
effects; therefore cell death will be considered as the endpoint for evaluating drug-
induced hepatotoxicity. Instead of aiming to detect an absence of toxicity, it is more
60
Introduction
interesting to determine the difference between an active concentration killing
tumour cells and achievable in the clinic, and a toxic concentration, killing
hepatocytes. A key strategy is therefore to set up assays that will assess drug-
induced liver injury based on the differential between normal and cancer cells.
Therefore the cancer type in which the anticancer drugs are intended to treat will also
be investigated. The "in vitro therapeutic index" may be able to discriminate which
drug is likely to induce significant liver toxicity, at predicted therapeutic doses. The
contribution of oncosis and/or apoptosis to cytotoxicity, and early detection of cell
damage during drug exposure will also be considered using assays to measure
caspase activation and ATP levels within drug-treated cells.
This approach is intended to allow the selection of the most appropriate in vitro cell
model to detect anti-cancer drug toxicity to the liver. Features to be considered
include ease of use, cost, reproducibility, and the predictive value of the models.
Ultimately, an in vitro system that bears the greatest resemblance to the response of
human liver to cancer chemotherapy is desired.
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2.1 INTRODUCTION
There are several cell types and systems that have previously been assessed for
studying liver toxicity, including isolated perfused livers, tissue slices, isolated cells
and cell organelles, membranes or enzymes, as described in section 1.2.4.
Interspecies differences have been reported for a number of liver enzymes involved
in drug metabolism and are of particular importance and relevance when considering
the models of choice to represent the liver in these studies. Therefore in this study,
solely cells of human origin that may represent hepatocytes were selected. Several in
vitro models were studied: hepatoma cell lines, an immortalised hepatocyte cell line,
fresh hepatocytes, and cryopreserved hepatocytes. The different in vitro models
were assessed for expression of liver-specific genes required for essential liver-
specific functions. Cell morphology, cell growth, and viability were also evaluated
to compare the characteristics of the different models. Fresh hepatocytes have been
described as the 'gold standard' for in vitro testing of drug candidates (Roymans et
al, 2004). Therefore, because the hepatocytes used in these studies are sourced
externally and transport is a requirement, variables including time and media for their
transport were evaluated.
2.2 CELL MORPHOLOGY
Initially cell morphology was examined using light microscopy. Cell morphology
and function are closely related characteristics (Wilkening et al, 2003). All of the
cell types considered adhere to tissue culture plastic, and form a monolayer culture
although some are more adherent than others. Cells were plated in the appropriate
media and allowed to attach to tissue culture plastic before photographing. The
hepatocytes and immortalised hepatocytes require the presence of an extra-cellular
matrix to maintain their morphology in culture (Kudryavtseva and Engelhardt, 2003),
and this was incorporated in the study design. The time between plating and
photographing varied for the different cell types.
2.2.1 Hepatocytes
The morphology of hepatocytes from all donors was examined under the microscope
after plating and at a maximum of 24-hour intervals throughout the course of the
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experiments (see figure 2.1 for an example from donor 12). They were strongly
attached to the collagen-1 pre-coated plastic and formed cell-cell contact. As
expected, they were polygonal and had single or double nuclei.
After recovery from liquid nitrogen, the cryopreserved hepatocytes that attach to the
plate look similar to the fresh hepatocytes, also being polygonal and having single or
double nuclei (see figure 2.2). However, in 1 of the 4 donors studied, following
resuspension the cells failed to attach to the tissue culture plastic. Furthermore, when
20000 viable cells that have been cryopreserved are plated per well it appears that
fewer cells attach than when 20000 viable fresh cells are plated per well
(observations suggested <50% cells attached). This suggests that the
cryopreservation and thawing process alters the cell membrane and affects cell
attachment, and has been reported previously (Garcia et al, 2003; Li et al, 1999).
64
Characterisation and optimisation of cell models
Figure 2.1: Morphological comparison of fresh hepatocytes in living
monolayers, 12- and 108- hours after plating
20000 viable fresh hepatocytes (from donor number 12) were plated per well in
supplemented WEM and photographed after attachment and before cytotoxicity
assays begun (12 hours after plating; A), and at the end of the 96-hour cytotoxicity
time-course experiments (108 hours after plating; B). To photograph the cells, media
was removed and attached cells photographed using a Diavert microscope at x200
magnification.
Figure 2.2: Morphological comparison of attached cryopreserved hepatocytes
in living monolayers
20000 viable cryopreserved hepatocytes (from donor C3 (A) and donor C4 (B)) were
plated per well in supplemented WEM and left to attach (for approximately 6 hours).
Media was then removed and attached cells were photographed using a Diavert
microscope at x200 magnification.
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2.2.2 Immortalised hepatocyte cell line
The immortalised hepatocyte cell line, THLE-2, was grown in a coated tissue culture
flask for 2 days before photographing. THLE-2 cells were dissimilar to polygonal
fresh hepatocytes, and were more epithelial-like in nature (figure 2.3).
Figure 2.3: Immortalised hepatocyte cell line, THLE-2
One vial of THLE-2 cells (approximately 2xl06 cells) was recovered from liquid
nitrogen into a T25 tissue culture flask. After 2 days the flask was confluent, and the
cells were photographed using a Diavert microscope at x200 magnification.
2.2.3 Hepatoma cell lines
When considering the hepatoma cell lines, there were marked morphological
differences not only between the cell lines, but also between the cell lines and
hepatocytes. Figure 2.4 shows photographs of the panel of hepatoma cell lines. The
Hep 3B2.1-7 cell line was epithelial-like and adhered well to the tissue culture
plastic. Hep G2 cells also had an epithelial-like morphology, and contained only one
nucleus (Wilkening et al, 2003). Huh-7D12 and PLC/PRF/5 were also epithelial-like
and formed distinct colonies. SK-HEP-1 cells initially growed in aggregates around
the few cells that manage to adhere to the plastic after which cells did grow in to
bundles of spindle-shaped cells and formed a complete monolayer.
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Figure 2.4: Morphological comparison of hepatoma cell lines in living
monolayers
Cell lines were plated in supplemented DMEM for 24 hours before photographing. 1
x 106 Hep 3B2.1-7 (A), Hep G2 (B), Huh-7D12 (C), PLC/PRF/5 (D), and SK-HEP-1
(E) cells were plated per 25cm2 petri dish and media removed before taking
photographs using a Diavert microscope at x200 magnification.
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2.3 VIABILITY OF HEPATOCYTES
During the procedure of isolating hepatocytes from liver, some of the cells suffer
membrane damage and were therefore not viable. The process of cryopreservation
reportedly further decreased the percentage of viable cells (Terry et al, 2005). The
vital dye, trypan blue, is routinely used following hepatocyte isolation, and following
the recovery of cells after cryopreservation, in order to determine the proportion of
viable hepatocytes.
2.3.1 Fresh human hepatocytes
2.3.1.1 Initial viability and loss of viability during transport
The viability of isolated hepatocytes was determined immediately following isolation
by the UKHTB, and at arrival in the laboratory in Edinburgh. Table 2.1 shows the
percent cell viability after isolation, after transport, and the loss of viability during
transport. The mean cell viability before and after transport was 82% and 67%
respectively (medians were very similar to the means at 82% and 66% respectively),
ranging from 70-92% initially, and 54-80% after transport. The median viability
before and after transport were significantly different (p<0.0001) as determined by
the non-parametric Wilkoxon matched pairs test.
Table 2.1: Fresh hepatocyte viability at isolation and after transport
% CELL % CELL % LOSS OF
SAMPLE I.D. VIABILITY WHEN VIABILITY AFTER CELL
ISOLATED TRANSPORT VIABILITY
DONOR 1 83 65 18
DONOR 2 76 59 17
DONOR 3 70 54 16
DONOR 4 81 66 15
DONOR 5 79 60 19
DONOR 6 83 65 18
DONOR 7 85 77 8
DONOR 8 89 76 13
DONOR 9 80 62 18
DONOR 10 81 71 10
DONOR 11 82 67 15
DONOR 12 92 68 24
DONOR 13 82 80 2
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The influence of donor factors on hepatocyte viability was assessed. Table 2.2
shows results of the statistical analysis performed. Donor age, sex or smoking status
had no significant effect on hepatocyte viability both at isolation and after transport.
Initial hepatocyte viability following isolation was found to be significantly
correlated with hepatocyte viability after transport (Spearman correlation, r=0.7107,
p=0.0065). However, the initial viability did not predict the extent of viability loss
(Spearman correlation, r=-0.1021, p=0.74).
Table 2.2: Influence of donor demographics on cell viability
ns= non-significant (p>0.05)























2.3.1.2 Viability during culture
The MTT assay, which is described in methods section 6.3.3, provides a measure of
cell viability and was used for all of the cytotoxicity testing with fresh hepatocytes.
OD values in control wells were monitored over the timecourse to be used in the
cytotoxicity assays: 24 hours after the start of drug treatment (36 hours after
plating), and 96 hours after the start of drug treatment (108 hours after plating). The
MTT assay data suggest that the viability of hepatocytes from 9 out of 13 donors
(69%) increased, and from 4 out of 13 donors decreased, over the 108-hour time
period (figure 2.5). The MTT assay was used after plating of hepatocytes to detect
viable cells, and has been recommended previously for the detection of hepatocyte
viability in culture (Mitry et al, 2002). This method of measuring cell viability is
more informative than using trypan blue as it measures cellular activity and requires
functional mitochondria. When examining the MTT over time in culture, the OD
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increased in hepatocytes from 9/13 donors and decreased in 4/13, over the time-
course of the experiment. There are several possible explanations for this
observation. The MTT assay measures a function of the mithochondria, therefore
any change in the number or size of mitochondria in cells (Nagata, 2006) would alter
the MTT conversion capability of the hepatocytes. The ability of cells to convert
MTT over time in culture may also vary depending on the availability of required
factors for metabolic conversion of MTT. The difference in attachment efficiency
may explain the actual differences in OD values, but attachment efficiency was not
measured in our experiments. For each experiment carried out using hepatocytes,
each treatment had a corresponding set of control wells that were used to allow
comparison of all the data, therefore the change in MTT conversion in control wells
over time was taken in to account. Poor attachment to the tissue culture plastic could
explain lower OD values obtained from the MTT assay, as number of functioning
mitochondria will be lower the fewer the number of cells present. No significant
correlation was found between initial hepatocyte viability or viability after transport
and MTT OD either 36- or 108-hours after plating (Spearman correlation). The













Figure 2.5: Cell viability determined by MTT assay overtime in culture
20000 viable hepatocytes were plated per well and OD as determined by MTT assay
was measured 36 and 108 hours after plating, as described in materials and methods.
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2.3.2 Cryopreserved human hepatocytes
Cryopreserved hepatocytes from 4 donors were also obtained from the UKHTB and
varied from donor to donor in terms of their viability and attachment. Viability at
isolation ranged from 85-91% and at recovery after thawing from 41-59%
(mean=49%) (See table 2.3), compared with 54-80% viability after transport in fresh
hepatocytes. One of the main considerations for maintenance of hepatocyte-specific
functions in culture, and ease of use for in vitro assays, is the attachment of cells to
tissue culture plastic.
Hepatocytes from donors C2 and C4 were recovered from liquid nitrogen, and 6
hours later, good cell attachment to the plate was observed. The cells that were
floating were removed and none of the floating fraction was viable as determined by
trypan blue. The attached cells were used for cytotoxicity testing and RNA was also
prepared from attached cells.
Sufficient attachment of hepatocytes from donor C3 (6 hours after recovery of cells
from liquid nitrogen) allowed cytotoxicity testing. However, there were not enough
cells available to extract RNA. Finally, hepatocytes from donor CI when examined
24-hours after recovery from liquid nitrogen showed that cells had failed to attach to
the tissue culture plastic. Trypan blue determination of cell viability revealed that
none of the floating cells were viable.














CRYO 1 (#5460) 91 49 42
CRYO 2 (#5514) 85 41 44
CRYO 3 (#5654) 89 47 42
CRYO 4 (#5354) 91 59 32
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2.4 CELL GROWTH CHARACTERISTICS
An important factor to consider when selecting an in vitro model to represent the
liver is the capability of the cells to proliferate. Whilst the liver does not proliferate
in humans under normal conditions, the liver does have the ability to regenerate, for
example after partial hepatectomy. The use of cell lines originating from the liver
such as hepatoma cell lines to represent the fresh hepatocytes is based on the
retention of some biochemical features of hepatocytes, and their capability of
unlimited proliferation. There are technical advantages of using proliferating over
non-proliferating cells for in vitro studies to represent the liver, and two different
types of proliferating cell lines are considered here. For this study, the growth
parameters evaluated were the doubling time, the plating efficiency (fraction of cells
adhering to substratum), and the optimal plating density for 96-hour cytotoxicity
assays in 96-well plates.
2.4.1 Hepatoma cell lines and immortalised hepatocytes
The doubling times for the five hepatoma cancer cell lines selected did not vary
greatly from one another (table 2.4). Fluh-7D12, HepG2 and SK-HEP-1 had similar
doubling times (39-40 hours), whereas PLC/PRF/5 proliferated more rapidly
(doubling time 33 hours) and Hep3B more slowly (54 hours). The immortalised
hepatocyte cell line THLE-2 had a doubling time of 53 hours, and due to preliminary
observations, a higher starting density of cells (20000 cells per well) was required for
this replication rate otherwise the cells do not appear to proliferate. The plating
efficiencies also vary (50-88% for cells lines and -100% for THLE-2), as did the
time to reach confluence, which resulted in different seeding densities for the
cytotoxicity assays.
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Huh-7 D12 40 88 5000
HepG2 39 71 5000
Sk-Hep-1 40 50 5000
Hep3B 54 77 5000
PLC/PRF/5 33 73 3000
THLE-2 53 oo7 20000
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2.5 GENE EXPRESSION OF IN VITRO MODELS
The expression of genes with particular relevance to the liver (see table 2.5) was
assessed by qRT-PCR. Several liver-specific genes were selected to compare the
gene expression profile of the different cell lines to fresh hepatocytes. Alpha
fetoprotein (AFP) was also evaluated as it can be used as a marker in humans for the
detection of hepatocellular carcinoma and therefore is likely to be expressed in
hepatoma cell lines. In order to evaluate the level of stress induced in the
hepatocytes due to transport and plating, HIFla, HSP70 and p21 gene expression
was determined as these are all genes that may be upregulated in response to stress
stimuli. Gene expression was determined in all of the liver models considered in
these studies (fresh, cryopreserved and immortalised hepatocytes and hepatoma cell
lines). mRNA expression was detected by qRT-PCR in fresh hepatocytes from 13
donors, cryopreserved hepatocytes from 2 donors, 5 hepatoma cell lines and the
immortalised hepatocyte cell line, THLE-2.
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2.5.1 Quantitative RT-PCR set-up
One of the critical requirements in order to produce reliable and reproducible qRT-
PCR data is the RNA quality. Therefore, the quality of the RNA extracted from the
hepatocytes was verified by miniaturised electrophoresis using an Agilent
Bioanalyser with the RNA 6000 Nano Assay (see chapter 6). All hepatocyte RNA
samples had RNA integrity numbers (RIN) between 6.7 and 9.3, with the exception
of one sample from donor 10 (H24d) (RIN = 2.5), which was excluded from the
analysis of gene expression.
Another issue to be considered for qRT-PCR is the design and optimisation of
suitable primers. The primers were designed using primer3 software (see chapter 6).
Optimisation was carried out using the melting curve of the PCR products to ensure a
single product (Figure 2.6 A), and product size was verified by separating products
by agarose gel electrophoresis (see chapter 6).
Standard curves were established using a commercial supply of adult human liver
RNA for all genes of interest, except AFP for which commercially available pooled
foetal liver RNA was used. A standard curve was generated from the cycling data
during the exponential phase of the PCR reaction (see figure 2.6 B) and used to
determine gene expression in samples. The range of linearity of the standard curves
and the efficiency of the amplification were verified for each primer set (see table
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2.5.2 Reference Gene Selection
Accurate determination and quantification of gene expression requires normalisation
of the results using the expression of an ubiquitously expressed internal standard,
reference gene, or housekeeping gene (HKG) (Blanquicett et al., 2002; Bustin and
Nolan, 2004) (see table 2.5). The accurate quantification of a true reference gene
allows the normalisation of differences in the amount of amplifiable RNA or cDNA
generated in different samples by different amounts of starting material; the quality
of the starting material, and; differences in RNA preparation and cDNA synthesis,
since the reference gene is exposed to the same preparation steps as the gene of
interest (Radonic et al., 2004). However, several studies (e.g. Blanquicett et al.,
2002) have suggested that many HKGs demonstrate variability between different
tissues and/or disease states. An ideal reference gene would be constantly
transcribed in all cells and tissues, and its RNA transcription level would not be
altered by internal or external influences. When dealing with patient samples, it is
recommended to evaluate several reference genes and to normalise the results by the
geometric mean of the most appropriate ones (Vandesompele et al., 2002).
Significant variation in the expression of reference genes between carcinomatous and
normal liver samples has been reported (Blanquicett et al., 2002) and has
implications for the studies presented here. Therefore selection and validation of
possible reference genes was undertaken.
Three reference genes were tested: 18S rRNA, P2-microglobulin (P2-M) mRNA, and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA. 18S is ribosomal
RNA (rRNA) and together with 28S makes up 80% of total RNA, is transcribed by a
different polymerase from mRNAs, and its level is less likely to fluctuate with the
test sample (Huggett et al, 2005). P2-M is involved in the immune response, and is
the P chain of major histocompatibility complex class I molecules. GAPDH is a
glycolytic enzyme that is widely cited and commonly used as a housekeeping gene
(Huggett et al, 2005).
B2M, GAPDH and 18S mRNA expression was determined in hepatocyte samples
from donors 1-11. The resulting expression was analysed using GeNorm software
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(Vandesompele et al., 2002). and a 'normalisation factor' was generated using the
B2M. GAPDH and 18S mRNA expression data from hepatocyte donors 1 to 11.
Based on the GeNorm analysis B2M and GAPDH mRNA expression was found to be
less variable than 18rRNA expression between samples (figure 2.7), therefore the
geometric mean of GAPDH and B2M was also calculated. The gene or combination
of genes that shows least variability between samples should be selected to normalise
the gene expression data for the genes of interest. For practical considerations and
accuracy the geometric mean of the 2 reference genes with least variability between
samples (GAPDH and B2M), was calculated for each sample and used to normalise
the gene expression data (see figure 2.7). It should also be noted that the geometric
mean is better than the arithmetic mean for this purpose because the former controls
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Figure 2.7: Comparison of reference genes expression in hepatocytes
18S, B2M, and GAPDH mRNA expression was determined by qRT-PCR in
hepatocytes from donors 1-11. The geometric mean of B2M and GAPDH, and the
normalization factor as determined by Genorm software is also plotted.
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2.5.3 Expression of liver-specific genes in fresh hepatocytes
The expression of a selection of liver-specific genes (see table 2.5) was determined
in fresh hepatocytes from 13 donors at two time-points: after transport and arrival in
Edinburgh, and 12 hours after arrival, following plating in collagen-I pre-coated
tissue culture flasks. The mean gene expression decreased from after transport to
after plating for all investigated genes except CYP1A1, the expression of which was
maintained, and ABCB1 the expression of which increased following plating. For all
genes except CYP1A1, hepatocytes from the majority of donors had expression >1
when compared to the standard liver RNA that was used for relative quantification.
Possible reasons for this are discussed in section 2.7. For several of the investigated
genes in hepatocytes from the majority of donors, expression was maintained >1
after plating and therefore at the start of drug treatment. The examination of
individual samples revealed that the expression of all genes except ABCB1
decreased in expression between arrival and overnight plating in hepatocytes from
the majority of donors.
Normalised a-1-antitrypsin mRNA expression (see figure 2.8) ranged from 0.63 to
5.10 in fresh human hepatocytes before plating, and from 0.39 to 2.10 12-hours
following plating. For all donors (excluding donors 4 and 8 in which expression
increased, and donor 10 for which sample H24d was not analysed) AAT mRNA
expression decreased between the two time-points. In hepatocytes from 50% of
donors, albumin mRNA expression was >1 at the start of drug treatment and
therefore at a higher level than in the commercially available reference RNA.
Normalised albumin mRNA expression ranged from 0.63-5.6 in fresh human
hepatocytes before plating, and from 0.22-2.6 12-hours following plating and
transthyretin ranged from 0.19 to 3.3 before plating, and from 0.08 to 2.5 12-hours
following plating (see figure 2.8). For all donors (excluding donor 10 for which
sample H24d was not analysed) albumin and TTR mRNA expression decreased
between the two time-points. Flowever, it should be noted that for 7 out of 12 donors
albumin mRNA expression was >1 at the start of drug treatment and therefore at a
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higher level than in the commercially available reference RNA. Conversely, for 7
out of 12 donors TTR mRNA expression was <1 at the start of drug treatment.
Normalised CYP3A4 mRNA expression ranged from 0.02 to 12 in fresh human
hepatocytes before plating, and from 0.24 to 4.4 12-hours following plating, with
CYP3A4 not being detectable in hepatocytes from donor 5 12-hours following
plating (see figure 2.8). Normalised PXR mRNA expression ranged from 1.7 to 8.3
in fresh human hepatocytes before plating, and from 0.95 to 3.6 12-hours following
plating (see figure 2.8). For all donors (excluding donor 10 for which sample H24d
was not analysed) CYP3A4 and PXR mRNA expression decreased between the two
time-points. For 8 out of 12 donors CYP3A4 and PXR mRNA expression >1 at the
start of drug treatment and therefore at a higher level than in the commercially
available reference RNA.
The expression of the UGT2A* and UGT2B* subfamilies of UDP-GTs was also
analysed by qRT-PCR (see figure 2.8). Normalised UGT1A* mRNA expression
ranged from 0.50 to 3.9 in fresh human hepatocytes before plating, and from 0.15-2.0
12-hours following plating. Normalised UGT2B* mRNA expression ranged from
0.78 to 3.70 before plating, and from 0.21-2.50 12-hours following plating. For all
donors (excluding donor 8 which increased, and donor 10 for which sample H24d
was not analysed) UGT1A* and UGT2B* mRNA expression decreased between the
two time-points. For 7 and 9 out of 12 donors for UGT1A* and UGT2B*
respectively, mRNA expression was <1 at the start of drug treatment and therefore at
a lower level than in the commercially available reference RNA.
Normalised CYP1A1 mRNA expression (see figure 2.8) ranged from 0.14 to 3.03 in
fresh human hepatocytes before plating, and from 0.03 to 5.60 12-hours following
plating. For all donors (excluding donors 2, 5 and 13 in which expression increased,
and donor 10 for which sample H24d was not analysed) CYP1A1 mRNA expression
decreased between the two time-points. For 10 out of 12 donors CYP1A1 mRNA
expression was <1 at the start of drug treatment and therefore at a lower level than in
the commercially available reference RNA.
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The only gene whose expression increased following plating in all donors (excluding
donor 10 for which sample H24d was not analysed) was ABCB1. Normalised
ABCB1 mRNA expression (see figure 2.8) ranged from 0.43 to 5.40 in fresh human
hepatocytes before plating, and from 4.0 to 18.0 12-hours following plating. For all
donors ABCB1 mRNA expression was >1 at the start of drug treatment and therefore
at a higher level than in the commercially available reference RNA.
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Figure 2.8: Gene expression in fresh human hepatocytes
mRNA expression of liver-specific genes as determined by qRT-PCR in fresh human
hepatocytes from donors 1-13 before and 12-hours after plating. Results are
expressed as normalized gene expression per time point per donor. A) demonstrates
the interindividual variability and the red line represents the mean of 13 donors. B)
demonstrates before and after plating gene expression data for each donor.
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2.5.4 Expression of liver-specific genes in cryopreserved
hepatocytes
The gene expression analysis was only possible in cryopreserved hepatocytes from
two donors, due to the limited number of cryopreserved hepatocytes available for
RNA extraction. The results are presented in figure 2.9 and are summarised in table
2.7 below. In summary cryopreserved hepatocytes from donors C2 and C4
expressed detectable levels of all the liver-specific genes investigated (except AFP,
as expected). ABCB1, CYP3A4, UGT1A* and UGT2B* mRNA expression levels
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Figure 2.9: Gene expression in cryopreserved human hepatocytes
mRNA expression was determined by qRT-PCR in hepatocytes from donors C2 and
C4 and normalised to the geometric mean of B2M and GAPDH. The red line
represents the mean normalised mRNA expression from the 2 donors.
Table 2.7: Gene expression in cryopreserved hepatocytes

















C2 13 0.29 nd 0.06 0.02 0.12 0.05 0.18 0.17
C4 3.8 0.37 nd 0.10 2.5 0.14 0.24 0.33 0.26
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2.5.5 Expression of liver-specific genes in immortalised and
hepatoma cell lines
The liver-specific genes that were assessed in the fresh and cryopreserved
hepatocytes were also investigated in 5 hepatoma cell lines and in THLE-2 cells. An
additional gene was also investigated, namely alpha-fetoprotein, in the cell lines.
AFP is produced during human embryonic development by the foetus and is
detectable in the serum of pregnant women because it crosses the placental barrier.
Levels are undetectable after a year of age in humans and AFP is not detectable in
healthy adults. AFP expression can increase in the presence of hepatocellular
carcinoma or germ cell tumours and is used as a marker in patients these diseases.
High AFP levels suggest the presence of liver cancer, and AFP may be expressed in
hepatoma cell lines. AFP expression was assessed in all of the models investigated
in this project. Four of the hepatoma cell lines (FlepG2, Flep3B, PLC/PRF/5 and
Fluh-7D12) expressed AFP, with HepG2 and FIuh-7D12 having the highest levels of
expression, as can be seen in figure 2.10. AFP expression was not detectable in any
of the hepatocytes or in the THLE-2 cell line.
Generally expression levels were lower in the hepatoma cell lines than had been
identified in the fresh hepatocytes. Albumin mRNA expression was not detectable in
PLC/PRF/5 or SK-HEP-1 and ranged from 0.02 (relative to HKG) in Huh-7D12 to
0.19 in Hep G2 cells. AAT was expressed at a low level (0.02) in THLE-2 cells, and
in the hepatoma cell lines mRNA expression was not detectable in SK-HEP-1 and
ranged from 0.05 in Huh-7D12 to 0.58 in Hep G2 cells. CYP1A1 was expressed at a
low level (0.03) in THLE-2 cells, and in the hepatoma cell lines mRNA expression
was not detectable in SK-HEP-1 and ranged from 0.01 in Hep G2 to 0.45 in
PLC/PRF/5 cells. CYP3A4 was not detectable in THLE-2 cells, or in any of the
hepatoma cell lines except for Hep 3B2.1-7 cells (0.01). TTR mRNA expression
was not detectable in SK-HEP-1, PLC/PRF/5 or Hep 3B2.1-7 cells and was
expressed at low levels in Huh-7D12 and HepG2 (0.01 and 0.04 respectively).
UGT1A* and PXR mRNA expression was not detectable except in Hep G2 cells
(0.01 and 2.60 respectively). UGT2B* mRNA expression ranged from undetectable
in SK-HEP-1 and PLC/PRF/5 to 0.35 in Hep 3B2.1-7 cells. ABCB1 mRNA
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expression was not detectable in SK-HEP-1 or PLC/PRF/5 and ranged from 0.30 in
HepG2 to 0.60 in Hep 3B2.1-7 cells. ALB. CY3A4. TTR. UGT1A*, UGT2B*, PXR
















Figure 2.10: Gene expression in 5 hepatoma cell lines and immortalised
hepatocyte cell line THLE-2
mRNA expression was determined by qRT-PCR in 5 hepatoma cell lines and THLE-
2 and normalised to the geometric mean of B^M and GAPDH.
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2.5.6 Comparison of gene expression between in vitro models
A selection of 10 genes whose expression is particularly relevant to the liver has
been investigated. There was marked variability in mRNA expression of each gene
between the models and the range of normalised gene expression is presented in
figure 2.11. Fresh hepatocytes from all 13 donors expressed all of the liver-specific
genes investigated (except AFP, as expected). In general, for the genes investigated,
mRNA expression was higher in fresh hepatocytes from all donors than in any of the
other models investigated.
With regards to the fresh hepatocytes, there is inter-donor variability for all genes
both before plating (after transport) and after plating (at the start of drug treatment)
(figure 2.11). For the liver-specific genes investigated, the mean expression from all
fresh hepatocyte donors is higher immediately after transport than after plating, with
the exception of CYP1A1 and ABCB1. Gene expression in the cryopreserved
hepatocytes is less than in fresh hepatocytes both before and after plating and lower
than that in the reference RNA for all genes except ABCB1 and CYP1A1. In all the
hepatoma cell lines investigated, expression of all genes was lower than the mean
expression in fresh hepatocytes (before and after hepatocyte transport) and lower
than in the reference RNA. Expression of the investigated genes varied widely
between the hepatoma cell lines. AFP expression was detected in the hepatoma cell
lines, and the highest expressers were HepG2 and Huh-7D12 when compared with
all the other models. HepG2 expressed all genes except CYP3A4, but only AAT and
UGT2B* mRNA expression levels were comparable with those of fresh hepatocytes,
with all of the other genes being expressed at a lower level. Fluh-7D12 expressed
all of the liver-specific genes investigated, with the exception of CYP3A4 and
UGT1A*. For all genes except CYP1A1, mRNA expression was lower than in the
fresh and cryopreserved hepatocytes from all donors. Hep3B2.1-7 expressed all
liver-specific genes except TTR and UGT1A*, and for all genes the expression was
lower than that in the majority of fresh hepatocytes. PLC/PRF/5 had only very low
expression of AAT, AFP and CYP1A1, and SK-HEP-1 expressed none of the
investigated genes. The only genes that were detectable in the TF1LE-2 cell line were
87
Characterisation and optimisation of cell models
AAT and CYP1A1, and mRNA expression was extremely low (0.02 and 0.03
respectively).
In summary, the fresh hepatocytes recapitulate the expected expression of the
selected genes after plating better than any of the other models investigated.
Therefore if a decision was to be made as to the most appropriate in vitro model to
represent the liver solely based on the gene expression analysis, fresh hepatocytes
would be selected. There is variation in expression of all genes between donors and
this is representative of the situation in humans where inter-individual variation in
gene expression occurs.
Figure 2.11: Gene expression in hepatocytes before and after plating,
cryopreserved hepatocytes and hepatoma cell lines
mRNA expression of liver-specific genes as determined by qRT-PCR in fresh human
hepatocytes from donors 1-13 before (A) and 12-hours after (B) plating,
cryopreserved hepatocytes from 2 donors (C), and in 5 hepatoma cell lines (D).
Results are expressed as mean and standard deviation of normalised gene expression.
The red line indicates a normalised gene expression value of 1, equivalent to the
expression in the liver standard RNA.
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2.5.7 Expression of stress-induced genes in hepatocytes
During liver resection, the cells are subjected to several stress stimuli, including
innate and antigen-independent stresses. These may include the hepatic response to
systemic cytokines activated in response to the stress of surgery or brain death, and
hypothermia and preservation injury of cold ischaemia (Borozan et al, 2006).
Furthermore, the isolation of hepatocytes from the liver with collagenase may result
in stress response and hypoxia. In order to determine the extent of stress response
induced in the fresh hepatocytes used in these studies, the expression of hypoxia-
inducible factor 1, alpha subunit (HIF1A), heatshock protein 70kDa protein 1A
(HSP70) and Cyclin-dependent kinase inhibitor 1A (CDKN1A, p21. Cipl) was
determined.
p21 is involved in cell cycle regulation and is a target gene for p53 during apoptosis
(Dotto, 2000). A study by Borozan et al. (2006) demonstrated that p21 was
upregulated during liver resection, compared to when the liver was first exposed and
confirmed this finding by both RT-PCR and microarray techniques. The authors
suggest that p21 may have an important role in regulating hepatocyte cell cycle
progression in liver regeneration (Crary et al, 1998). Heat shock proteins are a group
of proteins whose expression may be increased in response to elevated temperature
and other 'stress' conditions, and Borozan et al (2006) also demonstrated that HSP-
70 was upregulated in response to acute hepatic stress. The isolation of hepatocytes
from the liver with collagenase may also result in hypoxia. HIF1A functions as a
master transcriptional regulator of the adaptive response to hypoxia, and under
hypoxic conditions activates the transcription of more than 60 genes (Lee et al,
2004).
2.5.7.1 HIF1A, p21 and HSP-70 mRNA expression in fresh
hepatocytes
In all pairs of hepatocytes samples, HIF1A expression increased between arrival and
12-hours after plating (see figure 2.12A), with mRNA expression ranging from 3.5 to
7.3 after transport, and from 13.8 to 44.5 after plating. Similarly, in all pairs of
hepatocyte samples with the exception of donor 12, p21 expression increased
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between arrival and 12-hours after plating (see figure 2.13A), with mRNA
expression ranging from 3.15 to 11.76 after transport, and from 6.48 to 14.87 after
plating. Finally, heat shock 70kDa protein (FISP70) expression increased in all pairs
of hepatocytes samples from initially after transport to 12-hours after plating (see
figure 2.14A), from 0.27 to 1.11 after transport, to 0.38 to 12.72 after plating. The
difference in gene expression after transport and after plating for all genes was found
to be statistically significant with a non-parametric Wilcoxon matched pairs test (p=
0.0005, 0.0093 and 0.0005 for HIF1A, p21 and HSP-70 respectively). In all cases,
the gene expression at arrival did not correlate with gene expression after plating
(figures 2.12B, 2.13B and 2.14B).
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Figure 2.12: HIF1A mRNA expression in fresh hepatocyte samples
Gene expression determined after qRT-PCR analysis. HIF1A expression was
determined following arrival of the hepatocytes in Edinburgh, and after plating for 12
hours (A). Results are normalised to the geometric mean of GAPDH and P2M, and
are mean of triplicates. The relationship between normalised H1F1A expression after
transport, and normalised HIF1A expression after plating was also investigated (B).
91




































0 5 10 15
normalised p21 expression after transport
Figure 2.13: p21 mRNA expression in fresh hepatocyte samples
Gene expression determined after qRT-PCR analysis. p21 expression was
determined following arrival of the hepatocytes in Edinburgh, and after plating for 12
hours (A). Results are normalised to the geometric mean of GAPDH and P2M, and
are mean of triplicates. The relationship between normalised p21 expression after
transport, and normalised p21 expression after plating was also investigated (B).
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Figure 2.14: HSP-70 mRNA expression in fresh hepatocyte samples
Gene expression determined after qRT-PCR analysis. HSP-70 expression was
determined following arrival of the hepatocytes in Edinburgh, and after plating for 12
hours (A). Results are normalised to the geometric mean of GAPDH and (32M, and
are mean of triplicates. The relationship between normalised HSP70 expression after
transport, and normalised HSP70 expression after plating was also investigated (B).
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2.5.7.2 Stress-induced genes in cryopreserved hepatocytes
The expression of p21, HSP-70 and HIF1A was also determined in cryopreserved
hepatocytes. Normalised HIF1A and FISP-70 expression levels were similar in
cryopreserved hepatocytes from both donors, however p21 expression was higher in
donor C4 than in C2 (17.5 compared to 4.3) (see figure 2.15). Similar to the fresh
hepatocytes, mRNA expression of all stress genes investigated was higher in these
samples than in the RNA standard and also higher than the expression of liver-
specific genes. FIIF1A and p21 expression was within the same range of that in fresh
hepatocytes after plating, however the mean FISP-70 expression was higher in the


























Figure 2.15: HIF1A, FISP70 and p21 expression in cryopreserved human
hepatocytes
Gene expression determined after qRT-PCR analysis of stress in genes in
cryopreserved hepatocytes from donor C2 and C4. Results are normalised to the
geometric mean ofGAPDH and P2M, and are mean of triplicates.
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2.5.7.3 Effect of stress gene expression on hepatocyte viability
and liver-specific gene expression
Hepatocyte viability was measured at the time of isolation by the UKHTB before
transport to Edinburgh, and after transport and arrival in Edinburgh. Stress gene
mRNA expression was determined after transport to Edinburgh, and 12-hours after
plating in Edinburgh. The relationship between expression of p21, HIF1A and
HSP70 and hepatocyte viability was investigated, as it was hypothesised that the two
factors may be linked. For p21 and HIF1A no relationship between the two variables
were found. However, a significant correlation was found between HSP-70
expression after plating and viability before and after transport (Spearman correlation
r=0.6061, p-value=0.03 for the HSP-70 and viability before transport; and r=0.7418,
p-value = 0.004 for HSP-70 and viability determined after transport) (see figure
2.16). The lower the cell viability the lower the HSP-70 expression suggesting that
HSP-70 expression has a protective effect.
The relationship between the expression of stress genes and liver-specific genes was
investigated and no correlation was found between the expression of HIF1A. p21 or
HSP-70 and any of the liver-specific genes investigated.
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Figure 2.16: Correlation between HSP-70 mRNA expression and hepatocyte
viability
The relationship between hepatocyte viability before and after transport, and
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2.6 OPTIMISATION OF FRESH HEPATOCYTE TRANSPORT
The results presented in section 2.3.1 demonstrate that the viability of hepatocytes
decreased between isolation and arrival at the laboratory in Edinburgh. For several
research purposes fresh human hepatocytes must be transported to the place of
research. All of the fresh hepatocytes used in these studies for cytotoxicity testing
were sourced externally from the UKHTB (couriered to and from the airport by car
and transported by aeroplane), and were transported in the UKHTB transport media
(DMEM).
The initial viability significantly correlated with viability after transport (Spearman
correlation: r = 0.71, p-value = 0.0065) in the hepatocytes that were subsequently
used for cytotoxicity testing, after transport in DMEM (see figure 2.17). As the
initial viability increases so too does the viability after transport. Because viability is
a fundamental issue in research using fresh hepatocytes, and because transport of the
isolated cells was a requirement for these studies, the effect of the media used for the
transport and the time of transport on fresh human hepatocytes was investigated.
The impact on cell viability and gene expression was investigated, as the media used
for transport may influence maintenance of both viability and gene expression. The
best media will provide the best environment for preservation of the cells and
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Figure 2.17: Impact of initial hepatocyte viability on viability after transport
Cell viability was determined by trypan blue exclusion immediately after isolation,
and after transport in DMEM, in hepatocytes from donors 1-13.
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There are several cold storage media available for the transport of isolated organs to
be used for transplantation, and these media may also be used to transport isolated
cells. The media investigated in these studies were DMEM, Celsior (CS), and
University of Wisconsin (UW) solution. CS and UW media have been compared
previously for the preservation of whole livers to be used for transplantation, and
were found to impact on liver preservation but the authors concluded that a larger
patient cohort was required to determine the most suitable media (Cavallari et al,
2003). Abrahamse et al (2003) showed that induction of necrosis and DNA
fragmentation during hypothermic preservation of porcine hepatocytes was reduced
by storage in UW and Celsior media when compared with two other storage
solutions (histidine-tryptophan-ketoglutarate media or phosphate-buffered saline).
Following the observation of the loss of viability after transport in DMEM of the
hepatocytes used for cytotoxicity testing, a separate set of samples were transported
in 3 different media to assess the influence of the cold storage media on hepatocyte
viability and gene expression. The correlation previously established between initial
viability and viability after transport with DMEM medium was confirmed when
pooling all samples (r=0.44 and p=0.03) (see figure 2.18). In contrast to earlier
studies, when considering the subset of hepatocytes from the 11 donors tested using
three different media, there was no significant correlation found between viability at
isolation and viability after transport in any of the three transport media. This is
likely due to the greater range of initial viabilities in the samples tested.
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Figure 2.18: Impact of initial hepatocyte viability on viability after transport
Cell viability was determined by trypan blue exclusion immediately after isolation,
and after transport in DMEM hepatocytes from donors 1-13 (green) and Tl-Tll
(blue).
98
Characterisation and optimisation of cell models
2.6.1 Impact of transport media on hepatocyte viability
The impact of transport media on hepatocyte viability was assessed. Because the
initial viability varied from donor to donor, the viability determined after transport is
expressed as a percentage of the initial viability of hepatocytes isolated from that
donor. UW and CS maintained the viability of hepatocytes better than DMEM
during transport (figure 2.19). The loss in viability was 11-48% and 1-40% for CS
and UW respectively. DMEM did not maintain viability in the hepatocytes as well
as the other media, and resulted in a loss of viability of 8-85%. A non-parametric
Friedman test revealed that the median of the 3 paired groups were significantly
different (p=0.01) and with Dunn's Multiple Comparison post-test revealed that the
only pair of results when compared that were significantly different (P<0.05) were
when comparing UW and DMEM, indicating that the differences in the mean
viability (expressed as % of initial viability) between these two groups is not likely
due to chance. Therefore, for future studies UW would appear to be preferable for































Figure 2.19: Impact of transport media on hepatocyte viability
Viability of fresh human hepatocytes (donors Tl-Tl 1) after transport on melting ice
in three different transport media: CS, DMEM, or UW. Cell viability was
determined by trypan blue exclusion, and is expressed as a percentage of the cell
viability determined when the cells were initially isolated. Red lines indicate the
mean.
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2.6.2 Impact of transport time on hepatocyte viability
Because the source of the liver used for hepatocyte isolation may not be at the place
of isolation and because the cells are then transported further after isolation, the time
taken from liver resection to the final researcher receiving the isolated cells varies.
The time of transport for cells used in these studies varied from 6.5 to 26.5 hours,
and the impact of time in transport on loss of viability was investigated. Per donor
the transport time does not vary. Time of transport in UW did not significantly
correlate with loss of viability during transport (Spearman correlation coefficient
r=0.2661, p=-0.43), however there was a significant correlation between time of
transport in Celsior or DMEM and loss of viability (see figure 2.20) (Spearman
correlation r= 0.8074 and 0.6698 and p=0.003 and 0.02 for Celsior and DMEM
respectively). For hepatocytes transported in Celsior or DMEM, as the time in
transport increased, so too did the loss of cell viability. These findings confirm that
UW is the most suitable media for maintenance of hepatocyte viability during
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Figure 2.20: Time in transport vs. loss of hepatocyte viability
Cell viability was assessed by trypan blue exclusion immediately following isolation
of hepatocytes and after transport in the different sold storage media on melting ice.
The time taken from resection of the liver to receiving them is plotted against
percentage loss of hepatocyte viability (initial viability minus viability after
transport).
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2.6.3 Impact of transport time on hepatocyte gene expression
Gene expression of AAT, ALB, CYP1A1, CYP3A4, TTR, UGT1A*, UGT2B*, and
p21 was determined by qRT-PCR at the same time-points and under the same
conditions as cell viability. RNA was prepared from the 'transport' set of donors
(Tl-Tl 1) as described in chapter 6. For 8 out of 11 donors RNA was prepared at the
time of initial hepatocyte isolation at the UKHTB, as well as after transport in
Celsior, DMEM, or UW. For the other 3 out of 11 donors unfortunately this initial
RNA sample is unavailable.
The impact of time in transport on gene expression of several liver-specific genes,
and the stress-induced gene p21 was assessed. RNA was extracted from cells at the
time of initial isolation (hepatocytes mixed with Tri® reagent by staff at the
UKHTB) and from cells put into Tri® reagent after transport in Celsior, DMEM or
UW to Edinburgh. The change in gene expression was calculated as a percentage of
the expression after transport to the expression at initial isolation. There was no
significant correlation between time in transport and gene expression for any of the
genes investigated in hepatocytes transported in Celsior, DMEM or UW (see table
2.8).
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Table 2.8: Spearman correlation between time from resection and change in
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Figure 2.21: Influence of transport time on CYP1A1, CYP3A4 and UGT2B*
expression
Fresh hepatocytes were transported in Celsior solution for varying lengths of time.
Time in Celsior for transport negatively correlates with maintenance of mRNA
expression ofCYP1Al, CYP3A4 and UGT2B*.
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2.6.4 Impact of transport media on hepatocyte gene expression
The impact of transport media on hepatocyte gene expression was also investigated
(see figures 2.22 to 2.23). When comparing the effect of the 3 transport media on
hepatocyte gene expression, no statistically significant differences were found
between any of the groups using a non-parametric Friedman test. Similarly, when
comparing the change in gene expression no statistically significant differences were
found between any of the groups using a non-parametric Friedman test.
Normalised AAT expression was >1 (range= 1.1-2.4) after initial isolation in
hepatocytes from the 8 donors investigated. AAT mRNA expression varied widely
among hepatocytes stored after transport in CS from 0.4-4.1, in DMEM from 0.05 to
5.2 and in UW from 0.4-3.9. When considering the changes in gene expression for
each donor, CS maintained AAT mRNA expression after transport at 37-180% of the
initial value in hepatocytes, DMEM from 3-188% and UW from 34-166%.
Following transport AAT expression was maintained at 50% or greater of the initial
value in 6/8 donors transported in CS, 5/8 donors transported in DMEM, and 7/8
donors transported in UW. There were no significant differences detected between
hepatocytes transported in either of the 3 transport media when considering AAT
expression as determined by a non-parametric Friedman test. No differences were
found for any of the investigated genes using the same statistical testing.
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Figure 2.22: Gene expression before and after transport in Celsior, DMEM,
and UW
RNA was prepared from hepatocytes initially after isolation (donors Tl, 2, 5, 6, 8, 9, 10, ll) and after
transport in CS, DMEM or UW (Tl-ll). mRNA expression is normalised to geomean of GAPDH
and P2M.
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Figure 2.23: Gene expression before and after transport in Celsior, DMEM,
and UW
RNA was prepared from hepatocytes initially after isolation (donors Tl, 2, 5, 6, 8, 9, 10, 11)
and after transport in CS, DMEM or UW (T1-11). mRNA expression expressed as a
percentage ofmRNA expression initially after isolation in donors Tl, 2, 5, 6, 8, 9, 10, 11.
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2.7 DISCUSSION
In vitro models of the liver play a vital role in many pharmacological studies,
including those of metabolism and toxicity, and the study of toxicity is the purpose of
the work contained in these studies. These models can be used during the
development of a drug to try and detect or predict toxicity before trials of a new
compound in humans, or after use in humans to investigate mechanisms of toxicity.
The question of how relevant in vitro laboratory-based models are to the in vivo
situation in animals and to humans is often raised and requires consideration.
Different models may be more suitable depending on the investigation in question,
and the determination of the most appropriate system depends on several factors
ultimately decided by the needs of the user. When choosing a model and considering
what may be the most appropriate to represent the liver, thought must be given to
several factors. There is a need for the artificial system to accurately reflect the
situation it represents. However, in some situations the most appropriate model is
not just the most similar. Consideration should also be given to cost, ease of use, and
reproducibility and there are also ethical considerations when using tissue from
animals or humans.
One of the first considerations is whether to use an animal or human system, and
there are several studies that point towards human systems being more representative
of some toxicities detected in humans than animal-derived models. For example, for
several of the dose-limiting toxicities caused by anticancer drugs, pre-clinical testing
in rodents was found to be useful in detecting toxicities that were later revealed in
patients (7/7 haematological and 3/3 neurological toxicities detected), however pre¬
clinical testing in in vivo rodent models was not predictive for the topic of this thesis,
hepatotoxicity (Newell et al, 1999). Conversely, when studying the predictive value
of pre-clinical toxicology studies with 12 anti-cancer platinum analogues, 6 drugs
caused elevated liver enzymes in dogs and no hepatotoxicity was detected during
phase I studies demonstrating hypersensitivity of the pre-clinical model (Clark et al,
1999). These examples illustrate misleading results from pre-clinical testing of anti¬
cancer agents in animals, and suggest a need for using human systems for
investigation of in vitro detection of the hepatotoxic potential of anti-cancer agents.
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Despite the variety of models to represent the liver and the multitude of compounds
that have been tested in preclinical models, there are few published comparisons as
to which models are relevant to study hepatotoxicity in humans (Guillouzo, 1998;
Dambach et al, 2005). Following a thorough review of the literature, no publications
were found that considered the most appropriate model for detection of
hepatotoxicity caused by anti-cancer agents. Studies using one cell type in vitro (e.g.
hepatocytes) offer the substantial advantage of being a simple model, and therefore
detection of toxicity and the study of the mechanism of toxicity can be undertaken
without the influence of interfering factors. However, there are several cell types in
the liver, and undoubtedly one of the biggest problems in using only one cell type to
detect toxicity is that any interactions between cell types that may be involved in
eliciting a toxic drug response are missed. It is acknowledged that drugs can target
other cells and cause toxicity to other cells in the liver resulting in other types of
toxicity for example biliary tract toxicity (e.g. ecteinascidin-743) or veno-occlusive
disease (e.g. actinomycin). The only human models that are available for studying
more than one cell type in the liver are liver slices (Olinga et al, 1997) and co-
cultures usually of hepatocytes with another cell type. However, hepatocytes are the
predominant cell type in the liver and are a relevant model in which to test
hepatotoxicity. In vitro hepatocyte-directed toxicity models are considered in these
studies.
There are many published studies in which the mechanism of drug induced
hepatotoxicity is investigated in only one hepatoma cell line, for example
troglitazone in HepG2, paracetamol in Hep3B, and cisplatin in HepG2 (Tirmenstein
et al, 2002; Manov et al, 2002; Lu and Cederbaum, 2005) without consideration of
how the characteristics of the model may affect the results obtained. Davila et al
(1998) reviewed in vitro model systems for prediction of liver toxicity. Isolated
hepatocytes, whether they are fresh or cryopreserved, are a widely accepted model
for many types of studies, and play a vital part in much research of the liver.
Therefore, several types of model have been considered and characterised in this
chapter as possible predictors of anti-cancer drug-induced hepatotoxicity, including
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fresh and cryopreserved hepatocytes, hepatoma cell lines and an immortalised
hepatocyte cell line.
2.7.1 Hepatocyte Viability, Attachment, and Culture
Following isolation, hepatocyte viability varied from donor to donor, and between
the fresh and cryopreserved hepatocytes. The variation seen in viability of the fresh
hepatocytes used in these studies is commonly encountered in studies using fresh
hepatocytes (Wilkening et al. 2003; Blanchard et al, 2005, Ostrowska et al, 2000).
The experimental procedure used for isolation of hepatocytes from liver tissue (two-
step collagenase perfusion) involves perfusion with an isotonic buffer to remove
blood and loosen cell-cell junctions (Step 1) followed by perfusion with isotonic
collagenase solution to dissociate the liver parenchyma into single cells (Step 2) (Li
et al, 1992). It has been reported that factors such as the quality of the liver tissue
used, the composition of the isotonic buffer, and the protease composition of the
collagenase used for hepatocyte isolation can effect the viability of the hepatocytes
isolated (Mitry et al, 2002; Li, 2007). The perfusion buffer and collagenase solution
used for hepatocyte isolation were the same for all donors in these studies; therefore
the composition of these is not accountable for the variation in viability seen in these
studies. Following hepatocyte isolation, the cells for these studies required transport
to our laboratory, the duration of which lasted 6.5-26.5 hours. Hepatocyte viability
was found to drop significantly during transport on ice in DMEM. The cryo¬
preserved hepatocytes from 4 donors included in these studies had significantly
lower viability after recovery from cryopreservation than the same cells before
cryopreservation and the fresh hepatocytes (before and after transport). The loss of
hepatocyte viability following cryopreservation has been widely acknowledged
(Hengstler et al, 2000; Terry et al, 2005), and research is ongoing for techniques to
improve cryopreservation and utility of hepatocytes to increase the use of this
valuable research resource.
The source of hepatocytes (from 12/13 donors) for the studies presented here was the
healthy tissue resected at the time of surgery for liver metastases. The effect of
donor characteristics on hepatocyte viability was assessed, and no correlation was
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found between sex, age, or smoking status of the donors and the viability of isolated
hepatocytes used in these studies. The retrospective analysis of donor characteristics
in 149 patients on the outcome of isolated hepatocytes by Alexandre et al (2002),
also revealed no effect of age and sex of the patient or tobacco consumption on
viability of isolated human hepatocytes. The study by Alexandre et al also
demonstrated that additional factors (e.g. previous chemotherapy and alcohol
consumption) did not affect yield, viability, attachment rate and function of the
isolated hepatocytes. A further study by Hewes et al (2006) confirmed that pre-
resection chemotherapy does not affect the integrity of hepatocytes isolated from
healthy liver tissue after resection for colorectal liver metastases (in 47 patients
studied), which is of key importance considering the source of the fresh hepatocytes
used in these investigations.
Mitry et al (2002) report that under standard in vitro cell culture conditions, mature
hepatocytes usually survive for 10-14 days. Whilst the cells can survive for this
length of time in culture, maintenance of liver specific functions can only be
maintained for approximately one week (Gomez-Lechon et al, 2003) and the culture
conditions required for this include the presence of an extracellular matrix and media
supplementation. These factors were incorporated in this experimental design, with
hepatocytes (fresh and cryopreserved) plated on collagen-I pre-coated flasks and
media supplemented with dexamethasone and insulin (LeCluyse et al, 2005). The
maximum length of experiment, and therefore maximum time for hepatocytes in
culture was 108 hours.
For the purpose of the studies presented here, the ability of cells to adhere to their
tissue culture substratum is imperative. This is one of the fundamental criteria for
the assays used for detection of response of these cells to anti-cancer agents (that are
presented in chapters 3 and 4). Additionally, hepatocytes in suspension can only
survive for short periods of time in culture. Not all hepatocytes maintain their
adherence capabilities after cryopreservation, and only the cryopreserved hepatocyte
batches that attached to the pre-coated tissue culture plates were suitable for use in
these assays. Terry et al (2005) found that the source from which the hepatocytes
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were isolated can impact on parameters including viability after thawing, attachment
efficiency and albumin production which could explain why some of the
cryopreserved hepatocytes used in these studies never attached.
2.7.2 Cell Proliferation
The liver is normally a quiescent organ, which makes the establishment of a reliable
and reproducible model in which to study hepatic toxicity problematic. Arguably the
most pronounced difference between fresh or cryopreserved hepatocytes and the cell
lines investigated is that the hepatocytes do not proliferate in vitro under standard
culture conditions as used for these studies (Gomez-Lechon et al, 2003), whereas the
other models investigated do. All of the hepatoma cell lines replicated in culture and
the doubling times varied. The THLE-2 cell line was found to be able to replicate in
culture as reported by Pfeifer et al (1993), and had a doubling time similar to
Hep3B2.1-7: the longest doubling time of the hepatoma cell lines. Proliferating cells
are more appealing to work with in vitro in that a supply is readily available and
costs are greatly reduced compared with primary human hepatocytes. However they
are not quiescent like the liver. The cellular targets of anti-cancer drugs vary,
however the primary mode of action is to target proliferating cells and
consequentially cause cell death. Therefore the choice between a proliferating and
non-proliferating cell line becomes even more critical when detecting liver toxicity
with anti-cancer drugs. The cytotoxicity of anticancer agents targeting DNA may be
overestimated in proliferating cell lines as compared to fresh hepatocytes, because
their target is DNA and DNA replication will be ongoing in cell lines. This may
have implications when considering whether or not to select a replicating or non-
replicating cell model.
2.7.3 Liver gene expression
Detection of mRNA levels by qRT-PCR was used as a technique to compare the
models in these studies. The cost of microarray and proteomic technologies and the
quantity of RNA and protein required for these techniques were prohibitive for this
work. The gene expression analysis has revealed several differences in liver-specific
genes between the in vitro models. In summary, the fresh hepatocytes expressed all
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of the liver specific genes investigated at detectable levels, albeit with variation
between donors and a time-dependent decrease of mRNA content in hepatocytes
from the majority of donors for the majority of genes. The cryopreserved
hepatocytes also expressed all liver-specific genes investigated at detectable levels,
with the level of expression of 4 genes involved in drug metabolism and transport
(ABCB1, CYP3A4, UGT1A* and UGT2B*) being comparable with the fresh
hepatocytes from some donors. Two of the hepatoma cell lines (PLC/PRF/5 and SK-
HEP-1) and THLE-2 cells had no detectable expression of the liver-specific genes
with the exception of AAT, AFP and CYP1A1 expression in PLC/PRF/5, and AAT
and CYP1A1 expression in THLE-2 cells. The remaining three hepatoma cell lines
(Hep3B2.1-7, Huh-7D12 and Hep G2) expressed 7 or more out of the 10 liver-
specific genes investigated. AFP was only found expressed in the hepatoma cell
lines, with the highest expression being in Hep G2 and Huh-7D12 and lower
expression detected in Hep3B2.1-7 and PLC/PRF/5. Therefore based on the gene
expression data obtained, fresh hepatocytes would be the best model to represent the
liver, followed by the cryopreserved hepatocytes. Of the replicating cell lines,
Hep3B2.1-7 would appear the most appropriate as it expressed 7/10 of the genes
investigated and had lower levels ofAFP than Hep G2 and Huh-7D12.
With regards to the gene expression studies, the standards used for relative
quantification were the same for all cell types for each gene. RT-PCR gene
expression is expressed relative to commercially available RNA from one 51-year
old male Caucasian liver for all genes except AFP where foetal liver (pooled from 63
spontaneously aborted male/female Caucasian foetuses, ages 22-40 weeks) is used.
For some genes it is possible that the reference standard may have particularly high
or low expression of a particular gene. For example normalised ABCB1 expression
in hepatocytes from all 12 donors detected was >1 so it is possible that the standard
had low ABCB1 expression. The reference RNA is made from whole liver as
opposed to hepatocytes and could also explain higher relative expression in
hepatocyte samples compared to the standard for many of the genes investigated. It
is acknowledged that the gene expression considered to be closest to that of human
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liver is that in isolated hepatocytes. It is unknown if the procedure of hepatocyte
isolation alters the gene expression to that in situ.
The mRNA expression data obtained demonstrated variability in all genes in fresh
hepatocytes from 13 donors. For some genes there were outliers whose expression
was very different from other donors, for example CYP1A1 expression in donor 12.
CYP1A1 is an inducible CYP isoform by inducers such as polyaromatic
hydrocarbons, however donor 12 was not a known smoker and it not known that
donor 12 was exposed to any other CYP1A1 inducers. Dexamethasone is used as an
additive in the culture media and is a CYP3A4-inducer (Roymans et al, 2005) and
could therefore explain the relative higher expression of CYP3A4 in 8 out of 12
donors when compared with the reference standard RNA, despite the drop in
CYP3A4 in all donors from arrival time to 12-hours after plating. Loss of CYP3A4
gene expression during culture follows the same trend as protein and activity levels
decline, however the decrease in mRNA levels precedes CYP protein content and
activity loss (Gomez-Lechon et al, 2003). Additionally, because CYP regulation is
predominantly pre-translational, mRNA levels allow a good estimation of CYP
activity (Gomez-Lechon et al, 2003).
It may also be possible to assess the requirement of CYP activation of a drug to toxic
metabolite(s) for toxicity induction by the use of CYP-nonexpressing hepatoma cell
lines (ie ready-made knockout).
Pfeifer et al (1993) generated the THLE-2 cell line from human liver epithelial cells
and reported expression of hepatocyte phenotypic traits. These included expression
of cytokeratins 18 and 19, AAT and albumin secretion, and no AFP expression at
early passage. By qRT-PCR, the only assessed genes that were detectable in THLE-
2 cells were AAT and CYP1A1, but they were expressed at lower levels than in the
hepatocytes (50-fold and 33-fold lower than in the reference RNA, respectively).
There are very few other published papers with data obtained using the THLE-2 cell
line. The cell lines SK-HEP-1 and THLE-2 that express 0 and 2 genes respectively
may therefore be considered less suitable models to represent the liver in vitro.
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In summary, there are fundamental differences in expression between the models
investigated, which may influence the potential of these models to detect drug-
induced toxicity. For example with drugs that are metabolised by CYP3A4, use of a
model with no CYP3A4 expression (e.g. THLE-2, HepG2, Huh-7D12, PLC/PRF/5
or SK-HEP-1) may result in overestimation of cytotoxicity due to lack of detoxifying
drug metabolism. Conversely, if a drug were metabolised by CYP3A4 to a toxic
metabolite, choice of a model lacking expression would under-predict toxicity due to
lack of activation of drug. Flowever, metabolism could be evaluated prior to toxicity
testing using microsomal systems. Similarly, high ABCB1 expression (e.g. fresh
hepatocytes) may lead to under-prediction of toxicity if drug is transported out of
cells at a faster rate than would occur in humans, and an ABCB1 non-expressing
model (THLE-2, PLC/PRF/5 or SK-HEP-1) may over-predict hepatotoxicity due to
build up of drug within hepatocytes. These examples demonstrate how knowledge of
gene expression may aid interpretation of data generated using these in vitro models.
2.7.4 Stress gene expression
The analysis of p21, HSP-70 and HIFla mRNA revealed an increase in p21, HSP-70
and HIFla expression following plating in hepatocytes from all donors except donor
12 for which p21 mRNA expression decreased. One factor that could influence the
increase in stress gene expression is the change in temperature following the
isolation of hepatocytes. The liver will be removed from the body at 37°C, stored at
4°C until hepatocyte isolation, warmed to 37°C during isolation, transported on
melting ice and then transferred to an incubator once plated in media at 37°C. The
removal of the liver from the body requires stoppage of blood flow to the isolated
part of the liver being removed, and means the liver will no-longer be exposed to
circulating factors and nutrients in the blood. This, along with disruption of the
normal liver architecture, and an adaptation to in vitro culture conditions could result
in increased stress-induced gene expression.
An interesting correlation was found between HSP70 expression and hepatocyte
viability. The higher the cell viability both before and after transport, the higher the
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HSP70 expression, suggesting that HSP-70 expression may protect against cell
death. Increased expression of HSPs has been shown to be protective in many
cultured cells and animal tissues under a variety of conditions (Kiang and Tsokos,
1998, Hassen et al, 2005). HSP-70 is inducible and induction following plating may
be due to an increase in transcription after transport. The correlation was found
using hepatocytes from 13 donors which is a small sample size. If this correlation
can be confirmed in a larger cohort of patients it may be useful to consider the
development of HSP-70 agonists to maintain hepatocyte viability either for use in in
vitro assays or it may help in the development of cells for transplant in humans.
There are several similarities between HSP-70 and HSP-90 and there are HSP-90
inhibitors currently in clinical development for the treatment of cancer (Vastag,
2006). For example, 17-allylamino, 17-demethoxygeldanamycin was the first HSP-
90 inhibitor to enter clinical trials because the first pre-clinically studied HSP-90
inhibitor geldanamycin was not tested in humans due to the detection of
hepatotoxicity pre-clinically.
HSP-70 expression is linked to cell viability in the fresh hepatocytes. Intriguingly
HSP-70 expression is higher in the cryopreserved hepatocytes than in fresh
hepatocytes, and the cryopreserved hepatocytes have a lower viability. This is
contradictory to the pattern observed in fresh hepatocytes, but it is likely that the
cryopreservation process is responsible for the lower viability in cryopreserved
hepatocytes. It is possible that only the cryopreserved hepatocytes with higher HSP-
70 expression survive the cryopreservation process, which is consistent with the
suggestion that HSP-70 expression may protect against cell death.
2.7.5 Comparison of fresh hepatocyte transport media
Laboratories in several cities in the UK source fresh hepatocytes from the UKHTB
and therefore transport is a requirement for these cells. Transport of isolated
hepatocytes is required throughout the world where laboratories do not have the
facilities and/or expertise for hepatocytes isolation. The choice of media used for
storage and transport of organs for transplantation influences the organ (e.g. Feng et
al, 2007) and therefore it is likely that the media used for transport of isolated
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hepatocytes would impact on the quality of the transported cells. Indeed, the studies
reported here demonstrated a loss of viability following transport in DMEM.
Therefore, the effect of 3 transport media on hepatocyte viability and gene
expression was investigated. An increase or decrease in gene expression during
transport is undesirable. The study of transport media revealed that UW maintained
the highest viability during transport when compared with DMEM and celsior, but
there were no significant differences between the 3 transport media in terms of
maintenance of gene expression of any of the genes investigated. Time in transport
was also considered and was found to be associated with loss of viability when
hepatocytes were transported in DMEM or celsior, but to have no effect on gene
expression.
Studies have previously been carried out assessing the influence of cold storage
media for liver storage on the fresh hepatocytes subsequently isolated. A study by
Donato et al. (2005) investigated cytochrome P450 expression in human hepatocytes
isolated from human liver grafts preserved in CS prior to isolation and reported that
CYP1A1 showed greater variability in mRNA expression between donors than any
of the other cytochrome P450s they investigated, which did include CYP 3A4
(Donato et al, 2005).
Gene expression will impact on protein expression and therefore activity, and from
these studies no difference was found between the 3 media investigated in their
ability to maintain mRNA of several genes during transport.
2.7.6 Conclusions
In conclusion, the studies presented in this chapter provide a valuable comparison
between the selected in vitro models. The similarities and dissimilarities of the
different cell types have been considered, and revealed that the models differ in all
parameters considered (morphology, viability, proliferation, and gene expression).
Based on the findings presented in this chapter fresh hepatocytes would be
considered the most similar model to hepatocytes in humans, in that they do not
proliferate and they express the liver-specific genes investigated. The viability
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varied between fresh hepatocyte donors and it would be desirable to maintain it at a
higher level during transport, perhaps by transporting cells in UW media. The
cryopreserved hepatocytes were similar to hepatocytes in humans, with no
proliferation in culture and expression of liver specific genes albeit at lower levels,
however methods of cryopreservation need to be developed to increase their post-
thaw viability and attachment properties. Morphology, gene expression, and lack of
proliferation in culture were similar in the fresh and cryopreserved human
hepatocytes. These data allow more informed interpretation of further studies of
drug-induced toxicity in these models.
As discussed previously, consideration of hepatotoxicity with anti-cancer agents is
different from that of other classes of agents. Due to the mechanism of action of
anti-cancer drugs and the fact that the liver under normal circumstances is a
quiescent organ the differences in growth capabilities of these cell models may
influence toxicity detection. An understanding of the differences in morphology and
gene expression may aid understanding of differences in response to anti-cancer
agents. With the knowledge of the basal differences between the models in the
parameters considered in this chapter, anti-cancer drug treatment of the models was
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Using the in vitro models that have been considered in the previous chapter, the
hepatotoxicity caused by treatment with anti-cancer drugs will be investigated. The
benefits of in vitro tests to detect drug-induced liver toxicity relates to their minimal
cost and their relatively good predictability when compared to animal testing (Xu et
ah 2004). The mechanisms of cell death induced by chemicals in hepatocytes are
diverse, and cell death can be considered as a suitable endpoint for studying
anticancer drug-induced toxicity.
Initially three drugs were selected to assess the predictability of the in vitro models
with the chosen assays. A known hepatotoxic drug, mithramycin, and 2 drugs used
for the treatment of colorectal cancers (5-FU and oxaliplatin) were selected for
treatment of the in vitro models.
Two in vitro assays were used for detection of cell death (the sulforhodamine B
(SRB) and 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT)
assays) to measure the response of the different cells to drug treatment and to
determine the best model for accurate prediction of hepatotoxicity. The most
appropriate and accurate time-point for determining cytotoxicity and defining the
IC50 was investigated. Unlike other therapeutics, anticancer agents are inherently
cytotoxic. Therefore, the safety of anticancer agents is not assessed by their lack of
activity against normal cells but the difference between the cytotoxic effect induced
in tumour cells and normal cells (therapeutic index). As the kinetics of cell death
may differ between drugs and in vitro models, the kinetics of cell death was also
investigated for each of the three compounds in fresh hepatocytes.
The use of the in vitro models was then extended to include drugs in development.
Novel ruthenium compounds, which have been investigated pre-clinically, were
evaluated using the same assays to assess whether the in vitro assays would have
predicted the pre-clinical toxicology data obtained in mice.
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3.1.1 In vitro Cytotoxicity Assays
In order to study the effect of the anti-cancer drugs on cells in vitro, it is necessary to
detect living cells. Several methods can be employed for this purpose. Cytotoxicity
can be determined via assays that detect cell proliferation or viability, and are
available to detect different characteristics of cells. Plasma membrane leakage may
be detected using a lactate dehydrogenase release assay; metabolic activity of
mitochondria may be measured using a colorimetric substrate (WST-1, XTT, and
MTT) that requires conversion before detection; critical cellular macromolecules
such as ATP may be detected; or total cellular protein may be determined using
sulforhodamine B (SRB).
The main factors in selecting assays for use in these studies are suitability for 96-well
plate format, speed, ease of use, and cost. Therefore, the SRB and MTT assays were
selected because they meet these criteria, utilising colorimetric detection and being
suitable for microplate format.
3.1.1.1 SRB Assay
The SRB assay provides an indirect measure of cell number by binding to and
staining cellular protein in living cells (Skehan et al, 1990), and has been optimised
previously (Papazisis et al, 1997). The SRB assay is routinely used by the National
Cancer Institute (NCI) in the United States to screen anti-cancer drugs in their panel
of 60 cancer cell lines (NCI60). This assay is described in further detail (Chapter 6,
Materials and Methods) and its linearity was confirmed by plating a range of cell
densities as a calibration curve. Due to technical difficulties using the SRB assay
with fresh hepatocytes, the MTT assay was also investigated and used with the fresh
hepatocytes.
3.1.1.2 MTT Assay
The MTT assay provides direct measurement of cell viability. MTT is a yellow
water-soluble tetrazolium dye that is reduced by the mitochondria of viable living
cells to a water-insoluble purple formazan (Banasiak et al, 1999). The amount of
formazan can be determined by solubilising the purple-formazan in DMSO and
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measuring the OD spectrophotometrically. The ratio of MTT OD in drug-treated
cells compared to control cells allows determination of the surviving fraction of cells
at a particular drug concentration. By plotting the fraction of surviving cells against
drug concentration, determination of the drug concentration killing 50% of the cells
(IC5o) is possible (Alley et al, 1988). This assay will be described in Chapter 6,
Materials and Methods and its linearity was confirmed by plating a range of cell
densities as a calibration curve.
3.1.2 Pharmacological Properties and Hepatotoxic Potential of
Selected Drugs
Mithramycin, oxaliplatin and 5-FU were chosen as anticancer drugs to test the in
vitro models for the prediction of hepatotoxicity due to the reported presence or
absence of liver toxicity in patients following treatment in the clinic with these drugs.
3.1.2.1 5-fluorouracil
5-FU is a fluorinated analogue of uracil used for the treatment of common solid
tumours, and rapidly enters the cell using the same facilitated transport mechanism as






Figure 3.1: Chemical structure of 5-FU
5-FU follows the same metabolic pathway as uracil, forming fluorinated
deoxyribonucleotides incorporated into DNA, fluorinated nucleotides incorporated
into RNA and FdUMP, and is an inhibitor of thymidylate synthase (TS). 5-FU is
converted intra-cellularly to several active metabolites, which disrupt RNA synthesis
and the action of TS. Incorporation of 5-FU metabolites into RNA and DNA and
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inhibition of TS eventually leads to transcriptional error and arrest, ultimately
resulting in cell death and hence the drug's anticancer action.
5-FU is extensively inactivated by the enzyme dihydropyrimidine dehydrogenase
(DPD) into dihydrofluorouracil. DPD is abundantly expressed in the liver, and over
80% of administered 5-FU is catabolised in the liver (Longley et al, 2003). Patients
genetically deficient in DPD can experience severe toxicities with 5-FU (Raida et al,
2001). Because of the role of the liver in 5-FU catabolism, the liver is a relevant
target organ for drug toxicity. 5-FU has been reported to cause mild and infrequent
liver toxicity in patients identified by increases in amino-transferases (Witte et al,
2001) or the development of fatty infiltration of the liver (steatosis) (Peppercorn et
al. 1998).
3.1.2.2 Oxaliplatin
Oxaliplatin is a platinum derivative that is mainly used in the treatment of cancer of
the large bowel. Furthermore, in vitro oxaliplatin demonstrates activity in colorectal
cancer cells (Arango et al, 2004) and in human gastric cancer cell lines (Eriguchi et
al (2003). Oxaliplatin acts by creating intra- and inter-strand DNA adducts (Graham
et al, 2004), and subsequently irreversible DNA replication error and cell death. The
chemical structure of oxaliplatin is shown in figure 3.2. The liver does not play a
major role in the metabolism of oxaliplatin and therefore would not be at any
increased risk of toxicity due to its high drug metabolising capability. One study has
reported that oxaliplatin is well tolerated in patients with liver dysfunction, and there
was no apparent alteration in the clearance of either total or ultra-filterable platinum
species from plasma, even in patients with severe hepatic functional abnormalities
(Doroshow et al, 2003).
Oxaliplatin was selected as a negative control for this project; however, more
recently there have been reports of oxaliplatin treatment in patients resulting in
adverse effect on the liver (Tisman et al, 2004; Rubbia-Brandt et al, 2004). Pre¬
operative administration of oxaliplatin in patients with hepatic colorectal metastases
has been noted to result in fatty change and severe steatohepatitis, especially in the
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obese (Fernandez et al, 2005). Additionally, toxicity of oxaliplatin-containing
neoadjuvant chemotherapy has been reported by Arotcarena et al (2006), and was
detected as changes in LFTs manifesting as an increase in GGT and ALP, and when
examined histologically hepatic sinusoidal lesions were present and thought to be
caused by injury initially to the sinusoidal endothelial cells causing sinusoidal wall
disruption (Rubbia-Brandt et al, 2004).
Mithramycin is no longer used routinely for the treatment of cancer; however it has
been used for the treatment of testicular cancer in the past and can be used to treat
tumour hypercalcaemia refractory to other chemotherapy (Zojer et al, 1999). The
possibility of using mithramycin in combination regimens with another anticancer
agent (bevacizumab) is currently being investigated (Jia et al, 2007) and therefore
study of the hepatotoxicity caused by mithramycin is of interest. Mithramycin is the
most hepatotoxic chemotherapeutic agent available (King and Perry, 2001), and was
selected as a positive control for these studies. The chemical structure of
mithramycin is shown in figure 3.3. Mithramycin is a potent inhibitor of
transcription, binding to GC rich regions in promoter sequences of DNA (Miller et
al, 1987), and is a potent inhibitor of RNA transcription, decreasing protein
synthesis. Mithramycin can therefore block the production of many intracellular
enzyme systems necessary for normal hepatic function (King and Perry, 2001).
Elevations of aminotransferases and lactate dehydrogenase occur in almost all
patients treated with mithramycin, and milder elevations in alkaline phosphatase
levels also occur (King and Perry, 2001). These changes begin on the day of drug
Pt




administration, peak on the second day, and return to normal by 4 to 21 days after
treatment.
OH
Figure 3.3: Chemical structure of mithramycin
3.1.2.4 Ruthenium compounds HC11 and RM175
Several metal-containing complexes have anti-cancer properties and those licensed
for use in the UK include cisplatin, carboplatin and oxaliplatin. The metal ruthenium
has recently formed the basis for development of new anti-cancer compounds
(reviewed by Kostova, 2006). [(Ti6-C6H5C6H5)Ru(en)Cl]+ (RM175), and [(r|6-
tetrahydroanthracene)Ru(en)Cl]+ (HC11), are two ruthenium-containing anti-cancer
compounds investigated in this study. The chemical structures of RM175 and HC11
are shown in figure 3.4. Pre-clinical trials involving RM175 and HC11 have
demonstrated activity of these compounds in ovarian cancer cell lines and small cell
lung cancer cell lines (Aird et al, 2002). Brabec and Novakova (2006) investigated
the DNA binding mode of ruthenium complexes and their relationship to tumour cell
toxicity. Pre-clinically, liver toxicity caused by ruthenium compounds RM175 and
HC11 has been detected in mice (Guichard et al, 2006). Analysis of blood from the
mice revealed increased ALT, particularly following HC11 treatment, and
histopathological examinations revealed necrotic foci in some of the drug-treated







Figure 3.4: Chemical Structure of RM175 and HC11 (Guichardet al, 2006)
3.1.3 Principle of Therapeutic Index
When determining the potential usefulness of any drug the benefits and risks must be
considered. Most anti-cancer drugs cause toxicity if the administered dose is high
enough. Drugs interact with a specific therapeutic target and the specificity of the
reaction is based on the affinity of the drug for its target. At higher drug
concentrations, interactions with targets for which the drug has lower affinity may
occur, leading to 'off-target effects' which are often related to adverse drug reactions
(Guengerich and MacDonald, 2006). One criterion of drugs selected for
development is that they have high affinity and specificity for the drug target so as to
minimise potential off-target effects.
For a drug to be useful and feasible for administration in humans, the efficacious
dose must be lower than the dose that causes toxicity. The therapeutic index is
defined as the difference between dose associated with toxicity and efficacious dose.
During treatment with anticancer drugs it is necessary to produce maximal benefit
and minimal toxicity. Anticancer drugs are designed to kill cells i.e. they are
cytotoxic. For interpretation of the data produced from cytotoxicity assays presented
in these studies, the principal of the therapeutic index will be considered.
Ehrlich first recognised that a drug must not be solely judged by its useful properties,
but also by its toxic effects, and he described the therapeutic index (TI) of a drug in
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terms of the ratio between the average minimum effective dose and the average
maximum tolerated dose in a group of patients (Rang et al, 2001):
TI = maximum tolerated dose
minimum effective dose
However, in the definition of the TI given above, interindividual variability is not
considered. A widely used definition that does take into account interindividual
variability and may be defined from preclinical studies is:
TI = LD50
ED50
When defined as LD50 (lethal dose for 50% of a group of animals) over ED50
(effective dose for 50% of a group of animals), the TI gives some indication of the
safety margin in the use of a drug. Of interest, the LD10 in pre-clinical animal studies
with anti-cancer agents is considered to be the maximum tolerated dose, and one-
tenth of the LD10 in animal studies is often used as the starting dose in humans.
For interpretation of data presented in this chapter, the principle of determining a TI
from a group of animals has been adapted for description of the proportion of cells
killed by drug treatment in vitro. To indicate the window between effective and
toxic dose in these cell models, TI is defined as:
TI= IC50 in hepatocyte model (toxic)
IC50 in colon cancer model (therapeutic);
where a ratio of 1 would indicate no difference in IC50 between the two cell types, a
ratio of <1 indicating that the drug was more toxic to the liver than in the target cell,
and a ratio of >1 indicating that the IC50 in the hepatocyte model is higher than in the
target cell and active drug concentrations may be achieved without resulting in
toxicity.
3.2 IN VITRO ASSAYS
Two cytotoxicity assays (SRB and MTT) were used to detect cell viability in vitro
with a variety of cell types, and the proportion of cells that were killed by drug
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treatment was assessed. Assessment of the time-point at which to detect maximum
cytotoxicity, and a comparison between the MTT and SRB assays was carried out.
3.2.1 Determination of Optimal Time-point to Detect Cytotoxicity
In order to determine the most appropriate timepoint for accurate detection of cell
death, a time-course with measurements made every 24 hours was undertaken
(starting 24 hours after addition of drug, and at 48-, 72- and 96-hours after drug
addition) and measurement of cellular response to drug using SRB or MTT assays.
Both the PLC/PRF/5 cell line and fresh human hepatocytes were investigated. The
surviving fractions compared to controls were determined using the MTT and SRB
assay every 24 hours for fresh hepatocytes and PLC/PRF/5 respectively. It was
desired to define the time for IC50 measurement at which maximal cytotoxicity was
observed.
Cells were plated and allowed to attach to the tissue culture plastic (time for
attachment was dependent upon cell type) before the addition of a concentration
range for each drug for 24 hours. After 24 hours, the drug was removed, cells were
washed, and the MTT or SRB cytotoxicity assays performed, or media replaced and
cytotoxicity assays performed every 24 hours until 96 hours after the start of drug
treatment.
The cytotoxic effect increased over time using both assays in fresh hepatocytes as
well as in the hepatoma cells. Figure 3.5 shows examples of dose response curves
for each drug at each 24-hour time-point investigated in the hepatoma cell line
PLC/PRF/5, and in fresh hepatocytes from donor number 4. A similar pattern was
observed with hepatocytes from the other donors and with the other cell lines.
The assays at 24-hour intervals from the start of drug exposure showed the
progressive loss of viability of treated cells compared to control cells Drug
concentrations which led to 50% growth inhibition in PLC/PRF/5 decreased between
24 and 96 hours from 1 to 0.1 pM for mithramycin, from >10mM to 75pM for 5-FU
and from 100 pM to 1.75 pM for oxaliplatin (SRB assay). A similar decrease was
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seen in fresh hepatocytes: from >10pM to 1 pM for mithramycin, from >10mM to
460 pM for 5-FU and from >100 pM to 20 pM for oxaliplatin.
The maximum cytotoxic effect of all three drugs investigated is seen 96 hours after
the start of drug treatment, regardless of cell model and method of estimation. Time
points beyond 96 hours were not studied, as a short assay was felt to be desirable and
there was concern about maintaining fresh hepatocytes in vitro for longer than this
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Figure 3.5: Time-course of cytotoxicity in PLC/PRF/5 and fresh hepatocytes
PLC/PRF/5 (A, C, E) and fresh hepatocytes Donor 4 (B, D, F) were exposed to a
concentration range of mithramycin (A, B), Oxaliplatin (C, D), and 5-FU (E. F) for
24 hours. 24-, 48-, 72- and 96-hours after the start of drug treatment, the MTT or
SRB assay was performed as described with fresh hepatocytes and PLC/PRF/5
respectively. Results are expressed as percentage of growth (PLC/PRF/5) or survival
(hepatocytes) as compared to untreated cells and are the mean ± SEM of triplicate
samples.
3.2.2 Comparison of SRB and MTT assays
HCT116 cells were assessed following drug treatment with oxaliplatin (figure 3.6).
Cell viability (MTT) and the surviving fraction (SRB) was measured at 96 hours
after the start of 24-hour drug treatment. It can be seen from figure 3.6, that the IC50
values obtained from the MTT and SRB assays at the 96 hour time point are
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equivalent: 0.8± 0.1 qM and 0.7 ± 0.1 qM for MTT and SRB assays respectively. The
IC50 values determined in this example with oxaliplatin-treated HCT 116 after 96
hours are identical, and therefore it is feasible that either assay may be used with this
cell line (and the other colon cancer cell lines tested). This does not hold true for all
cell types investigated but providing that the colon cancer cell lines MTT and SRB
determined IC50S are the same, it is valid to compare other data to only the SRB
colon cancer cell line data at 96 hours.
• SRB 96 hour
• MTT 96 hour
1
3
Figure 3.6: Comparison of MTT and SRB assays
1500 HCT 116 cells/well were plated 24 hours before the assay, and then treated for
24 hours with oxaliplatin. The MTT assay was performed at 24hour, 48hour,
72hour, and 96hour after the start of drug treatment and the SRB assay after 96
hours.
3.3 DRUG TREATMENT OF CELLS
The cytotoxic effect of mithramycin, oxaliplatin and 5-FU was determined in
colorectal cancer cell lines and hepatocyte models (fresh hepatocytes, immortalised
hepatocytes and hepatoma cell lines) to allow determination of 'active' and 'toxic'
drug concentrations.
3.3.1 Cytotoxicity in Colon Cancer Cell Lines
The activity of 5-FU, oxaliplatin and mithramycin was determined in a panel of six
colorectal cancer cell lines (HCT-8, HCT-15, HCT 116, HT-29, SW-620 and COLO
205) as all three drugs are active in this cancer type and allow estimation of the
active concentration of these drugs.
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An example of the dose response curves produced following treatment of a colorectal
cancer cell line (HCT-15) with 5-FU and the SRB assay can be see in figure 3.7. The
three separate curves represent 3 independent experiments carried out on separate
days, making up new drug dilutions each time. Similar curves were produced for
each drug and cell line. The mean of three IC50 values determined in independent
experiments was calculated for each cell line after 24hour drug treatment and the
SRB assay 96 hours after the start of drug treatment. It was verified that the IC50 in
the colon cancer cell lines determined 96-hours after the start of 24-hour drug
treatment were similar using the SRB and MTT assays. The IC50S can be seen in



























Figure 3.7: 24-hour 5-FU treatment of colon cancer cell line HCT-15
1500 HCT-15 cells/well were plated 24 hours before assay. Cells were exposed to
concentrations of 5-FU ranging from InM to 1000pM for 24 hours, followed by SRB
cytotoxicity assay 96 hours after the start of drug treatment. The experiment was




Table 3.1: Colon cancer cell line 50% inhibitory concentrations (IC50)











HCT-8 4.9 ±2.3 0.05 ±0.006 0.62 ±0.16
HCT-15 12.4 ± 2.9 0.25 ±0.006 2.35 ±0.86
HCT 116 7.8± 1.2 0.03 ±0.006 0.63 ±0.05
HT-29 6.1 ±2.1 0.04 ±0 1.76 ±0.78
SW-620 18.6 ±4.1 0.03 ±0 0.52 ±0.21
COLO205 2.4 ±0.6 0.02 ±0.006 1.15 ± 0.16
Mean 8.7 ±5.9 0.07 ±0.09 1.17 ± 0.74



























Figure 3.8: IC50 values in colorectal cancer cell lines
IC50 values were determined in 6 colorectal cancer cell lines. Cells were plated 24
hours before 24 hour drug incubation, and IC50 determined using the SRB assay, 96
hours after beginning drug treatment. IC50 values were determined from the results
of at least three independent replicate experiments.
It can be seen from table 3.1 and figure 3.8 that there is variability in IC50 values
between the different cell types treated with each of the three drugs and the potency
of the 3 drugs is also very different. The cell lines were most sensitive to
mithramycin with IC50S ranging from 0.02 to 0.25 pM. The HCT-15 cell line is the
most resistant cell line to both mithramycin and oxaliplatin, and the second most
resistant to 5-FU. COLO 205 is the most sensitive cell line to both mithramycin and
5-FU. There was an 8-fold variation in IC50 for 5-FU across the cell lines ranging
from 2.4 pM in COLO205 to 18.6 pM in SW620 cells. SW620 were the most
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sensitive to oxaliplatin (IC50 - 0.52 pM) and HCT15 was the most resistant (IC50 =
2.35 pM).
For the purpose of determining a true picture of a likely IC50 value in the cell type in
which the drugs are intended to treat, it is good to include a range of resistant and
sensitive cell lines to provide a true picture. However, when the mean IC50 may be
skewed by a particularly resistant or sensitive cell line (as was the case for
mithramycin in the HCT15 cell line (Figure 3.8)) and therefore may be more
appropriate to compare the toxic IC50 values determined in the hepatocyte models to
the median IC50 in the colorectal cancer cell lines, as opposed to the mean.
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3.3.2 Cytotoxicity in in vitro liver models
The cytotoxicity of mithramycin, 5-FU and oxaliplatin was next determined in
different in vitro models of hepatocytes: 5 hepatoma cell lines, 1 immortalised
hepatocyte cell line, and fresh (13)- and cryopreserved (2)- hepatocytes, with drug
exposure for 24 hours in all cases. It should be noted that for the cell lines that
proliferate, a dose-dependent decrease in cell growth is observed. For the fresh
hepatocytes a dose-dependent decrease in cell survival is observed, as these cells do
not proliferate in culture.
3.3.2.1 Cytotoxicity in hepatoma and immortalised hepatocytes
cell lines
Table 3.2 and figures 3.9 show the IC50 values that were determined in the hepatoma
cell lines (Hep 3B2.1-7, Hep G2, Huh-7D12, PLC/PRF/5, SK-HEP-1), and
immortalised hepatocyte cell line (THLE-2) as determined by the SRB assay. These
IC50S were determined in the same way as described for the colon cancer cell lines,
with mean and standard deviation calculated from 3 independent experiments.
The hepatoma cell lines showed very different sensitivity to the three drugs.
Mithramycin was highly cytotoxic in all 5 cell lines with IC50S ranging from 0.05 to
0.1 pM. There was wider variation in the IC50S for oxaliplatin and 5-FU determined
in the hepatoma cell lines. The IC50 values ranged from 0.21 to 7.4|iiM for
oxaliplatin and from 8 to 136 pM for 5-FU, therefore a 35- and 17-fold difference
respectively.
The sensitivity of THLE-2 cells to the three drugs differed greatly. THLE-2 cells
were as sensitive as hepatoma cell lines to mithramycin, and the IC50 values for both
oxaliplatin and 5-FU were consistent with those of fresh hepatocytes and much
greater than those in the hepatoma cell lines.
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Table 3.2: Liver cell lines 50% inhibitory concentrations (IC50)
IC50+ standard deviation for liver cell lines, determined 96hours after the start of












Hep3B2.1-7 135.5 ±65.8 0.08 ± 0 7.24 ±4.19
Hep G2 8.0 ±2.5 0.06 ± 0.01 0.21 ± 0.05
Huh-7D12 58.3 ± 7.0 0.10 ± 0.01 4.04 ± 1.96
PLC/PRF/5 75.0 ±52.3 0.10 ± 0 1.75 ± 0.91
SK-HEP-1 25.2 ± 3.25 0.05 ± 0.01 2.51 ± 0.52
Mean hepatoma
IC50





























Figure 3.9: Spread of IC50s in mithramycin, oxaliplatin and 5-FU-treated cell
lines
IC50 values were determined in 5 hepatoma cell lines and the immortalised
hepatocyte cell line THLE-2. Cells were plated 24 hours before 24 hour drug
incubation, and IC50 determined using the SRB assay, 96 hours after beginning drug
treatment after fitting data with a Sigmoidal dose response curve. IC50 values were
determined from the results of at least three independent replicate experiments.
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3.3.2.2 Cytotoxicity in cryopreserved hepatocytes
The sensitivity of cryopreserved hepatocytes to mithramycin, oxaliplatin and 5-FU
was investigated using the MTT assay, similar to the fresh hepatocytes. The cells
could only be kept in culture for a short period of time therefore surviving fractions
96 hours after the start of 24 hour drug treatment could not be detected and
cytotoxicity was measured immediately following 24-hour drug treatment in the
cryopreserved hepatocytes. Two drug concentrations were selected for investigation
of each drug (1 and 25pM mithramycin, 25 and 250 pM oxaliplatin, and 5 and
1 OmM 5-FU) because the number of cells available was limited. The MTT values in
control samples were much lower than usually observed in fresh hepatocytes, despite
equivalent plating densities. Table 3.3 shows the surviving fraction that were
determined in the cryopreserved hepatocytes at the end of 24-hour drug treatment
and out of all of the drug treatments drug concentrations causing greater than 50%
cell death could only be determined in hepatocytes from 1 donor. In cryopreserved
hepatocytes from donor C2, the mithramycin IC50 was less than 25 pM and the
oxaliplatin IC50 was less than 250pM. For all of the other donors and drugs IC50
concentrations were not reached.
Table 3.3: Cryopreserved hepatocyte cytotoxicity
Cytotoxicity was determined in cryopreserved hepatocytes, 24 hours after the start of
24-hour drug treatment, by MTT assay. The percentage of surviving cells at 2 drug
concentrations per drug was calculated as OD as % of control cells' OD, and












5000 85 104 93
10000 61 87 83
Mithramycin
1 59 95 78
25 37 80 54
Oxaliplatin
25 75 105 63
250 38 92 60
3.3.2.3 Cytotoxicity in fresh hepatocytes
Table 3.4 and figures 3.10 and 3.11 show the IC50 values that were determined in the
fresh hepatocytes (donors 1-13), as determined by the MTT assay. Fresh
hepatocytes, like the hepatoma cell lines, show similar sensitivity to mithramycin
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with IC50 values between 0.3 and 1.5pM. with the exception of hepatocytes from
donor 11 which had a very high IC50 (>10pM). Minor variability was observed for
oxaliplatin, but at IC50 values much greater than for mithramycin (13 to >100pM).
5-FU was the most variable among patients but also the least cytotoxic: hepatocytes
from 2/13 donors were very resistant (IC50 >10mM), and from 9/13 donors the
concentration of 5-FU that caused 50% inhibition of cell growth was between ImM
and lOmM (mean in 11/13 was 1,75mM).
Table 3.4: Fresh hepatocytes 50% inhibitory concentrations (IC50)
IC50 values for fresh hepatocytes, determined 96 hours after the start of drug treatment by MTT assay.













1 269.2 0.66 19.5
2 1548.8 0.50 27.5
3 4265.8 0.93 57.5
4 457.1 0.91 19.1
5 1995.3 1.17 39.8
6 1445.4 0.38 13.4
7 1148.2 0.55 15.1
8 2570.4 1.48 >100
9 >10000 1.55 47.9
10 1995.3 0.78 30.2
11 >10000 >10 45.7
12 2570.4 1.39 44.7

























Figure 3.10: IC50s in mithramycin, oxaliplatin and 5-FU-treated hepatocytes
IC50 values were determined in fresh hepatocytes from 13 donors. Cells were plated 12 hours before




























































Figure 3.11: Range of IC50 in all cell models
IC50 values were determined in all models following 24-hour drug incubation, and





The dose response curves and the IC5o values provide information regarding the
cytotoxicity of mithramycin, oxaliplatin and 5-FU but from these data in isolation it
is not possible to discriminate which drugs are likely to be hepatotoxic. By
comparing the drug concentration required for effect in hepatocyte models to that in
colon cancer cell lines, a clearer picture may be revealed. A ratio of the IC50 in
hepatocyte model (toxic) to the median IC50 in colorectal cancer cell lines
(therapeutic) can provide a therapeutic index (TI). A ratio close to 1 would suggest
there is little difference between active and toxic drug concentrations and the greater
the ratio between liver and colon models, the greater the therapeutic margin. For
cells where it was not possible to determine an IC50 the TI was not calculated.
Figure 3.12 shows the therapeutic indices determined in the range of models
investigated and it is apparent that there are varying sensitivities of the different cell
types to each drug. In the hepatoma cell lines, mithramycin had the lowest and least
variable TI with values ranging from 0.7 to 1.4. Oxaliplatin had TI values between
0.18 and 6.2. Finally, 5-FU had the highest TI ranging from 0.09 to 15.6. The TIs in
THLE-2 were 27, 0.14 and 10 for 5-FU, mithramycin and oxaliplatin respectively.
The TIs varied most in the fresh hepatocytes. Mithramycin again had the lowest TI
ranging from 5.4 to 22.4 (donor 11 excluded because IC50 not reached). Oxaliplatin
had higher TI values ranging from 11 to 50 (hepatocytes from donor 8 excluded
because TI not reached). Finally, 5-FU had the highest TI (ranging from 31 to 490)
with the exception of hepatocytes from 2 donors (9 and 11) with resistance to 5-FU
at the highest drug concentration investigated and therefore it was not possible to
determine the TI (>10mM).
When comparing each drug in the different models, mithramycin had the lowest TI
in all cases. When using mithramycin as a reference for hepatotoxicity, the
difference in median TI values with oxaliplatin and 5-FU values was greater in
THLE-2 (71- and 192-fold respectively) than in fresh hepatocytes (1- and 10-fold
respectively) and hepatoma cells (2- and 8-fold respectively). Mithramycin is the
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most hepatotoxic of the three drugs and has the lowest therapeutic index. Therefore,
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Figure 3.12: Therapeutic Index
The ratio of IC50 between hepatocyte models and the median IC50 of colorectal




3.4 POTENTIAL INFLUENCES ON CYTOTOXICITY IN FRESH
HEPATOCYTES
The cell lines included in this study are well established and have been used
previously for several different types of investigations. However, the fresh
hepatocytes that have been used for the cytotoxicity studies presented here are all
from individual donors. The IC50 and TI values varied more in the fresh hepatocytes
than in the other models tested. In order to identify potential confounding factors
affecting the cytotoxicity of the drugs evaluated in fresh hepatocytes several factors
were considered. The impact of hepatocyte viability and age, sex and smoking status
of the hepatocyte donors on the IC50 for each drug was considered. Gene expression
of each investigated gene at the start of drug treatment, and changes in gene
expression from isolation to plating was also investigated.
3.4.1 Donor Demographics
Hepatocyte viability both at isolation and after transport were investigated. Neither
donor age nor hepatocyte viability correlate significantly with the IC50 value
determined for each drug (table 3.5). This may be considered to be a benefit, as a
wide variety of donor demographics were included in this thesis, and inter-
individual variability in response to drugs is to be expected. However, it does mean
that these parameters do not help explain the interpatient variability in response to
the drugs tested.







Mithramycin p=0.88 p=0.69 p=0.63
ns ns ns
r=-0.1513 r=-0.1154 r=0.2637
Oxaliplatin p=0.62 p=0.71 p=0.39
ns ns ns
r=-0.2365 r=-0.2210 r=-0.0470




The effect of donor sex and donor smoking status on the IC50 of mithramycin,
oxaliplatin and 5-FU was investigated (table 3.6). The 2 populations (male/female)
do not have significantly different median IC50S (p<0.01) for any of the drugs
investigated. Similarly, when comparing the IC50 of all drugs between smokers and
non-smokers, there was no significant difference in the median IC50S between
smokers and non-smokers for mithramycin, oxaliplatin and 5-FU.
Table 3.6: Mann Whitney test of donor sex or smoking status and IC50 values
The median IC50S of male vs female and smoker vs non-smoker were compared
using a Mann Whitney test. The statistical significance of the difference in the
medians is presented below (p-values are presented and p<0.01 is considered to be
significant)





The impact of gene expression on IC50 was also considered. Both the change in gene
expression from arrival of the hepatocytes in Edinburgh until the start of drug
treatment, and the gene expression of each gene at the start of drug treatment were
plotted against the IC50 determined for each drug for correlation analysis. Samples
which did not achieve 50% growth inhibition were excluded from the analysis.
Because several genes are being compared to the IC50S the p-value considered to be
significant has been lowered to p<0.001 using a Bonferroni correction because when
making several comparisons the likelihood of detecting a significant correlation by
chance is increased. None of the drug metabolism-related genes influenced the
sensitivity to the three drugs tested.
Table 3.7 and 3.8 report the results of Spearman correlation analysis between gene
expression at the start of drug treatment and change in gene expression from arrival
of the hepatocytes in Edinburgh to the start of drug treatment and the IC50
determined for mithramycin, oxaliplatin and 5-FU respectively. No significant
correlations were found.
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3.5 KINETICS OF CELL DEATH
The data obtained 96 hours after the start of 24-hour drug treatment has been
analysed and used to determine IC50 values and subsequently TIs. Additionally, cell
death over time was investigated in fresh hepatocytes and hepatoma cell lines. The
kinetics of cell death was investigated to attempt to provide further insight into which
drugs may be toxic to the liver. It was hypothesised that there may be a difference in
kinetics of cell death between drugs that are intrinsically hepatotoxic and those that
are not, with anti-cancer drugs that cause liver toxicity in humans causing cell death
sooner than a non-hepatotoxic drug in an in vitro model of the liver. The loss of cell
viability over time may be an indicator of the hepatotoxic potential of a drug, and
cell viability was measured 24-, 48, 72- and 96-hours after the start of 24-hour drug
treatment.
In order to assess progressive cell death over time one drug concentration was chosen
for investigation of each cell type. A drug concentration was selected that resulted in
approximately the IC50 value in the majority of cell samples 96-hours after the start
of drug treatment (table 3.9). The percentage of surviving cells at these drug
concentrations was plotted against time after drug treatment of hepatoma cell lines
(figure 3.13) and fresh hepatocytes (figure 3.14). There is progressive loss of cell
viability with increasing time after drug treatment in all cells. No pattern between
the assays or drugs was detected for example in cells of the same type or with one
particular drug there was not consistency with when the maximal cytotoxic effect
was seen.













Mithramycin 0.95 pM 0.91 pM 1 pM
Oxaliplatin 33 pM 31 pM 50 pM
5-FU 1.74mM 1.50 mM 1 mM
Hepatoma
cell lines
Mithramycin 0.08 pM 0.08 pM 0.1 pM
Oxaliplatin 3.05 pM 2.51 pM 3 pM























I I I I 1
0 24 48 72 96 120
time (hours)after start of drug treatment
Figure 3.13: Kinetics of cell death in hepatoma cell lines after drug treatment
HepG2, Huh-7, PLC/PRF/5, Hep3B and SK-HEP-1 cells were treated with 0.1 pM
Mithramycin (A), 3 pM Oxaliplatin (B) and 100 pM 5-FU (C) for 24-hours
followed by the SRB assay 24-, 48-, 72- and 96-hours after the start of drug
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Figure 3.14: Kinetics of cell death in fresh hepatocytes after drug treatment
Fresh hepatocytes from 13 donors were treated with 1 pM Mithramycin (A), 50 pM
Oxaliplatin (B) and 1 mM 5-FU (C) for 24-hours followed by the MTT assay 24-,
48-, 72- and 96-hours after the start of drug treatment. The percentage of surviving
cells compared to control is plotted against time.
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3.6 APPLICATION OF IN VITRO HEPATOTOXICITY TESTING TO DRUGS
IN DEVELOPMENT
So far in these studies, it has been demonstrated that hepatocyte models are more
sensitive to the hepatotoxic drug mithramycin and are less sensitive to oxaliplatin
and 5-FU than the colon cancer cell lines. The therapeutic index defined for
mithramycin could perhaps be used as a reference to study novel agents before they
enter clinical development. New anti-cancer agents that have caused liver toxicity in
pre-clinical animal models include the ruthenium compounds RM175 and HC11
(Guichard et al, 2006), and these compounds continue to be studied in clinical
development.
3.6.1 Ruthenium Compounds: HC11 and RM175
In order to further test the in vitro models and parameters investigated so far in this
thesis, RM175 & HC11 were investigated. Cells were exposed over a concentration
range of both drugs for 24 hours. 24-, 48-, 72-, and 96-hours after the start of drug
treatment, the MTT or SRB assay was performed (figures 3.15 and 3.16).
Both ruthenium compounds induced a rapid cytotoxic effect, detectable at the end of
drug exposure (24 hours). IC50 values for the two ruthenium compounds were
markedly different, with HC11 being 40-fold more potent (RM175 IC50 = 24pm,
HC11 IC50 = 0.6pm) in the fresh hepatocytes (Donor 5).
The A549 small cell lung cancer cell line was sensitive to both RM175 and HC11.
The IC50 values were 3 and 0.5pM for RM175 and HC11 respectively (Guichard et
al, 2006) in fresh hepatocytes. The therapeutic index between A549 small cell lung
cancer cell line (activity) and fresh hepatocytes are low: 9 for RM175 and 1 for
HC11. In comparison, mithramycin has a TI of 11 in this donor suggesting that both
RM175 and HC11 might induce hepatocyte toxicity (figure 3.17). HC11 was found
to be more hepatotoxic than RM175 in in vivo mouse models (Guichard et al, 2006)
and this pattern is confirmed in vitro with both fresh hepatocytes and hepatoma cell



















































Figure 3.15: Cytotoxicity of RM175 (A) and HC11 (B) in 4 hepatoma cell lines
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Figure 3.16: Cytotoxicity of HC11 (left) and RM175 (right) in fresh
hepatocytes DONOR 5
Cells were treated over a concentration range for 24 hours. 24-, 48-, 72- and 96-hours after
the start of drug treatment, the MTT assay was performed as described, and at 96-hours the
SRB assay as described. Results are expressed as percentage of survival as compared to
untreated cells and are the mean of triplicate samples.
hepatotoxic
DRUG
Figure 3.17: Therapeutic index of 5 anti-cancer agents
Using IC50 concentrations determined in fresh human hepatocytes (donor 5) and in non-
small cell lung cancer cell line A549, Tls were calculated for 5-FU, oxaliplatin,
mithramycin, RM175 and HC11. The dotted line represents the TI of mithramycin, which
may be used as a reference below which a drug could be considered hepatotoxic. The Tls




In vitro models are used to investigate liver toxicity with many classes of drugs. As
highlighted earlier, the differences between anticancer drug mode of action,
combined with the fact that the liver is a non-replicating organ, necessitates that the
study of anti-cancer drug induced liver toxicity requires special consideration. The
selection of drugs with characterised effects in humans has aided the testing of the
suitability of the in vitro models for detecting liver toxicity.
The concept of accurate prediction of anticancer-drug induced toxicity using in vitro
models has been investigated for the detection of other toxicities, for example
myelotoxicity, caused by anti-cancer drugs. The colony-forming unit granulocyte
macrophage (CFU-GM) assay has been developed for the evaluation of human
myelotoxicity, defining IC50, IC75 and IC90 values (Masubuchi et al, 2004). Using
human and murine IC90 values for myelotoxicity of the investigated compounds (5
campothecin derivatives) in combination with other tests, the human MTDs were
predicted retrospectively (Masubuchi et al, 2004) and it was suggested by the authors
of this paper and others (Malerba et al, 2004, Pessina et al, 2003) that the CFU-GM
in vitro model could be used in the investigation of toxicity during the development
of new anti-cancer agents. This example shows that it is possible to develop in vitro
assays to predict specific anticancer drug toxicities, but they require thorough
validation. There is no published validated model routinely used for the prediction
of liver toxicity with anti-cancer agents, and the investigation of this is the purpose of
this thesis.
3.7.1 In vitro cytotoxicity assays
The two assays selected were the MTT and SRB assays and both are suitable for use
with cancer cell lines and hepatocytes. The SRB assay is an established technique
used by the National Cancer Institute (NCI) for cytotoxicity studies with cancer cell
lines (http://dtp.nci.nih.gov) and there are many published papers that present results
from the SRB assay. The MTT assay is used by Celsis (formerly Invitrotech) with
human hepatocytes (http://www.celsis.com), and again there are many published
papers using the MTT assays with cell lines.
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Several other models have been used for investigation of hepatotoxicity with other
classes of drugs, and there are no publications suggesting that an accurate model for
prediction of anti-cancer drug induced hepatotoxicity has been thoroughly
investigated or determined. Examples of published research using different assays
and model systems are provided below.
Biagini et al (2006) performed in vitro MTT and ATP assays using liverbeads®
(cryopreserved hepatocytes entrapped in alginate beads) and WIF-B9 (hybrid cell
line obtained by fusion of rat hepatoma [Fao] and human fibroblasts [WI38]) to
investigate hepatotoxicity. They used several reference hepatotoxic compounds,
none of which were anti-cancer agents, and found that both models could be useful
for investigating the hepatotoxic potential of the selected chemicals using MTT and
ATP assays.
Kikkawa et al (2005) investigated hepatotoxicity using FDH release and WST-1
assays in rat hepatocytes with reference hepatotoxic compounds, and found that the
WST-1 assay that assesses mitochondrial respiration detected cytotoxicity earlier
than the FDF1 release assay with the same compounds, and therefore concluded that
an assay that detects mitochondrial function was useful for predicting hepatotoxicity.
Harries et al (2001) investigated the use of genomics technology to investigate gene
expression changes associated with hepatotoxicity in Hep G2 cells following
exposure to carbon tetrachloride and ethanol. Microarray mRNA analysis revealed
that different groups of genes were up-/down-regulated by ethanol or carbon
tetrachloride and suggested that different mechanisms of hepatotoxicity may be
associated with particular patterns of gene expression, however further investigations
into this would be required. Similarly, HepG2 cells were used by Burczynski et al,
2000 to perform microarray analysis in cells treated with cisplatin and non-steroidal
anti-inflammatory drugs. It was concluded that whilst the results from HepG2 may
be useful in some settings Burczynski et al were going to investigate other biological
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systems that could yield more reproducible and robust transcriptional profiles than
HepG2 cells, however to date they have not published any similar work.
A similar approach to that used in the studies presented in this thesis was employed
by Li et al (1999) using cryopreserved hepatocytes with the MTT assay and they
found this combination to be a useful model for predicting hepatotoxicity with
known hepatotoxic compounds.
The above examples demonstrate that several model systems have been investigated
for the study of hepatotoxicity. For this thesis, it was decided to select assays that
would assess different stages of cell death for the assessment of hepatotoxicity. The
MTT assay detects mitochondrial function whereas the SRB assay detects the total
protein. Using the MTT and SRB assay in all colon cancer cell lines, no differences
were detected in the IC50S 96-hours after the start of drug treatment between the
assays. However, in the fresh hepatocytes and the other cell lines there were
differences between IC50S determined using MTT and SRB after 96hours, but a
donor- or drug-specific pattern of which assay was more sensitive was not revealed
by examining IC50S at 96-hours for the three drugs from all 13 fresh hepatocyte-
donors.
3.7.2 Drugs tested and Therapeutic Index
5-FU and oxaliplatin are used in the clinic for treatment of patients with colorectal
cancer. Mithramycin is infrequently used to treat patients due to the liver toxicity it
causes, however from the NCI60 panel of cell lines, the sensitivity of colorectal cell
lines (used in this thesis) and several others in which mithramycin has been used in
the clinical setting (e.g. testicular, leukaemic) is equivalent (http://dtp.nci.nih.gov/).
The cell models were treated over a range of drug concentrations. It was of interest
to compare the IC50 concentrations determined in vitro to concentrations of drug
achievable in patients. The dose of anti-cancer agents administered to patients is
calculated based on their body surface area, to allow the maximum dose for efficacy
and minimising toxicity in different patients. Pharmacokinetic studies allow
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detection of drug concentration of administered drugs in humans. 5-FU
concentrations have been reported in humans (n=39) following oral treatment with
5'-DFUR for at least 5 consecutive days at a mean total dosage per patient of 6.4g,
with blood and liver samples collected 3-5 hours after final administration (Zheng
and Wang, 2005). The mean plasma and liver 5-FU concentrations were 8.5pM and
43pM respectively (Zheng and Wang, 2005). Another study by Findlay et al (1996)
demonstrated that plasma 5-FU concentrations following administration of 5-FU on a
protracted venous infusion for 8 weeks (300mg/m /day) ranged from less than
0.192pM to 192pM maximum over the 8 weeks, and commented that these plasma
concentrations were higher than those previously reported where steady state plasma
5-FU levels were up to 1.5pM in the first 48 hours of infusion. Therefore the IC50
drug concentrations causing cytotoxicity in vitro for 5-FU in the cells lines in this
thesis are equivalent to drug concentrations achievable in humans, and for the fresh
hepatocytes from the majority of donors, 5-FU concentrations achievable in humans
are lower than those required to cause 50% inhibition of cell survival of hepatocytes
in vitro. The concentration of 5-FU required to cause hepatocyte cell death in vitro
are high and therefore the concept that dose determines poison is relevant here, given
that 5-FU is not widely hepatotoxic in patients. Oxaliplatin concentrations in human
plasma following a single 1-4 hour infusion of 130mg/m oxaliplatin were reported
to range from 3.8juM to 8.1pM in a review of 7 studies on oxaliplatin
pharmacokinetics published by Graham et al (2000). Similar to 5-FU, the
concentration of oxaliplatin achievable in patients is similar to the IC50S determined
in the cell lines and lower than those determined in the fresh hepatocytes in this
thesis. A thorough literature review revealed no human pharmacokinetic studies of
mithramycin, perhaps due to its limited clinical use; therefore comparison with
concentrations achievable in patients is not possible. It should be noted though that
again the IC50S for mithramycin determined in the cell lines is approximately 10-fold
lower than those in hepatocytes, and the molar IC50S for mithramycin are lower than
for oxaliplatin or 5-FU. The type of experiments presented in this thesis may be used
to provide an idea of risk with novel agents at concentrations beyond those used in
the clinic. Knowing the concentrations of drugs achievable in patients it would be of
interest to see how many donors would reach loss of viability at clinically achievable
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concentrations, however with these data not being available for mithramycin, this
could not be investigated.
The drugs selected (mithramycin, oxaliplatin and 5-FU) do not require cytochrome
P450 enzymes for their metabolic activation or detoxification, although 5-FU is
metabolised by other enzymes in the liver and it is likely that these are differentially
expressed between hepatocyte donors and cell lines. A preclinical study from our
laboratory recently showed that liver gene expression can inform the drug
metabolism of capecitabine, a 5-FU pro-drug (Guichard et al, 2007). Whilst the
metabolism of 5-FU was not extensively studied in this paper, an enzyme involved in
5-FU catabolism was evaluated and dihydropyrimidine dehydrogenase expression
was found to be higher in human liver than in HCT116 xenografts in mice.
Evaluation of enzymes involved in metabolism of 5-FU and other drugs may provide
further insight into hepatotoxic potential of drugs, but would have to be considered
on a case-by-case basis. Oxaliplatin was selected as a negative control when these
studies began, however there is an increasing body of evidence that oxaliplatin can
cause liver toxicity. The studies presented in this thesis found oxaliplatin to have a
higher therapeutic index than mithramycin in all groups of cell models, agreeing with
clinical study suggesting that oxaliplatin is not acutely toxic to hepatocytes.
Mithramycin has been infrequently used due to the liver toxicity it can cause,
however more recently the use ofmithramycin in combination with bevacizumab has
been investigated (Jia et al, 2007). Duverger et al (2004) found that mithramycin A
sensitises tumours cells to apoptosis induced by tumour necrosis factor (TNF).
These examples highlight the issue that increased knowledge could lead to increased
use and adaptive dosing strategies for example in combination at lower doses of
drugs, or prolonged administration to avoid peak concentrations, when knowledge of
their hepatotoxic potential is obtained.
The data presented in these studies assess acute toxicity in that a single short
exposure of drug was used. The majority of 'classical' cytotoxic anticancer agents
are administered cyclically where a period of recovery between each dose is allowed.
Perhaps the study of acute toxicity and not long-term toxicity is indeed more relevant
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with anticancer drugs because cytotoxic anti-cancer drugs are used cyclically and the
body is allowed to recover in between, and generally these drugs are only used over a
period of a few months. The experimental design of the studies presented herein is
therefore relevant for cytotoxics.
The IC50 concentration was chosen to compare the two models as it is a commonly
accepted method for reporting cytotoxicity caused by anticancer agents. The
maximum cytotoxic effect reached using the chosen concentration ranges was not
100% in most cell models and to achieve complete cell kill exceptionally high drug
concentrations may have been required, that would be irrelevant in vivo. Also the
aim was to detect clinically significant toxicity and this will occur at doses lower
than those required to induce complete hepatocyte cell death. At very low drug
concentrations it has been observed that in some cases an increase in viable cells is
seen before any decrease and therefore determining a small percentage of cell death
(at lower drug concentrations) may be more difficult and less informative.
The concept of defining a therapeutic index is used for several classes of drugs, not
solely anticancer agents. Another example is antiretroviral agents for which the ratio
of efficacy to toxicity in vitro is often defined to provide information of a drugs
potential clinical utility (Buss and Cammack, 2001). The therapeutic index defined
for mithramycin, oxaliplatin and 5-FU by comparing cytotoxic concentrations in
hepatocyte models and colon cancer cell lines revealed differences between the
known hepatotoxin mithramycin and the other two drugs (5-FU and oxaliplatin).
The use of a therapeutic index as defined in these studies has the potential to increase
drug safety. Currently, the development of anti-cancer agents will assess the active
concentrations of the new compound against a range of cancer cell lines derived from
different cancer types. The use of human liver is often limited to the exploration of
metabolism with short term studies in either intact cells or microsomes. The studies
presented here have demonstrated that, for cytotoxic agents, the use of hepatocytes
over 96 hours using cell viability as the endpoint provides more information as to the
hepatotoxic potential of a compound. Furthermore, the calculation of the TI provides
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insight into the likelihood of achieving active concentrations of the compounds
without hepatic side effects.
The approach of defining a TI was useful when investigating the novel anticancer
agents RM175 and HC11. Preclinical data obtained in mice indicated potential liver
toxicity after treatment with HC11, and to a lesser extent with RM175. When tested
in vitro HC11 was found to be more hepatotoxic than RM175 in fresh hepatocytes,
confirming pre-clinical rodent data. This finding further alerted to the hepatotoxic
potential of HC11 for its clinical development, and provided more confidence in the
in vitro models for detecting hepatotoxicity.
In summary, defining the therapeutic index of the investigated drugs revealed a wide
range of therapeutic indices in the different models. It is promising that the known
hepatotoxic agent mithramycin has lower TI than with 5-FU or oxaliplatin and that
the more hepatotoxic of the novel agents investigated, HC 11, had a lower TI than the
other compound investigated.
3.7.3 Influences on Cytotoxicity in Fresh Hepatocytes
Several parameters were investigated that could impact on cytotoxicity in the fresh
hepatocytes, and these included hepatocyte viability, donor sex, age and smoking
status, and gene expression of selected genes. No donor factors were found to
associate with the IC50 values. The impact of gene expression on hepatocytes IC50S
for each drug was also considered and of the investigated genes, none were found to
correlate with the IC50S for any of the investigated drugs.
3.7.4 Time-points selected and Kinetics of cell death
The time-points of 24-, 48-, 72- and 96- hours after the start of 24-hour drug
treatment were selected to allow detection of progressive toxicity. The time-course
of the assays selected was based on the optimum duration of culture for the
hepatocytes and is also the length of assay used by the NCI for the SRB assay (based
on average doubling time of their panel of 60 cancer cell lines).
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It was hypothesised that due to the different mechanisms of action of the 3 drugs
tested, that differences in the kinetics of cell death would be noted, but on analysis of
this in the hepatoma cell lines and in the fresh hepatocytes no pattern between the
different drugs was observed. This is important because it suggests that short-term
assays may not detect accurately the hepatotoxic potential of some agents. It would
therefore be suggested that a 96-hour assay assessing cell viability is set up to
evaluate the impact of drugs tested on in vitro liver models.
3.7.5 Conclusions
Based on the data presented in this chapter the majority of the in vitro liver models
(fresh hepatocytes, THLE-2 and three of the hepatoma cell lines) can discriminate
the hepatotoxic drug mithramycin from other anticancer compounds (5-FU and
oxaliplatin). THLE-2 cells are more sensitive to mithramycin than the tumour cells
and accurately discriminated mithramycin as hepatotoxic. THLE-2 is a single cell
line that did not express significant levels of several of the liver-specific genes.
Whilst it was predictive for these three drugs it may not be in other situations,
therefore further exploration of the use of THLE-2 cells should be undertaken. The
SK-HEP-1 cell line could not discriminate the hepatotoxic drug and are therefore
unlikely to be useful. The SK-HEP-1 cell line is derived from endothelial cells and
not from hepatocytes, which may help explain its lack of ability to discriminate
hepatotoxic drugs. The method of determining a therapeutic index is proposed to be
useful for the detection of hepatotoxic anti-cancer agents. Further work using HC11
and RM175 confirmed the possibility of detection of hepatotoxicity using fresh
hepatocytes and hepatoma cell lines. However, it would be desirable to investigate
more compounds to confirm these findings.
Drawing conclusions from 13 donors would generally be considered a very small
sample. However, several published reports of work using human hepatocytes
reports results from 4 or less donors (Baughman et al, 2005; Kostrubsky et al, 2003;
Kostrubsky et al, 2005). By comparison the number of samples from which data has
been generated in these studies is high. However, there is significant inter-donor
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variability in response to each drug tested. Notably the least variation is seen in
response to mithramycin.
The comparison of therapeutic and toxic drug concentrations to determine
hepatotoxic drugs is potentially very useful and has not been reported previously.
Whilst the response of the cells to the drug treatment is interesting alone, the
comparison allows more meaningful conclusions to be drawn. However, the
prospect of detecting cell death sooner and obtaining insight into the mechanism of
cell death caused is appealing and will be investigated in the following chapter.
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CHAPTER 4: Results
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4.1 INTRODUCTION
In the previous chapter, drug-induced hepatocyte toxicity was detected using
cytotoxicity assays; therefore cell death was considered as the endpoint. However, it
would be desirable to detect cell stress induced by anti-cancer agents earlier
following drug treatment. As outlined in section 1.2.2, cells die via two main
mechanisms, namely apoptosis and oncosis. The possibility of finding an assay to
detect oncosis or apoptosis and provide insight into the mechanism of cell death
resulting in toxicity, and to identify liver toxicity sooner than the cytotoxicity assays
presented in chapter 3, was investigated.
Different mechanisms of cell death have been identified following anti-cancer drug
treatment, based on biochemical and morphological features within cells. Notably,
drugs have different biochemical targets, e.g. platinum compounds target DNA, and
taxanes target microtubules (see section 3.1.2 for mechanism of action of drugs used
in this thesis), but all drugs ultimately kill cells by activating biochemical cascades of
apoptosis or by causing oncosis. Research until the end of the 1980s suggested that
anti-cancer drugs induced cell death by a non-specific and uncontrolled oncotic
mechanism (Martin et al, 2000). However, a greater understanding of apoptosis from
1990 onwards and many investigations involving anticancer agents, both in vitro and
in vivo, have proved the case for the involvement of apoptosis in tumour-cell death
following administration of several classes of anticancer drugs (Fulda et al, 2001;
Kim et al, 2002; Petak and Houghton, 2001). For example, 5-FU has been shown to
induce apoptosis in many cancer types including salivary gland cancer cell lines,
colon cancer cell lines and in liver metastases of colorectal cancer patients (Aota et
al, 2000; Backus et al, 2001).
There is now clear evidence that apoptosis and oncosis are not mutually exclusive
processes (Fink and Cookson, 2005; Jaeschke and Lemasters, 2003), but rather that a
combination of both may occur in different cells. The complexity of interacting
processes in dying cells occurring simultaneously should be acknowledged.
Furthermore, inhibiting one part of the cell death signalling pathways may not result
in cell survival and may solely act to execute another pathway (Nicotera et al, 1998).
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Leist et al, 1997 provide evidence that cells triggered to undergo apoptosis are
instead forced to die by necrosis when ATP energy levels are rapidly compromised.
The mechanism of cell death can also vary, depending on the drug in question, the
drug concentration and which model is being used to study it.
4.1.1 Methods Available for Detection of Cell Death
Several methods are available for the detection of apoptosis and oncosis in vitro (see
figure 4.1). Apoptosis involves a cascade of events occurring sequentially, and
methods are available to detect both early and late stages of apoptosis. The
characteristics of apoptosis are the same regardless of how apoptosis is initiated:
permeabilisation of the mitochondrial membrane; the appearance of
phosphatidylserine at the plasma membrane; chromatin condensation and
fragmentation in the nucleus; and caspase activation (Lawen, 2003), and methods are
available for detecting these different stages. Characteristics of oncosis are less well
defined than for apoptosis, however rapid permeabilisation of the plasma membrane
and leakage of intracellular contents occur during oncosis and there are methods
available for the detection of these parameters.
Plasma membrane permeability may be studied with a variety of techniques
including propidium iodide (PI) and annexin V (AV) staining, and ATP and LDH
depletion or leakage. Living cells with an intact plasma membrane exclude cationic
dyes such as PI or trypan blue under normal circumstances. When the cell
membrane becomes damaged, these dyes can enter the cell. Apoptotic cells will
maintain the integrity of the cell membrane for longer than oncotic cells, which
would be very quickly stained by dyes such as PI due to extensive membrane
damage. Analysis of PI positive and negative cells is usually performed by flow
cytometry and is not commonly used with adherent cells: trypsinisation of adherent
cells would be required to generate a cell suspension which can damage the cell
membrane and lead to artificial Pl-positivity.
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Figure 4.1: Summary of methods available for detection of apoptosis or
oncosis
Several methods are available for the detection of apoptosis and oncosis.
Morphological and biochemical changes occur and their cellular location is
demonstrated.
Early during apoptosis, phospatidylserine (PS) normally present in the inner layer of
the cell membrane, flips to the outer membrane. Annexin V readily binds to PS, and
conjugates of annexin V with a fluorescent dye such as fluorescein isothiocyanate
(FITC), are often used to detect cells with exposed PS. As with PI detection,
analysis of Annexin V-positive cells is performed using flow cytometry, meaning
that this technique is not ideal for adherent cells. If plasma membrane damage is
extensive, annexin V will gain access to and bind PS present in the inner membrane
of cells. It is therefore recommended to perform dual staining with both annexin V
and PI to discriminate apoptotic (AV+/PI-) from oncotic (AV+/PI+) cells.
Membrane damage during oncosis results in leakage of molecules from the cell in
vitro into the cell culture medium. Small molecules such as ATP leak rapidly, and
rapid and extensive loss of ATP is a marker of oncosis. Apoptosis is an energy
requiring process, however cells undergoing apoptosis will maintain higher levels of
ATP for a longer period of time than those cells dying by oncosis. It has been
reported that the ratio of ADP:ATP can be used to discriminate between cell death
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occurring via apoptosis and what is referred to as oncosis in in vitro systems
(Bradbury et al, 2000). Another cellular macromolecule, which can be studied to
assess cell death, is the cytoplasmic enzyme lactate dehydrogenase (LDH).
Following loss of plasma membrane integrity during apoptosis or oncosis, LDH will
exit the cells and colorimetric assays are available to detect LDH in tissue culture
medium.
Caspase activity can also be detected as a marker of early-stage apoptosis. Caspase-
3 is activated whether apoptosis occurs via the receptor or mitochondrial pathway
(Fulda et al. 2001). Caspase-3 and caspase-7 are effector caspases rather than the
initiator caspases, and therefore their activation occurs following activation of the
relevant initiator caspases. Pro-caspases are cleaved during apoptosis and it is
possible to detect caspase activation via Western blotting and via the use of a pro-
fluorescent substrate. As mentioned previously, Western blotting is not suitable for
screening purposes with many samples and the use of a pro-fluorescent substrate is
more suited to this purpose. This type of caspase assay requires a labelled dye which
fluoresces when cleaved by caspases. The intensity of the measured fluorescence is
therefore proportional to caspase activation, and this technique is suitable for
adherent cells.
Mitochondrial membrane permeability (MMP) is a relatively late event occurring
during apoptosis, and is usually detected using dyes with high affinity for the
mitochondria. JC-1 is a commonly used fluorescent cationic dye that accumulates in
the mitochondria of healthy cells as aggregates which fluoresce red. Upon the onset
of apoptosis, the mitochondrial membrane potential collapses and the JC-1 dye can
no-longer accumulate and aggregate in the mitochondria and therefore remains in the
cytoplasm in its monomeric form (which fluoresces green). The MMP is measured
as the differential distribution of red and green fluorescence, and is usually detected
by flow cytometry but analysis can also be performed by fluorescence microscopy.
Cytochrome c release from the mitochondria may also be detected, usually by
Western blotting. This technique is low-throughput, requires many cells and is
therefore not practical for screening purposes.
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Finally, DNA fragmentation is characteristic of late-stage apoptosis, and can be
detected using several techniques. PI staining with flow cytometric or microscopic
detection can be used to assess DNA fragmentation as PI also readily binds to DNA.
Another technique used to examine DNA fragmentation during apoptosis is the
terminal uridine deoxynucleotidyl transferase dUTP nick end labelling (TUNEL)
assay. DNA fragments generated during apoptosis can react with the terminal
deoxynucleotidyl transferase enzyme which catalyses the addition of dUTPs that are
labelled with a marker, which allows the DNA fragmentation to be detected.
4.1.2 Chapter Aims and Overview
Understanding more about the mechanism of cell death induced by anticancer drugs
in hepatocyte models may provide a better understanding of the observed toxicities
in humans. The mode of cell death induced is relevant to the subsequent fate of the
tissue in that apoptotic bodies are rapidly recognised and phagocytosed by either
macrophages (Kupffer cells are the resident macrophages of the liver) or adjacent
epithelial cells. Conversely, oncotic cell death results in cell rupture, releasing the
cell contents into the surrounding tissue and will most likely result in an
inflammatory response and potentially a greater area of damage in the liver.
A rapid, sensitive, specific assay was required, that can detect early rather than late
consequences of cellular response to drugs, and therefore 2 techniques from those
outlined in section 4.1.1 were selected. The cell models have been further
investigated, following 24-hour drug exposure, using an assay that measures ATP
levels in cells, and an assay that measures caspase-3/7 activity.
Four of the hepatoma cell lines (Hep3B, Huh-7D12, HepG2 and PLC/PRF/5), fresh
hepatocytes from 2 donors (12 and 13), and cryopreserved hepatocytes from 3 donors
(C2, C3 and C4), were exposed to 5-FU, mithramycin and oxaliplatin to evaluate
whether the 2 selected assays could detect hepatocyte toxicity earlier than the
cytotoxicity assays described in chapter 3. It should be noted that the number of
cryopreserved hepatocytes available were limited, and therefore selected doses of
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each drug were tested. The response of the models to drug treatment in terms of
caspase-3/7 activation and/or ATP loss may aid in the investigation of which in vitro
models respond in a similar way to the hepatocytes in response to particular drugs
and provide insight into the mechanism of cell death occurring after drug exposure.
4.2 ESTABLISHMENT OF THE SELECTED IN VITRO ASSAYS
After assays were selected to measure ATP, ADP and caspase-3/7 in drug treated in
vitro models of the liver, preliminary experiments were carried out to establish their
performance and sensitivity. To validate these assays, initial experiments were
carried out using known apoptosis and oncosis inducers. TNF-related apoptosis
inducing ligand (TRAIL)-treatment of the HCT116 colorectal cancer cell line was
performed as a positive control for apoptosis, and heatshock and kahalalide F
treatment ofHepG2 cells was performed as a positive control for oncosis.
4.2.1 Adenylate Nucleotide Ratio Assay
Bioluminescent detection and measurement of ATP, that is present in all
metabolically active cells, has been undertaken since the mid-1980s (Kangas et al,
1984; Higashi et al 1985). Initially, solely ATP was measured by this method to
determine cell viability, however more recently it has been reported that by
measuring levels of both ADP and ATP in cells it is possible to discriminate between
apoptotic and oncotic cell death (Bradbury et al, 2000). ATP levels are simply
measured by bioluminescence: luciferase consumes ATP to convert luciferin to light.
ADP can be converted into ATP and by making 2 successive measurements (before
and after addition of ADP-CR), an indirect measurement of ADP levels and a direct
measurement of ATP is provided.
The adenylate nucleotide ratio assay from Cambrex, ApoGlow™, was initially
selected to measure both ADP and ATP in cells, but proved to be unreliable and
results were not reproducible (see chapter 6). The CellTiter-Glo® assay (Promega)
was therefore used to measure ATP levels in cells, followed by the use of ADP
converting reagent (ADP-CR) from the Cambrex ApoGlow™ kit to measure ADP.
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In order to confirm the finding of Bradbury et al (2000) that ADP and ATP levels
could be used to discriminate between cells dying by apoptosis or oncosis,
preliminary experiments were carried out. HepG2 cells were heat-shocked for 1 hour
at 57°C to induce oncosis. Heat-shock results in massive cell death, and ATP
depletion as demonstrated in figure 4.2. ADP levels are in fact higher than ATP
levels in heat-shocked cells, resulting in a high ADP:ATP ratio as reported by
Bradbury et al (2000). Control cells showed an ADP:ATP ratio of 0.25, lower than 1
as expected. In heat-shocked cells, the ADP levels were higher than ATP levels, and
ADP:ATP ratio was 4.8 similar to ADP:ATP ratios reported in oncotic cells by
Bradbury et al. However this is mainly due to ATP depletion subsequent to massive
cell death as can be seen in figure 4.2.
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Figure 4.2: ADP and ATP levels in HepG2 cells after heat-shock
HepG2 cells were incubated at 37°C (control) or at 57°C (heated) for 1 hour, before
5000 cells were aliquoted per well and ADP and ATP assay performed. A, raw RLU
data from luminometer. B, ATP levels.
To assess whether ADP:ATP ratios could discriminate oncosis from apoptosis,
HepG2 cells were exposed to increasing concentrations of Kahahlide F; an
anticancer drug previously shown to induce oncosis (Sewell et al, 2005). Profound
ATP depletion occurred in a dose-dependent manner from 99% of control after
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0.05 pM of kahalalide F to 15% after 1 pM and <1% after 5 pM drug, and ADP
depletion followed the same trend. The ADP:ATP ratio increases only slightly at 1
and 5 pM Kahalalide F (0.81 and 0.7 respectively), compared with 0.61 in control
cells and these ratios are not of the same magnitude of changes as those reported by
Bradbury et al (2000) in cells dying by oncosis.
As a low ADP:ATP ratio has been reported to correspond to apoptotic cell death
(Bradbury et al, 2000), HCT116 cells were treated with TRAIL, an agent known to
induce apoptosis (figure 4.4). After treatment of HCT116 cells with TRAIL for 2.5
hours, levels of ATP and ADP were normalised to SRB assay data (to account for
differences in cell number) and did not change significantly with increasing TRAIL
concentration. HCT116 cells did not show any change in ATP levels except at the
highest concentration of TRAIL (50ng/ml) by which time 40% of the cells had died
(determined via SRB assay) (figure 4.4). ADP:ATP ratios did not change compared
to control (-0.66) whatever the TRAIL concentration although a slight increase
(0.77) was observed after exposure to 50ng/ml ofTRAIL.
This study therefore shows that, under the conditions tested, the ratio of ADP:ATP
could not discriminate between apoptosis and oncosis as previously published. The
Apoglow™ kit from Cambrex and the paper by Bradbury et al (2000) reported
ADP:ATP ratios of 0.1 in control cells, 0.11-1 in celld dying by apoptosis and
ADP:ATP ratios >15 in cells dying via an oncotic mechanism. Despite the
ADP:ATP assays not being used for the studies presented in this thesis. ATP levels
may inform whether or not profound ATP depletion leading to oncosis would take
place.
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Figure 4.3: Oncosis induction by Kahalalide F in HepG2 cells
13000 HepG2 cells were plated per well, and allowed to attach overnight. Cells were
then treated with a concentration range of kahalalide F for 24 hours before ADP and
ATP assay.
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Figure 4.4: ADP and ATP levels in HCT116 cells after TRAIL exposure
25000 HCT116 cells were plated per well, and allowed to attach overnight. Cells
were then treated with a concentration range of TRAIL for 2.5 hours before ADP and
ATP assay.
4.2.2 Caspase-3/7 Assay
Caspase-3/7 activity was measured using the Apo-ONE® Homogeneous Caspase-3/7
assay from Promega. Induction of apoptosis has been reported in the HCT116 colon
cancer cell line, following treatment with tumour necrosis factor-related apoptosis
inducing ligand (TRAIL) (Cummins et al, 2004) and was used as a positive control.
HepG2 cells exposed to Kahalalide F were used as a negative control.
TRAIL induced a dose-dependent and linear increase in caspase-3/7 in HCT116 cells
(see figure 4.5) from 120% of control at 0.5ng/ml TRAIL to 970% at lOng/ml
consistent with reports of apoptosis induction. The caspase-3/7 assay was also tested
with Kahalalide F, known to induce cell death via oncosis rather than apoptosis.
Levels of caspase-3/7 remained comparatively low even at high concentrations of
Kahalalide F (300% at 5 pM)(see figure 4.6). This suggests that apoptosis if present,
is limited after Kahalalide F exposure using the caspase-3/7 assay, which is
consistent with published reports (Sewell et al, 2005).
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Figure 4.5: Induction of apoptosis in HCT116 cells treated with TRAIL
HCT116 cells (25000 per well) were plated and left overnight to attach. Cells were
exposed to TRAIL (0.5ng/ml to lOng/ml) for 2.5 hours before caspase-3/7 reagent
was added. Measurements were made 21 hours after addition of caspase-3/7 reagent.









































0.001 0.01 0.1 1
Kahalalide concentration (uM)
10
Figure 4.6: Caspase-3/7 activity in FlepG2 cells exposed to kahalalide F
13000 HepG2 cells were plated per well, and allowed to attach overnight. Cells were
then treated with a concentration range of kahalalide F for 24 hours before caspase-
3/7 assay. Results are presented as mean and S.D. of triplicates.
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4.3 ATP LEVELS IN CELLS FOLLOWING DRUG TREATMENT
ATP levels were measured in hepatoma cell lines and human hepatocytes following
24-hour drug treatment with mithramycin, oxaliplatin and 5-FU. Following drug
treatment for 24 hours, a proportion of the cells treated with some of the higher drug
concentrations in all cell lines and types had died, as detected by the SRB assay. In
order to determine the ATP levels within the cells that were living at the end of drug
treatment compared to the ATP levels in untreated control cells, the results obtained
from the ATP assay were normalised to the results from the SRB assay.
4.3.1 ATP Levels in Cells Following Mithramycin Treatment
Hepatoma cell lines were treated with a concentration range of mithramycin for 24
hours before determination of ATP levels in cells (see figure 4.7). Both Huh-7D12
and PLC/PRF/5 showed an increase in intracellular ATP content at the lowest
concentration of mithramycin tested (0.1 pM), which decreased slightly in both cell
lines with increasing mithramycin concentration. However, ATP content was still
greater than in the control cells at the highest drug concentration tested (25pM) for
both cell lines. Hep3B2.1-7 and Hep G2 cells maintained similar ATP levels to
control cells at the lowest drug concentration tested (0.1 pM), which decreased with
increasing drug concentration to 67% and 93% of the ATP content respectively when
compared to control cells, at the highest mithramycin concentration tested (25pM)
suggesting that oncosis was not occurring.
The hepatocytes (fresh and cryopreserved) were also treated with increasing
concentrations of mithramycin for 24 hours before determination of intracellular
ATP levels (see figure 4.8). Donors 12 and 13 responded similarly to increasing
concentrations ofmithramycin. with ATP approximately 100% of control ATP levels
at the lowest drug concentration investigated (0.01 pM) and decreasing ATP content
with increasing mithramycin concentration. At the highest mithramycin
concentration tested (25pM), ATP content was at its lowest and was 71% and 87% in
hepatocytes from donors 12 and 13 respectively.
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Figure 4.7: ATP levels following mithramycin treatment in hepatoma cell lines
Cell were plated (5000cells/well for Hep3B, HepG2, Huh-7D12 and 3000cells/well
for PLC/PRF/5) and allowed to attach overnight before treatment with a range of
mithramycin concentrations. At the end of drug treatment CellTiter-Glo reagent was
added and RLU measured. Results are expressed as mean and S.E.M. of at least two
independent experiments.
The cryopreserved hepatocytes from donors C2, C3, and C4 were limited in
availability and therefore selected doses of each drug were used to treat these cells
rather than a full concentration range of drug concentrations (see figure 4.8). At the
lowest drug concentration tested (lpM), hepatocytes from donors C2 and C4
responded similarly to one another and to the fresh hepatocytes, with ATP content
being approximately equal to that of untreated control cells. Donor C3 responded
differently to the other hepatocytes and the ATP content was approximately 35% of
that in control cells when treated with lpM mithramycin. At the highest
mithramycin concentration investigated (25pM), ATP content in cryopreserved
hepatocytes varied between donors: 88%, 43% and 102% for donors C2, C3 and C4
respectively, when compared with untreated control cells.
When comparing the different models in terms of ATP content in response to
mithramycin treatment, hepatocytes from donors 12, 13, C2 and C4 appear to
respond similarly to increasing concentration of mithramycin as Hep3B2.1-7 and
Hep G2 cell lines.
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Figure 4.8: ATP levels following mithramycin treatment in hepatocytes
Cells were plated (20000 viable cells/well) from 2 fresh hepatocyte donors (12 and
13) and 3 cryopreserved hepatocyte donors (C2, C3 and C4) and allowed to attach
before treatment with a range of mithramycin concentrations. At the end of drug
treatment CellTiter-Glo reagent was added and RLU measured. Results are
expressed as mean and S.E.M. of triplicates.
4.3.2 ATP Levels in Cells Following Oxaliplatin Treatment
Hepatoma cell lines were treated with a concentration range of oxaliplatin for 24
hours before determination of ATP levels in cells (see figure 4.9). Huh-7D12,
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PLC/PRF/and Hep3B2.1-7 responded similarly to one another in response to
increasing oxaliplatin concentrations. From 5pM to 50pM little change in ATP
content was seen with increasing oxaliplatin concentration, however increasing
oxaliplatin concentration to 250pM resulted in loss of cellular ATP content to
approximately 50% of control ATP content for Hep3B2.1-7 and FIuh-7D12 and to
approximately 60% of control ATP content in PLC/PRF/5 cells. For comparison, the
mean IC50 in the hepatoma cell lines at 96-hours as determined in chapter 3 was
1.17pM. HepG2 cells demonstrated a slight increase in ATP content when compared






























Figure 4.9: ATP levels following oxaliplatin treatment in hepatoma cell lines
Cell were plated (5000cells/well for Hep3B, HepG2, Huh-7D12 and 3000cells/well
for PLC/PRF/5) and allowed to attach before treatment with a range of oxaliplatin
concentrations. At the end of drug treatment CellTiter-Glo reagent was added and
RLU measured. Results are expressed as mean and S.E.M. of at least two
independent experiments.
Fresh hepatocytes from donors 12 and 13 showed a similar response following
treatment with increasing concentrations of oxaliplatin as Huh-7D12, PLC/PRF/and
Hep3B2.1-7 cell lines (figure 4.10). Little difference in ATP content when compared
to untreated control cells was seen until a concentration of 50pM oxaliplatin was
reached, after which increasing oxaliplatin concentration resulted in decreased
cellular ATP content. The cryopreserved hepatocytes from donors C2, C3 and C4
varied widely to one another in response to treatment with oxaliplatin. Donor C3
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was the most sensitive to oxaliplatin with over 80% ATP loss compared to control
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Figure 4.10: ATP levels following oxaliplatin treatment in hepatocytes
Cells were plated (20000 viable cells/well) from 2 fresh hepatocyte donors and 3
cryopreserved hepatocyte donors and allowed to attach before treatment with a range
of oxaliplatin concentrations. At the end of drug treatment CellTiter-Glo reagent was
added and RLU measured. Results are expressed as mean and S.E.M. of triplicates.
4.3.3 ATP Levels in Cells Following 5-FU Treatment
Hepatoma cell lines were treated with a concentration range of 5-FU for 24 hours
before determination of ATP levels in cells. Hep3B2.1-7, PLC/PRF/5 and HepG2
responded similarly to one another in response to increasing 5-FU concentrations
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(figure 4.11). From lOpM to lOOpM little change in ATP content was seen with
increasing 5-FU concentration, however increasing 5-FU concentration to lOOOOpM
resulted in loss of cellular ATP content to approximately 50% of control ATP
content in all three cell lines. Huh-7D12 cells showed the same trend of ATP loss
with increasing 5-FU concentrations; however ATP loss reached a maximum of 82%































Figure 4.11; ATP levels following 5-FU treatment in hepatoma cell lines
Cells were plated (5000cells/well for Hep3B. HepG2, Huh-7D12 and 3000cells/well
for PLC/PRF/5) and allowed to attach before treatment with a range of 5-FU
concentrations for 24 hours. At the end of drug treatment CellTiter-Glo reagent was
added and RLU measured. Results are expressed as mean and S.E.M. of at least two
independent experiments.
Fresh hepatocytes from donors 12 and 13 responded differently to increasing 5-FU
concentrations. Hepatocytes from donor 12 showed an increase in cellular ATP
content over the 5-FU concentration range, lpM to lOOOOpM. Hepatocytes from
donor 13 showed a decrease in cellular ATP content with increasing 5-FU
concentration and ATP content was 60% of that in control cells at the highest drug
concentration investigated (lOOOOpM). The cryopreserved hepatocytes from donors
C2, C3 and C4 varied in response to treatment with 5-FU, but intracellular ATP
content decreased in hepatocytes from all 3 donors with increasing 5-FU
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concentration. Greatest ATP loss compared to control was observed in
cryopreserved hepatocytes from donor C3 treated with lOmM 5-FU (53%) followed
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Figure 4.12: ATP levels following 5-FU treatment in hepatocytes
Cells were plated (20000 viable cells/well) from 2 fresh hepatocyte donors and 3
cryopreserved hepatocyte donors and allowed to attach before treatment with a range
of 5-FU concentrations. At the end of drug treatment CellTiter-Glo reagent was
added and RLU measured. Results are expressed as mean and S.E.M. of triplicates.
When considering all three of the drugs tested. ATP depletion was limited in the
hepatoma cell lines : Hep3B2.1-7 was the only cell line showing significant decrease
of ATP for all drugs tested: 57% at lOmM 5-FU, 55% at 250pM oxaliplatin and 67%
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at 25 p.M mithramycin. These results suggest that oncosis, inducing profound ATP
depletion, does not occur in hepatoma cell lines after drug exposure unless
concentrations far beyond the IC50S determined in chapter 3 are applied. When
considering ATP levels for all three drugs in fresh hepatocytes from both donors, for
mithramycin and oxaliplatin the response in terms of ATP levels were similar,
whereas in response to 5-FU, ATP loss was observed in hepatocytes from donor 13
and not donor 12. As for the hepatoma cell lines, substantial ATP loss was only
observed at concentrations far higher than the IC50S determined in chapter 3.
4.4 CASPASE-3/7 ACTIVATION IN CELLS FOLLOWING DRUG
TREATMENT
Profound ATP depletion does not occur after exposure of the different cell models to
mithramycin, oxaliplatin or 5-FU, suggesting that apoptosis rather than oncosis is
induced by these drugs at cytotoxic concentrations. In order to confirm this
hypothesis, Caspase-3/7 levels were measured in the hepatocyte models following
24-hour drug treatment with mithramycin, oxaliplatin and 5-FU.
4.4.1 Caspase-3/7 Activation Following Mithramycin Treatment
Hepatoma cell lines were treated with a concentration range of mithramycin for 24
hours before determination of caspase-3/7 levels in cells (see figure 4.13).
PLC/PRF/5 and Hep3B2.1-7 responded similarly to increasing mithramycin
concentrations, with caspase-3/7 activity increasing with increasing mithramycin
concentration. The activation peaked at lpM mithramycin in Hep3B2.1-7 cells, and
at lOpM mithramycin in PLC/PRF/5 to an approximately 6-fold increase compared
to control in both cases. In these cell lines, caspase activation was lower at the
highest concentrations at 4 and 5.2-fold in Hep3B2.1-7 and PLC/PRF/5 respectively.
The Hep G2 and Huh-7D12 cell lines responded very similarly to one another in
response to increasing mithramycin concentrations with a dose-dependent but limited
increase in caspase-3-7 activity to approximately 2-fold when compared with control
cells at the maximum mithramycin concentration tested (25pM).
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In hepatocytes from donors 12 and 13 the response to increasing mithramycin
concentration in terms of caspase-3/7 activation varied greatly (figure 4.14).
Hepatocytes from donor 12 had a much larger increase in caspase-3/7 activity in
response to mithramycin than hepatocytes from donor 13, and in hepatocytes from
donor 12 peak caspase-3/7 activity was observed at 10p.M mithramycin (15-fold).
The cryopreserved hepatocytes from donors C2, C3 and C4 varied in response to
treatment with mithramycin, and caspase-3/7 activation was more similar to that in




















Figure 4.13: Caspase-3/7 following mithramycin treatment in hepatoma cell
lines
Cells were plated (5000cells/well for Hep3B, HepG2, Huh-7D12 and 3000cells/well
for PLC/PRF/5) and allowed to attach overnight before treatment with a range of
mithramycin concentrations. At the end of drug treatment caspase-3/7 reagent was
added and RFU measured after 21 hours. Results are expressed as mean and S.E.M.
of at least two independent experiments.
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Figure 4.14: Caspase-3/7 levels following mithramycin treatment in
hepatocytes
Cells were plated (20000 viable cells/well) from 2 fresh hepatocyte donors and 3
cryopreserved hepatocyte donors and allowed to attach overnight before treatment
with a range of mithramycin concentrations. At the end of drug treatment caspase-
3/7 reagent was added and RFU measured after 21 hours. Results are expressed as
mean and S.E.M. of triplicates.
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4.4.2 Caspase-3/7 Activation Following Oxaliplatin Treatment
Hepatoma cell lines were treated with a concentration range of oxaliplatin for 24
hours before determination of caspase-3/7 levels in cells. All four of the hepatoma
cell lines investigated demonstrated a dose-dependent increase in caspase-3/7
activation beginning at the oxaliplatin concentration of 5pM (see figure 4.15).
HepG2 cells showed caspase activation (5-fold) at the lowest oxaliplatin
concentration (lOpM) compared to the other cells lines. However, concentrations of
oxaliplatin greater than lOpM did not result in further caspase activation in HepG2
cells. In the other hepatoma cell lines, maximum caspase activation in response to
oxaliplatin was observed at 50pM, lOOpM and 250 pM in Huh-7D12 (6.5-fold),
Hep3B2.1-7 (8-fold) and PLC/PRF/5 (5-fold) respectively.
Similar to mithramycin response, in hepatocytes from donors 12 and 13 the response
to increasing oxaliplatin concentration in terms of caspase-3/7 activation varied
greatly (figure 4.16). Hepatocytes from donor 12 had a much larger increase in
caspase-3/7 activity in response to oxaliplatin than hepatocytes from donor 13, and
maximum activation was observed in donor 12 at 100 pM oxaliplatin (14-fold). The
cryopreserved hepatocytes from donors C2, C3 and C4 varied in response to
treatment with oxaliplatin, and caspase-3/7 activation was more similar to that in
hepatocytes from donor 13 than from donor 12 (figure 4.16).
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Figure 4.15: Caspase-3/7 levels following oxaliplatin treatment in hepatoma
Cells were plated (5000cells/well for Hep3B. HepG2, Huh-7D12 and 3000cells/well
for PLC/PRF/5) and allowed to attach overnight before treatment with a range of
oxaliplatin concentrations. At the end of drug treatment caspase-3/7 reagent was
added and RFU measured after 21 hours. Results are expressed as mean and S.E.M.
of at least two independent experiments.
cell lines
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Figure 4.16: Caspase-3/7 levels following oxaliplatin treatment in hepatocytes
Cells were plated (20000 viable cells/well) from 2 fresh hepatocyte donors and 3
cryopreserved hepatocyte donors and allowed to attach overnight before treatment
with a range of oxaliplatin concentrations. At the end of drug treatment caspase-3/7
reagent was added and RFU measured after 21 hours. Results are expressed as mean
and S.E.M. of triplicates.
4.4.3 Caspase-3/7 Activation Following 5-FU Treatment
Hepatoma cell lines were treated with a concentration range of 5-FU for 24 hours
before determination of caspase-3/7 levels in cells, and the results are presented in
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figure 4.17. Huh-7D12 showed no change in caspase-3/7 activity with increasing 5-
FU concentration. PLC/PRF/5 and Hep3B2.1-7 demonstrated a small dose-
dependent increase in caspase-3/7 activity with increasing 5-FU concentration.
Caspase-3/7 activity increased in Hep G2 cells with 5-FU concentration increasing
from lOOOpM to 10000 5-FUpM (to 3.5-fold).
Similar to the two drugs tested previously, in hepatocytes from donors 12 and 13 the
response to increasing 5-FU concentration in terms of caspase-3/7 activation varied
greatly. Hepatocytes from donor 12 had a much larger increase in caspase-3/7
activity in response to 5-FU than hepatocytes from donor 13 (figure 4.18), and
maximum caspase activation was observe in hepatocytes from donor 12 at 5-FU
concentration of lOOOOpM. The cryopreserved hepatocytes from donors C2, C3 and
C4 varied in response to treatment with 5-FU (figure 4.18). The cryopreserved
hepatocytes from donors C2, C3 and C4 varied in response to treatment with
mithramycin, oxaliplatin and 5-FU and caspase-3/7 activation was more similar to
that in fresh hepatocytes from donor 13 than donor 12.
In the fresh hepatocytes, all three drugs tested induced caspase-3/7 activation in
hepatocytes from donor number 12, and very limited caspase activation in
hepatocytes from donor number 13. The difference between the 2 samples may be
partially explained by the normalisation of caspase-3/7 data to the SRB optical
density data. In hepatocytes from donor number 12, a dose-dependent increase in
cell death was observed with increasing drug concentration whereas in hepatocytes
from donor number 13 very little cell death was observed immediately following 24-
hour drug exposure. The difference in normalised caspase-3/7 levels is therefore
greater in the data from donor 12 than 13. However, decrease in SRB OD confirms
cell death which is reflected by the increase in caspase-3/7 in donor 12.
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Figure 4.17: Caspase-3/7 levels following 5-FU treatment of hepatoma cell
lines
Cells were plated (5000cells/well for Hep3B. HepG2, Huh-7D12 and 3000cells/well
for PLC/PRF/5) and allowed to attach overnight before treatment with a range of 5-
FU concentrations. At the end of drug treatment caspase-3/7 reagent was added and
RFU measured after 21 hours. Results are expressed as mean and S.E.M. of at least
two independent experiments.
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Figure 4.18: Caspase-3/7 levels following 5-FU treatment of hepatocytes
Cells were plated (20000 viable cells/well) from 2 fresh hepatocyte donors and 3
cryopreserved hepatocyte donors and allowed to attach overnight before treatment
with a range of 5-FU concentrations. At the end of drug treatment caspase-3/7
reagent was added and RFU measured after 21 hours. Results are expressed as mean
and S.E.M. of triplicates.
4.5 COMPARISON OF EARLY (24-HOUR) AND LATER (96-HOUR) DATA
The MTT and SRB assays provide a measure of cell number either by detecting the
metabolic capacity of cells (MTT), or the amount of cellular protein (SRB).
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Individually, these assays allow the detection of changes in cell number in response
to drug treatment in vitro. Whilst useful on their own, it was also of interest to detect
the earlier response of cells to treatment with anti-cancer agents. It was hypothesised
that by measuring the levels of a nucleotide present in cells (ATP), immediately
following drug treatment it may be possible to detect the earlier response of cells to
drug-treatment. The ATP assay has been used to detect changes in drug-treated cells
at the end of 24-hour drug treatment. The data from the ATP assay will be compared
with the data from MTT and SRB assays at 96 hours after the start of drug treatment
(in chapter 3) to determine whether the ATP assay can provide an earlier indication
and the same pattern of cell death as the SRB and MTT assays at a later timepoint.
For comparison with the cytotoxicity detected after 96 hours with the SRB and MTT
assays, the ATP assay carried out immediately following 24-hour drug treatment will
be examined.
To determine whether ATP levels (normalised to SRB) in drug-treated cells detected
immediately following 24-hour drug treatment may be used as a method for earlier
detection of cellular response to drug treatment (than SRB or MTT assay at 96
hours), results from ATP and SRB assays immediately following drug treatment and
SRB and MTT assays at the end of drug treatment are plotted in figures 4.19 and
4.20, 4.21 and 4.22 for fresh hepatocytes and hepatoma cell lines respectively.
4.5.1 Mithramycin
In Hep3B2.1-7 cells intracellular ATP levels decrease with increasing drug
concentration and in HepG2, Huh-7D12 and PLC/PRF/5 cells intracellular ATP
levels do not change with increasing drug concentration. Caspase-3/7 activation
increases minorly in HepG2 and Huh-7D12 cells and increases more in PLC/PRF/5
and Hep3B2.1-7 cells with increasing drug concentration. At 96 hours the results
obtained using the SRB assay and MTT assays are similar in FIepG2 cells and in
Hep3B2.l -7, Huh-7D12 and PLC/PRF/5, at 96 hours the SRB assay is more sensitive
than the MTT assay.
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In hepatocytes from donor 12 and 13, intracellular ATP decreases minorly with
increasing drug concentration. Caspase-3/7 activation increases with increasing drug
concentration in hepatocytes from donor 12 and to a much lesser extent in
hepatocytes from donor 13. At 96 hours the MTT assay is more sensitive than the
SRB assay in donor 12 and the opposite is true for donor 13.
4.5.2 Oxaliplatin
In Hep3B2.1-7, Huh7D12 and PLC/PRF/5 cells intracellular ATP levels decreased
with increasing drug concentration. In the same three cell lines, caspase-3/7
activation increases with increasing drug concentration, and at 96 hours the SRB
assay is more sensitive than the MTT assay. In Hep G2 cells, intracellular ATP
levels do not change with increasing drug concentration. Caspase-3/7 activation
increases with increasing drug concentration, but to a lesser extent than in the other
hepatoma cell lines. At 96 hours the SRB assay is more sensitive than the MTT
assay.
In hepatocytes from donor 12, intracellular ATP decreases with increasing drug
concentration, and to a lesser extent in hepatocytes from donor 13. Caspase-3/7
activation increases with increasing drug concentration in hepatocytes from donor 12
and there is no caspase-3/7 activation seen with increasing drug concentration in
hepatocytes from donor 13. At 96 hours the results obtained using the SRB assay
and MTT assays are similar in donor 12, and in donor 13 the SRB assay is more
sensitive than the MTT assay.
4.5.3 5-FU
In Hep3B2.1-7, HepG2 and PLC/PRF/5 cells intracellular ATP levels decreased with
increasing drug concentration, and the same is true in Huh-7D12 cells except
intracellular ATP levels only decreased minorly. There is no caspase-3/7 activation
seen with increasing drug concentration in Hep3B2.1-7 and Huh-7D12 cells, a small
increase is seen in PLC/PRF/5 cells, and the greatest caspase activation in response
to 5-FU is seen in HepG2 cells. At 96 hours the SRB assay is more sensitive than the
MTT assay with all four hepatoma cell lines tested.
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In hepatocytes from donor 12, intracellular ATP does not change with increasing
drug concentration. Caspase-3/7 activation increases with increasing drug
concentration. At 96 hours the MTT assay is more sensitive than the SRB assay.
In hepatocytes from donor 13, intracellular ATP decreased with increasing drug
concentration. Caspase-3/7 activation increases minorly with increasing drug






















































































Figure 4.19: Comparison of ATP, SRB and MTT assay in fresh hepatocytes
treated with mithramycin, oxaliplatin or 5-FU
Fresh hepatocytes from donors 12 (A, C, E) and 13 (B, D, F) were treated with a
concentration range of mithramycin (A. B), oxaliplatin (C, D) or 5-FU (E,F) for 24
hours, followed by immediate ATP and SRB assays, and SRB and MTT assays 96
hours after the start of drug treatment. Results are expressed as mean and S.E.M. of
triplicates.
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Figure 4.20: Comparison of ATP, SRB and MTT assay in hepatoma cell lines
treated with mithramycin
Hep3B2.1-7 (A), Hep G2 (B), Huh-7D12 (C) and PLC/PRF/5 (D) cell lines were
treated with a concentration range of mithramycin for 24 hours, followed by
immediate ATP and SRB assays, and SRB and MTT assays 96 hours after the start
of drug treatment. Results are expressed as mean and S.E.M. of at least two
independent experiments.
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Figure 4.21: Comparison of ATP, SRB and MTT assay in hepatoma cell lines
treated with oxaliplatin
Hep3B2.1-7 (A), Hep G2 (B), Huh-7D12 (C) and PLC/PRF/5 (D) cell lines were
treated with a concentration range of oxaliplatin for 24 hours, followed by immediate
ATP and SRB assays, and SRB and MTT assays 96 hours after the start of drug
treatment. Results are expressed as mean and S.E.M. of at least two independent
experiments.
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Figure 4.22: Comparison of ATP, SRB and MTT assay in hepatoma cell lines
treated with 5-FU
Hep3B2.1-7 (A). Hep G2 (B), Huh-7D12 (C) and PLC/PRF/5 (D) cell lines were
treated with a concentration range of 5-FU for 24 hours, followed by immediate ATP
and SRB assays, and SRB and MTT assays 96 hours after the start of drug treatment.
Results are expressed as mean and S.E.M. of at least two independent experiments.
In conclusion, the MTT, SRB and ATP assays show the same pattern of dose-
dependent cell death with differences in decline with increasing drug concentration.
It is not possible to determine if the IC50 values determined after 96 hours correlate
with IC50 values determined immediately following drug treatment because an IC50 is
not always reached. However, the ATP level in cells at 24 hours was plotted against
the MTT and SRB assay data obtained after 96 hours for correlation analysis. When
observing these data for the 4 hepatoma cell lines and fresh hepatocytes from 2
donors, no significant correlation (p<0.008 to correct for multiple testing) was found
for any of the drugs or cells using a Spearman correlation. Therefore it would not be
suitable to substitute the ATP assay at 24 hours for the SRB or MTT assay at 96
hours.
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4.6 DISCUSSION
The cell models considered, for the prediction of hepatotoxicity, respond to
increasing concentrations of the three drugs investigated with varying levels of ATP
loss and caspase-3/7 activation. The investigation of these models was intended to
provide further insight into the mechanism of cell death and to assess if it was
possible to detect hepatotoxicity by considering changes in cellular ATP and caspase
activation earlier after drug exposure than the previously tested cytotoxicity assays.
The concept of using a variety of in vitro models to assess the effects of drugs on
cells has been considered previously, but never to specifically assess hepatotoxicity
of anticancer agents. For example, a variety of assays were investigated by Unilever
to determine which was most suitable for detecting cytotoxicity in HepG2 cells using
four compounds known to have cytotoxic activity (DMSO, butyric acid, carbonyl
cyanide 4-(trifluoromethoxy)phenylhydrazone and camptothecin) (Miret et al, 2006).
This research indicated that a combination of assays was the best approach to
evaluate the potential cytotoxicity of a compound and for the compounds they
investigated in HepG2 cells they found ViaLight Plus (that measures intracellular
ATP), ToxiLight (that measures cellular necrosis) and Caspsase-3 fluorometric assay
resulted in the most useful combination. Similarly, research carried out by Promega
demonstrated that the use of different assays to detect cell viability (including an
ATP assay), cytotoxicity, and apoptosis (including a caspase activity assay) in
HepG2 cells treated with tamoxifen and HL-60 cells treated with vinblastine
provided an indication of the mechanism of cell death and they state that the choice
of assay method is important (Riss and Moravec, 2004). The advantages and
drawbacks of the two assays selected for this thesis are discussed below.
4.6.1 Adenylate Nucleotide Ratio Assay and Results
It has been described in publications and in the commercially available Apoglow™
assay from Cambrex that determination of ADP:ATP ratio allows discrimination
between apoptosis and oncosis. Bradbury et al reported ADP:ATP ratios of 0.1 in
control cells, of 0.11-1.0 in cells dying by apoptosis and of >15 in cells dying via
oncosis. Contrary to results reported by Bradbury et al (2000), the use of the
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adenylate nucleotide ratio assay in these studies did not prove a useful parameter to
define the response to the three drugs tested here in terms of discriminating between
oncosis and apoptosis. Indeed the results obtained by Bradbury et al were
reproduced to an extent, where heat shock resulted in an ADP:ATP ratio
substantially greater than 1, however ATP is completely depleted and is responsible
for the higher ADP:ATP ratio observed: ADP levels remained lower in heat-shocked
cells than in the controls which does not indicate oncosis despite the ADP:ATP ratio
being high. Following none of the drug treatments where apoptosis was indicated as
the mechanism of cell death using the caspase-3/7 assay in these studies was the
ADP:ATP ratio consistent or interpretable, contrary to findings observed by
Bradbury et al.
Therefore, in this thesis, ATP levels only have been presented. ATP depletion
results in cell death and has been investigated as a therapeutic strategy for the
treatment of cancer (Martin et al, 2000). It has been reported by Leist et al (1997)
that in Jurkat cells treated with 1.2pM of the apoptosis-inducer staurosporin, ATP
depletion >50% was sufficient to change the mode of cell death from apoptosis to
necrosis, whereas higher ATP concentrations favoured apoptosis, and ATP loss
>70% invariably resulted in oncosis. It is well known that the availability of ATP is
a requirement for apoptotic cell death and this report suggests that cells can die via
apoptosis up until they have lost 70% of their ATP after which oncosis would occur.
Based on this fact, it is possible to assess in the studies presented in this thesis, where
ATP levels are measured immediately following drug treatment, whether apoptosis
or oncosis is likely occurring based on ATP levels. When cells were treated with
mithramycin, none of the cells reached ATP levels of below 50% with the exception
of the cryopreserved hepatocytes from donor C3 suggesting that these cells may be
dying via apoptosis, in agreement with the caspase-3/7 data. Following oxaliplatin
treatment, ATP levels reached approximately 50% when compared with control cells
in the majority of models at the highest drug concentration investigated (250pM),
again with the exception of cryopreserved hepatocytes (donors C2 and C3), again in
agreement with the caspase-3/7 data. Finally, in 5-FU-treated cells ATP levels also
reached approximately 50% when compared with control cells at the highest drug
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concentration tested (lOmM) in 3 of the hepatoma cell lines and in fresh hepatocytes
from donor 13 and cryopreserved hepatocytes from donor C3, and in the other cells
was higher than this. Again this would suggest that cells could die via apoptosis
however less caspase activation was observed in cells (with the exception of fresh
hepatocytes from donor 12) treated with 5-FU than for any of the other drugs.
4.6.2 Caspase-3/7 Assay and Results
The caspase-3/7 assay was used to detect caspase activity following treatment with
mithramycin, oxaliplatin and 5-FU and was found to vary between the drugs and cell
models. There have been isolated reports previously of the study of basal caspase
activity and cell death mechanism in some of the cell models considered in these
studies, and these are described below for comparison.
Caspase-3 was found to be over-expressed in hepatoma cell lines PLC/PRF/5,
HepG2 and Hep3B2.1-7 compared to non-tumour liver tissue using Western Blot and
immunohistochemistry techniques (Persad et al, 2004). Flowever, only in
PLC/PRF/5 and HepG2 did this result in an increased basal caspase-3 activity
compared to SK-HEP-1, FIep3B and non-tumour liver tissue. Whilst PLC/PRF/5 and
FIepG2 are reported to have higher basal caspase-3 activity, there was no pattern
detected in response to the three drugs considered in these studies and the response in
terms of caspase activation in PLC/PRF/5 and HepG2 was dissimilar after treatment
with mithramycin, oxaliplatin and 5-FU.
5-FU treatment (100pg/ml) for 24hr has been reported to induce -10% apoptosis in
Hep3B cells (Ganten et al, 2004). Similarly, in HepG2 cells treated with 100pg/ml
5-FU for 24hours, before identification of apoptotic cells by staining nuclear
chromatin with Hoechst 33342, less than 10% apoptosis was observed (Meurrette et
al 2005). At lower 5-FU concentrations (lpg/ml to 25pg/ml) HepG2 appeared more
sensitive than Hep3B to undergo apoptosis (Jiang et al, 1999). Similarly, when
caspase-3/7 activity was measured following 24-hour 5-FU treatment (10pM to
lOOOOpM 5-FU) in these studies, only modest caspase activation was observed in
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any of the cell lines and the maximum response in HepG2 cells (approximately 300%
of control) was seen at the highest drug concentration tested (1 OmM).
Leroy et al. 2006 treated Jurkat and KGla cells with mithramycin A and found that
mithramycin at high concentrations induces apoptosis in these cells. Cells were
treated for 48hours (in comparison with the 24hour incubation in this thesis) at
concentrations ranging from 10-lOOnM and 100-500nM for Jurkat and KGla cells
respectively. Percentage of apoptosis was evaluated by DAPI staining (a method
used to detect morphological changes) and reached approximately 30% apoptotic
cells in both cell lines at the maximum drug concentration tested. Leroy et al, 2006
demonstrate that mithramycin can induce the Fas apoptotic pathway in Jurkat and
KGla cells and speculate that mithramycin induces the Fas apoptotic pathway in
hepatocytes which may in part explain the hepatotoxicity of this drug. Caspase
activation activity was observed with increasing mithramycin concentrations
particularly in Hep3B2.1-7, PLC/PRF/5 and in hepatocytes from donor 12.
4.6.3 Mechanisms of Cell Death in Hepatocyte Models
The drugs selected target replicating cells (e.g. 5-FU interferes with DNA synthesis)
therefore it is likely that these drugs have other cellular targets in the liver which is a
non-replicating organ under normal circumstances. The investigation of different
models to assess liver toxicity was intended to allow understanding of the broad
mechanism of cell death induced by mithramycin, oxaliplatin and 5-FU (i.e. oncosis
or apoptosis) in the different models and should help assess which in vitro models
respond in the same way as the fresh human hepatocytes and the same as the human
liver.
It should be noted that not all cells in a tumour will die by the same mechanism after
exposure to a particular drug. In tumour and in liver, differences in the concentration
of drug exposed to and in the cellular energy status will occur and are likely to result
in differing cell death. The mechanism of cell death has been reported to differ
according to cell density, and will be affected by concentration and duration of drug
exposure therefore the conclusions presented herein are specific to the drug
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treatments used in these studies and may be applicable to other situations using the
same drugs.
4.6.4 Earlier Detection of Cell Death
The possibility of detecting hepatotoxicity earlier than was possible using the
cytotoxicity assays presented in chapter 3 was investigated, by observing data
obtained in cell models immediately following 24-hour drug treatment with three
drugs. With the 96-hour SRB and MTT data that was determined previously, it was
possible to detect the IC50 concentration in most cases. However, after treating cells
over a similar concentration of the three drugs 24-hours after the start of drug
treatment when the ATP assay was performed it was not possible to determine drug
concentrations resulting in 50% ATP loss compared to control in the majority of
cases. Therefore for several drug concentrations, the % ATP loss compared to
control was plotted against the % cell survival (detected by MTT or SRB assay)
obtained at 96-hours, to assess if there was a correlation between the two.
Using Spearman correlation analysis, no significant correlations were found between
the 2 parameters for any of the drugs in any of the cell models. Therefore it was
concluded that whilst the ATP assay is useful for providing insight into the
mechanism of cell death that could occur following drug treatment, it is not possible
to substitute the 96-hour SRB and MTT assays with an ATP assay at 24-hours.
4.6.5 Conclusions
In conclusion, the data presented in this chapter provides insight into the mechanism
of cell death in several in -vitro models of the liver treated with mithramycin,
oxaliplatin or 5-FU. Due to the difference in response to the three drugs tested in
these studies, particularly in terms of caspase activation in the fresh hepatocytes from
2 donors, it is difficult to ascertain the response of hepatocyte models to these drug
treatments. Certainly, all three of the drugs studied caused substantial caspase
activation and therefore apoptosis in some of the models studied: mithramycin
induced caspase activity in Hep3B2.1-7, PLC/PRF/5 and fresh hepatocytes from
donor 12, oxaliplatin in all four of the hepatoma cell lines investigated and in fresh
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hepatocytes from donor 12, and 5-FU in HepG2 cells and fresh hepatocytes from
donor 12. In order to further define the mechanism of response of fresh hepatocytes
to the drug treatment, it would be useful to study hepatocytes from more donors.
Due to the difference between the cell models in response to these drugs it has not
been possible to ascertain which is the most appropriate model to use for assessment
of hepatotoxicity. The ATP data obtained at the end of drug treatment for 24-hours
did not correlate with the SRB or MTT data 96-hours following the start of drug
treatment. On the basis of the data presented in these studies it would not be suitable
to replace the 96-hour SRB or MTT assay with an earlier assay detecting changes in
ATP or caspase-3/7 activity with drug treatment.
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CHAPTER 5: Conclusions and future directions
5.1 SUMMARY AND CONCLUSIONS
Drug-induced hepatotoxicity is a major cause of failure of drug candidates during
development and of drug withdrawal post-marketing. Exposure of individuals to
certain anti-cancer agents can result in liver toxicity. Anti-cancer drugs induce
cytotoxic effects in all proliferating cells and, to a certain extent, in non-dividing
cells. For some anti-cancer drugs this manifests as liver-related dose-limiting
toxicity. More toxicities are accepted with anti-cancer drugs than would be accepted
with other classes of agents (e.g. drugs that cause hair loss or vomiting are routinely
used in the treatment of cancer), however drugs that cause major liver toxicity cannot
be used in the treatment of patients. Liver toxicity has been identified in early-phase
clinical trials of anti-cancer agents and their clinical development stopped.
Unfortunately, current pre-clinical models poorly predict a potentially hepatotoxic
anti-cancer agent and an accurate and reproducible method for its detection would be
beneficial.
Therefore the aim of the studies presented in this thesis was to evaluate in vitro
models in which anti-cancer drug-induced hepatotoxicity may be detected, which
may aid the incorporation of appropriate hepatotoxicity screening pre-clinically and
decrease the likelihood of hepatotoxic anticancer agents entering clinical
development. In addition, for agents where hepatotoxicity has been detected during
clinical development and it is thought useful to study this toxicity in vitro,
knowledge of the most relevant in vitro model would be valuable.
To determine whether hepatotoxicity caused by anticancer agents can be detected in
in vitro models and find out which model may be the most appropriate, this study
considered several in vitro models and assays using anti-cancer agents with known
hepatotoxic or non-hepatotoxic properties in humans. The hypothesis was that
isolated fresh hepatocytes in vitro would be the most indicative model of human
hepatocytes in vivo, in which to detect toxicity. Due to the potential limitations
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associated with the use of fresh hepatocytes, including limited source, inter-donor
variability and relatively high cost, other models were also considered.
In vitro cell models of human origin were selected to represent hepatocytes: the
predominant cell type in the liver. As described in chapter 2, fresh and
cryopreserved human hepatocytes did not proliferate in culture and expressed several
liver-specific genes, although expression was generally lower in cryopreserved- in
than fresh- hepatocytes. Hepatoma cell lines and an immortalised hepatocyte cell
line were also investigated, and these cells proliferated in culture and expressed
lower levels of the liver-specific genes investigated than the fresh hepatocytes, with
the exception ofCYP1A1. These models therefore represent a spectrum of cell types
with different properties, most of which have previously been used for investigation
of hepatotoxicity in vitro with other classes of drugs. Based on these findings, fresh
hepatocytes would be selected as the model most similar and therefore relevant to the
human liver in that they have liver-specific gene expression and are non-
proliferating.
The in vitro models were treated with a range of concentrations of three anti-cancer
drugs (mithramycin, oxaliplatin and 5-FU) all of which have been used in the
treatment of patients with cancer for several years and therefore the ability of these
agents to cause hepatotoxicity in humans has been determined. As presented in
chapter 3, in all the cell models, drug treatment resulted in dose-dependent cell death,
as determined by SRB and MTT assays. By treating the in vitro models with a
concentration range of each drug, an IC50 for each drug in each model was
determined. The IC50 values determined in the different models varied considerably,
and within the fresh hepatocytes inter-individual variability was also observed. By
comparing the IC50 in each liver model (toxic) to the median IC50 in colon cancer cell
lines (therapeutic), it was possible to define a 'therapeutic index' for each drug in
each model. Based on these data, fresh hepatocytes, and the Hep3B2.1-7, Huh-
7D12, PLC/PRF/5 and THLE-2 cell lines were able to discriminate the hepatotoxic
drug mithramycin from the other 2 drugs investigated.
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In addition to the studies carried out with mithramycin, oxaliplatin and 5-FU,
investigations were carried out with the novel ruthenium compounds, RM175 and
HC11 using fresh hepatocytes and hepatoma cell lines. The cytotoxicity data
obtained and definition of a therapeutic index for these compounds suggested that
both of these compounds would have the potential to cause hepatotoxicity, and in
these models HC11 was found likely to be more hepatotoxic than RM175. These
findings agree with in vivo studies in mice using RM175 and HC11 which described
liver toxicity as being more severe with HC11 than RM175. If in vitro definition of
the therapeutic index had been carried out early in drug development, it may have
avoided the need to perform in vivo toxicity experiments.
ATP levels and caspase-3/7 activation was also investigated following drug
treatment and the results presented in chapter 4. ATP levels were found to drop with
increasing drug concentration in the majority of cell models investigated with the 3
drugs tested. Analysis of caspase-3/7 activity revealed that at the higher drug
concentrations, for each drug tested, there was caspase-3/7 activation suggesting that
apoptosis was occurring. However, no drug- or model-specific pattern of cell death
was observed. The ATP data obtained at the end of drug treatment for 24-hours did
not correlate with the SRB or MTT data 96-hours following the start of drug
treatment. On the basis of the data presented in these studies it would not be suitable
to replace the 96-hour SRB or MTT assays with an earlier assay detecting changes in
ATP or caspase-3/7 activity with drug treatment.
In summary, considering the gene expression and cytotoxicity data together has
revealed that there is no one model that would be ideal for the detection of
hepatotoxicity in vitro, and that rather a combined approach using more than one cell
model, knowing the limitations of each, is likely to provide the most useful
information in future studies. Defining a therapeutic index as described in chapter 3
could be used as an approach to investigate hepatotoxicity pre-clinically, but earlier
detection of cell death using an ATP or caspase-3/7 assay would not be suitable for
detecting the same hepatotoxicity at an earlier timepoint. Using fresh hepatocytes
from at least 3 donors, 1 or more hepatoma cell line and the THLE-2 cell line would
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be recommended based on the findings presented here. The cryopreserved
hepatocytes and SK-HEP-1 cells should be excluded from analysis of hepatotoxicity
in the way that is presented in this thesis: based on the gene expression analysis and
cytotoxicity data it is possible to rule out SK-HEP-1 as a relevant model in which to
study anti-cancer drug induced liver toxicity, and because the cryopreserved
hepatocytes are damaged following cryopreservation and thawing, they too have
been excluded. These data suggest that fresh hepatocytes are a suitable in vitro
model in which to accurately identify hepatotoxicity associated with anti-cancer
drugs: they express liver-specific genes, and are more sensitive to the hepatotoxic
drug mithramycin, than to oxaliplatin and 5-FU. However, it was noted that the
response of these cells from different donors was very variable. The fresh
hepatocytes to be used for in vitro assays, based on the findings presented in chapter
2, should be transported in UW media to maintain cell viability. The hepatoma cell
lines (Hep3B2.1-7, Huh-7D12, PLC/PRF/5) were also able to detect anti-cancer drug
induced hepatotoxicity, however the toxic concentrations determined were far lower
in these cell lines than in the fresh hepatocytes and they had lower expression of
liver-related genes compared to the fresh hepatocytes. Based on the principal of
defining a therapeutic index, THLE-2 cells were also able to discriminate
mithramycin and could also be used for further investigations. More than one in
vitro model should be used for future studies and a positive (e.g. mithramycin) and
negative (e.g. cisplatin) control should be included in each experiment to ensure that
the in vitro models respond as expected to known drugs and comparison between
different compounds is possible.
5.2 FUTURE DIRECTIONS
The data presented here have provided a considerable contribution, investigating an
appropriate model in which to study anti-cancer drug-induced hepatotoxicity.
However, further studies could be undertaken, that would be valuable to expand the
work presented here.
In terms of the models tested, hepatocytes were the cell type focused on due to their
abundance in the liver and the key functions they have. When considering the gene
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expression, fresh hepatocytes are the most similar to human liver, however as
discussed there are problems associated with performing assays using fresh
hepatocytes. There are several emerging systems that may provide practical
advantages when compared with undertaking work with fresh human hepatocytes,
including cryopreserved hepatocytes and immortalised cells. Cryopreserved
hepatocytes are reportedly problematic to use for in vitro assays where attachment to
a substratum and long periods of culture are required (Li et al, 1999) and this was
confirmed in these studies. Viability loss during cryopreservation of hepatocytes is
also a key concern, and in these studies cryopreservation resulted in few viable cells
being available to work with. If alterations in the way the cells are cryopreserved or
thawed could improve viability and attachment the use of cryopreserved human
hepatocytes may increase. One promising approach to try and overcome some of
these issues is the plating of fresh hepatocytes (and attachment to the substratum)
before cryopreservation in a monolayer culture (Hengstler et al, 2000; personal
communication with HannahCellScience). Cells are not commercially available that
have been cryopreserved in this way, and was outwith the scope of this project,
however if this technique does become available there is the likelihood that these
may be useful for studies such as those presented here. A similar approach to that
presented in chapter 3 could be investigated, treating the pre-plated cryopreserved
hepatocytes over a concentration range of drugs with known hepatotoxic and non-
hepatotoxic properties, to assess their use for the detection of hepatotoxicity.
Furthermore, the possibility of immortalising hepatocytes, and other cell type of the
liver could be considered to improve on the resources currently commercially
available.
Several studies are also being carried out regarding the use of embryonic stem cells
differentiated into many types of cells, one of which is hepatocytes (Cai et al, 2007).
The exciting prospect of using functional hepatic cells generated from embryonic
stem cells as a model in which to study hepatotoxicity is not yet possible. Once these
cells become more readily available they may be able to overcome the source and
supply problem encountered when fresh human hepatocytes are required.
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In the studies presented in this thesis, models that represent hepatocytes have been
investigated for the study of liver toxicity. One other system that may be of
relevance to consider is that of co-cultures in vitro. As discussed, there are several
other cell types in the liver (e.g. Kupffer cells, cholangiocytes), which can play a role
in the response of the liver to certain toxic compounds. Co-cultures of hepatocytes
with and without these cells may provide further information regarding the target
cells of toxicity, and could be considered for in vitro assays.
The results presented focus on the assessment of hepatotoxicity by studying three
anti-cancer drugs. Work was also undertaken to consider drugs that are currently
undergoing pre-clinical and clinical development, but in order to build more
confidence in the selected in vitro models, a larger group of anti-cancer compounds
should be investigated. Continuing from this idea the in vitro liver models could be
used to screen panels of drugs during the lead discovery phase of drug development.
Comparing several lead compounds (selected on the basis of their desired activity),
using in vitro hepatocyte models (e.g. fresh human hepatocytes, Huh-7D12,
PLC/PRF/5, Hep3B2.1-7 and THLE-2) to define a therapeutic index could assess the
hepatotoxic potential of each compound. This knowledge could aid in designing out
hepatotoxic drugs: only the most promising candidate would be developed further
based on both activity and toxicity considerations. This type of testing could be








6.1.3 RNA Extraction and qRT-PCR
6.1.4 Protein Isolation and Western Blotting
6.2 METHODS: CELL CULTURE
6.2.1 Maintenance of Cell Lines
6.2.2 Cell Harvesting
6.2.3 Cell Counting
6.2.4 Cryopreservation and Recovery of Cells from Liquid Nitrogen
6.2.5 Growth Characterisation of Proliferating Cell Lines
6.2.6 Fresh Hepatocyte Cell Culture
6.2.7 Counting & Assessment of Hepatocyte Viability by Trypan Blue
Exclusion
6.2.8 Cryopreserved Human Hepatocyte Cell Culture
6.3 METHODS: IN VITRO STUDIES
6.3.1 Drugs
6.3.2 Sulforhodamine B (SRB) Assay
6.3.3 MTT Assay
6.3.4 Cytotoxicity Studies with Hepatocytes
6.3.5 Analysis of Cytotoxicity Data
6.3.6 Detection of the Mechanism of Cell Death
6.4 METHODS: RNA EXTRACTION AND qRT-PCR
6.4.1 RNA Extraction
6.4.2 DNase Treatment of RNA Samples
6.4.3 Quantification of RNA by NanoDrop
6.4.4 Assessment of RNA Integrity
6.4.5 Quantitative Reverse Transcription Polymerase Chain Reaction
(qRT-PCR)
6.4.6 Size of qRT-PCR Products
6.4.7 Analysis of qRT-PCR data
6.5 METHODS: PROTEIN EXTRACTION AND WESTERN BLOT ANALYSIS
6.5.1 Protein Isolation from Tri Reagent





Materials are listed under the appropriate technique, detailing the product and the
supplier. All laboratory plastics (including tissue culture flasks, 96-well plates and
cryovials) were from NUNC™ (via Fisher Scientific, Loughborough, UK), unless




Fresh and cryopreserved human hepatocytes were obtained from the United
Kingdom Human Tissue Bank (UKHTB), and ethical approval was obtained from
NHS Lothian (LREC/2003/8/42). Transport of these cells from UKHTB (Leicester,
UK) to CRUK laboratory (Edinburgh, UK) involved car and aeroplane, and lasted in
duration from 7 to 26 hours.
6.1.1.2 Cell Lines
Colon cancer cell lines (HCT 116 and SW620 [SW-620]) were obtained from
American Type Culture Collection (ATCC; via LGC Promochem, Middlesex, UK),
and HCT-8 [HRT-181. HCT-15, HT-29 and COLO 205 were obtained from
European Collection of Cell Cultures (ECACC; Salisbury, UK). Hepatoma cell lines
Huh-7D12, Hep G2 [HepG2], Hep 3B2.1-7 [Hep 3B; Hep-3B; Hep3B] and
PLC/PRF/5 [Alexander cell line] were also obtained from ECACC, and SK-HEP-1
was from ATCC. The immortalised liver cell line THLE-2 was also from ATCC.
6.1.1.3 Cell Culture Mat
BD BioCoat™ Collagen I cellware
FNC coating mix®
RPMI 1640 (+L-glutamine, +phenol red)
DMEM (+1000mg/L glucose, +580mg/L
L-glutamine, + 1 lOmg/L pyruvate, +
15mg/L phenol red)
Bronchial Epithelial Medium (BEBM®)
BD Biosciences, Oxford, UK
Stratech Scientific Limited, Soham, UK
GIBCO, Invitrogen, Paisley, UK




William's Medium E (- phenol red)(WE
University ofWisconsin (UW) solution
Celsior® solution
Foetal calf serum (FCS)
Penicillin and streptomycin
BEGM® singlequots













Bristol-Myers Squibb, New York, USA
Sangstat, Fremont, USA
Harlan Seralab, Loughborough, UK




VWR International, Lutterworth, UK
GIBCO, Invitrogen, Paisley, UK
Sigma, Gillingham, UK
Sigma, Gillingham, UK
BD Biosciences, Oxford, UK
GIBCO, Invitrogen, Paisley, UK
Beckman Coulter, High Wycombe, UK
Grant Instruments Ltd, Cambridge, UK
Leitz, Wetzlar, Germany









Thiazolyl blue tetrazolium bromide (MTT)
Dimethyl sulfoxide (DMSO)
Trichloroacetic acid (TCA)
ApoONE® homogeneous caspase-3/7 assay




Peter Sadler, Edinburgh University, UK
Peter Sadler, Edinburgh University, UK
R&D Systems, Minneapolis, USA
Sigma, Gillingham. UK
Sigma, Gillingham. UK










Microlumat plus LB 96V Luminometer
Fluoroskan® Ascent FL Fluorometer
Biohit BP800 microplate reader
GraphPad Prism® software
BD Biosciences, Oxford, UK
BD Biosciences, Oxford, UK
Cambrex, Wokingham UK
Promega, Southampton, UK
Berthold Technologies, Redbourn, UK
Thermo Labsystems, Basingstoke, UK
Biohit, Helsinki, Finland
Version 4.00 for Windows, San Diego,
California, USA, www.graphpad.com





RNA 6000 Nano LabChip® kit
Agilent 2100 Bioanalyser
NanoDrop® ND-1000 Spectrophotometer
RT-PCR kit (SYBR® green system)
Sigma RT-PCR primers
CRUK RT-PCR primers
Human liver total RNA (adult & foetal)
Rotorgene™ RG-3000
RT-PCR analysis software












NanoDrop Tech., Delaware, USA
Qiagen Ltd, Crawley, UK
SigmaGenosys, UK
Oligo Synthesis Lab, Potters Bar, UK
BD Biosciences, Oxford, UK
Corbett research, Cambridge, UK
Corbett research version 6.1 (Build 25)
www.corbettresearch.com
Thermo Labsystems, Basingstoke, UK
UVP, Cambridge, UK
Sorvall, Bishop's Stortford, UK
Sorvall, Bishop's Stortford, UK
Corbett Research, Cambridge, UK
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6.1.4 Protein Isolation and V
Bicinchoninic acid (BCA) protein assay
lmg/ml BSA protein standard
(Bis)Acrylamide solution (30%w/v)
TEMED
Full-Range rainbow MW markers
TECHNE: DRIBLOCK®DB-2A
Electrophoresis and transfer tanks










Severn Biotech Ltd, Kidderminster, UK
Bio-Rad laboratories, Hertfordshire, UK
Amersham Biosciences, Chalfont St
Giles, UK
VWR International, Lutterworth, UK
Bio-Rad laboratories, Hertfordshire, UK
Bio-Rad laboratories, Hertfordshire, UK
Millipore, Watford, UK
Bio-Rad laboratories, Hertfordshire, UK
Sigma, Gillingham, UK
Santa Cruz Biotechnology, Inc, Santa
Cruz, CA
Amersham Biosciences, Chalfont St
Giles, UK
Hanna Instruments, Leighton Buzzard,
UK
6.2 METHODS: CELL CULTURE
All procedures were carried out at room temperature unless otherwise stated.
6.2.1 Maintenance of Cell Lines
All cell lines are of human origin, and further information regarding the cell lines can
be found in table 6.1. All cells were grown in a humidified 37°C 5% CO2 incubator,
and were regularly tested for mycoplasma contamination and found to be negative.
Penicillin and streptomycin (antibiotics) were aliquoted at concentrations of
lOOOOunits/ml and lOOOOpg/ml respectively and stored at -20°C. These were added
to all tissue culture medium at a 1:100 dilution. Foetal calf serum (FCS) was heat-




The colon cancer cell lines were grown as monolayers in RPMI (containing phenol
red) supplemented with 5% heat-inactivated FCS, and 1% antibiotics. The hepatoma
cell lines were grown as monolayers in DMEM (containing lOOOmg/L D-glucose, L-
glutamine, llOmg/L sodium pyruvate, and phenol red) and supplemented with 10%
heat-inactivated FCS and 1% antibiotics. Cultures of hepatoma and colon cancer cell
lines were split once per week, using cell dissociation solution, and the medium was
changed once per week.
Immortalised hepatocytes were grown as monolayers in BEBM® supplemented with
10% heat-inactivated FCS, 1% antibiotics, BEGM® singlequots (Bovine pituitary
extract, insulin, hydrocortisone, retinoic acid, transferrin, triiodothyronine, and
human epidermal growth factor), 5ng/ml EGF and 70ng/ml O-phosphoethanolamine.
Culture flasks and plates were pre-coated with FNC coating mix for growing the
immortalised liver cell line, medium was changed every second day, and cultures
were split when cells were 70-80% confluent using cell dissociation solution and a
cell scraper.
6.2.2 Cell Harvesting
Proliferating cell lines were grown in monolayers until they reached 70-80%
confluence, in 25, 75 or 175cm" tissue culture flasks. Media was removed from
flasks and the monolayer washed with pre-warmed PBS, pH 7.3 to remove traces of
serum that could affect dissociation of cells. l-3mls of cell dissociation solution was
then added to flasks at room temperature and left for 1-10 minutes at room
temperature. Cell dissociation solution was inactivated by addition of serum-
containing media, and cells were quickly pipetted up and down to remove any
clumps of cells.
6.2.3 Cell Counting
To obtain the appropriate cell concentration for experimental set up, cells were
counted on a Coulter Counter. Cells previously dissociated from the flask were
resuspended in 15mls media and the suspension was then passed through a syringe to
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ensure single cell suspension and accurate cell counts. Briefly, 200j.il of the cell
suspension was added to 9.8mls sterile sodium chloride (0.9%) and counted by the

























































6.2.4 Cryopreservation and Recovery of Cells from Liquid
Nitrogen
Cells to be stored in liquid nitrogen were dissociated from flasks as above, and
centrifuged for 5 minutes at 1800rpm (lOOOg). Supernatant was removed and the
cell pellet resuspended in lOmls of freezing mix (10% DMSO in 90% FCS). 1ml of
this solution was aliquoted into each labelled cryovial and frozen immediately to -
70°C overnight before transfer into liquid nitrogen tank at approximately -180°C.
Upon removal from liquid nitrogen, the cryovial was placed in a 37°C water bath for
l-2mins until thawed, and centrifuged for 5mins at lOOOg to obtain a cell pellet.
Supernatant was removed and the pellet was resuspended in pre-warmed medium.
Cells were left overnight to attach to the flask, before media was changed to remove
cell debris.
6.2.5 Growth Characterisation of Proliferating Cell Lines
To determine doubling times, plating efficiencies and seeding densities for
cytotoxicity assays, cell growth curves were produced, using the SRB assay to
provide a measure of cell number. Cells were plated in 96-well plates at increasing
densities from 500 to 5000 cells/well. Each cell density was plated as 6 replicates in
up to 7 plates, to produce a time-course over 7 days. Cells were also plated at
increasing densities for the calibration plate (500 to 50000 cells/well). All cells were
allowed to adhere overnight. Drug-treatment was mimicked 24 hours after plating
the cells, by changing media in 3 rows (out of 6 replicates), which allowed
assessment of plating efficiency. The calibration plate was fixed with trichloracetic
acid (TCA) 24hours after plating to verify the linearity of SRB staining with cell
density. One plate was fixed and quantified every 24 hours for 7 days according to
the SRB assay protocol, and the results were used to produce cell growth curves.
For each cell line, a calibration curve and growth curves were produced. An example
of the curves produced is shown in figures 6.1 and 6.2, using the hepatoma cell line
HepG2. The calibration curve (figure 6.1) was produced by SRB staining, and is
linear over a range of cell densities (500-50000cells/well, R =0.998). From the
plates stopped every 24 hours for 7 days, growth curves were generated and can be
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seen in figure 6.1. OD (optical density) increased over time at all cell densities
except where 500 cells/well were plated. Using the calibration equation (determined
from the calibration plate stopped on day two), optical density values from the
growth curves were converted to cell numbers. Cell growth is an exponential
process and the time taken for a population doubling can be calculated from the
graph in figure 6.2. Assuming cells grow at an exponential rate, doubling times were
calculated by plotting log cell number against time, and fitting the data with an
exponential trend-line. The plating efficiency was calculated as a ratio between
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Figure 6.1: Calibration, and OD per density of HepG2 cells
HepG2 cells were plated at increasing cell densities in supplemented DMEM media
in 96-well plates. The calibration plate was stopped on day 2 and number of cells
plated was plotted against OD at 540nm (A). One day-growth plate was stopped per










10 I 1 I I
0 50 100 150 200
time after plating (hours)
Figure 6.2: Exponential growth of HepG2 cells
Cells were plated in supplemented DMEM media in 96-well plates. The calibration
plate was stopped on day two along with one day-growth plate, and then one day-
growth plate per day afterwards. Cellular protein was stained using the SRB assay.
For comparison with cells in which the selected drugs are used to treat, some
characterisation is required for use of colon cancer cell lines in experiments. The
doubling times for the six colon cancer cell lines selected do not vary greatly from
one another (range 20.9-27.3 hours), and can be seen in table 6.2. However the
plating efficiency and time to reach confluence do vary, and result in different
seeding densities for the cytotoxicity assays.














COLO 205 26.2 22 3000
HCT-8 21 93 1500
HCT-15 20.9 100 1500
HCT 116 22.3 97 1500
HT-29 27.3 110 2000
SW620 23.5 94 5000
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6.2.6 Fresh Hepatocyte Cell Culture
Hepatocytes were isolated by the UKHTB by performing a 2-step collagenase digest
method following the published method of Seglen (1976). The UKHTB usually
receives liver tissue on ice in a kidney perfusion buffer from the surgery where
isolation took place. Any open vessels are cannulated and perfused. A peristaltic
pump with warming jackets (flow rate approximately 20 ml min) is used, and the
liver is perfused with perfusion buffer (Invitrogen), and digested with digest buffer
(Invitrogen). It is then minced with scissors to release hepatocytes, filtered through
100pm Nybolt gauze, and washed 3 times at 75g in modified DMEM. Isolated
hepatocytes were then ready for distribution.
Cells were obtained from UKHTB in suspension (transported either in Celsior®
solution, DMEM or University of Wisconsin solution) on melting ice. Cells to be
used for cytotoxicity studies were always transported in DMEM supplemented with
2g/l human serum albumin. Contents of the tube were resuspended and centrifuged
at 70g for 5minutes. The supernatant was aspirated and the pellet of hepatocytes
resuspended in WEM pre-warmed to 37°C. Media was supplemented with 2mM L-
glutamine, 1% antibiotics, lOnM insulin, and 30nM dexamethasone. Cells were
counted and viability assessed (see section 6.2.7) and either plated for cytotoxicity
testing (Donors 1-13), RNA assessment (Donors 1-13) or used for transport media
testing (Donors Tl-Tll). For donor demographics for cells used for cytotoxicity
testing in vitro, RNA extraction and for optimisation of transport media, please refer
to tables 6.3 and 6.4 respectively. It was found by Hewes et al (2006) that prior
treatment of patients with chemotherapy (5-FU ±oxaliplatin), whose hepatocytes
were subsequently isolated, did not affect the viability or function of the isolated
hepatocytes. Cell culture plates and flasks used for cells for cytotoxicity testing and
RNA assessment were pre-coated with collagen I (BD BioCoat™). Cells did not
proliferate in culture, however medium was changed every second day.
6.2.7 Counting & Assessment of Hepatocyte Viability by Trypan
Blue Exclusion
Following centrifugation and re-suspension of hepatocytes in William's media E
(WEM), cell viability was determined by trypan blue exclusion. Equal volumes of
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stock hepatocyte solution and 0.4%(w/v) trypan blue (in PBS) were mixed and
allowed to incubate for 3 mins at room temperature before counting of viable (white
cells that excluded dye) and blue cells (compromised cells that took up the dye) in a
haemocytometer. Briefly, cell suspension was placed on the haemocytometer before
covering with cover slip and counting cells in appropriate chambers using a
microscope.
Cell viability (%) = number of viable cells x 100
number of cells counted
6.2.8 Cryopreserved Human Hepatocyte Cell Culture
Frozen cells in freezing mix were received on dry ice from UKHTB and were
transferred to a liquid nitrogen storage tank immediately upon arrival.
Cryopreserved cells from 4 donors were investigated and the demographics of donors
from which the hepatocytes were received can be seen in table 6.5. When required,
vials of cryopreserved hepatocytes were removed from liquid nitrogen, and rapidly
thawed in a 37°C water bath. Vials were then inverted gently to ensure contents
were free of ice crystals (approximately 90seconds), before the contents of the vial
were emptied into pre-warmed WEM and inverted to mix. The cells were then
centrifuged at 40g for 5mins at 19°C, supernatant removed, and the pellet of cells
was re-suspended in WEM heated to 37°C. The concentration and viability of cells
was then determined as described in section 6.2.7 and cells plated immediately for
cytotoxicity studies, or plated for 12hours before RNA extraction.
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6.3 METHODS: IN VITRO STUDIES
A selection of in vitro assays were used to detect cell death or initiation of cell death
in drug-treated cells. For all assays, cells were treated over a range of drug
concentrations for each drug to be studied for 24hours before detection of cell death.
Cytotoxicity studies for which cell death was considered as the endpoint were
performed using the sulforhodamine B (SRB) assay and the 3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay. Levels of ATP and caspase
activity in cells were also measured following drug treatment.
6.3.1 Drugs
Stock solutions of mithramycin, oxaliplatin, and 5-fluorouracil were prepared using
sterile water. Mithramycin was prepared as 0.5mg/ml (460.7pM) stock solution, and
aliquots were stored at -80°C. Stock solutions of oxaliplatin and 5-FU were prepared
fresh before use at concentrations of lmg/ml (2.519mM) and lOmg/ml (76.9mM)
respectively. The ruthenium compounds RM175 and HC11 have poor aqueous
solubility and were therefore made up in a 5% DMSO (v/v) solution fresh before use
at a concentration 10-times higher than the top concentration required to treat the
cells. Kahalalide F was also prepared in a 5% DMSO solution at a concentration of
2mM fresh before use, and the top dilution was also always at least 10 fold lower
than the stock concentration. TRAIL was reconstituted in sterile PBS containing
0.1% bovine serum albumin to a stock concentration of 20 pg/ml as per
manufacturer's instructions. Aliquots of TRAIL were stored at -20°C and thawed
before use. The appropriate TRAIL concentration was made up in the cell culture
media for the appropriate cell line fresh before use.
6.3.2 Sulforhodamine B (SRB) Assay
The SRB assay is a colorimetric assay using the staining of cellular protein by SRB
as a measure of cell number in 96-well plates (Skehan et ah 1990). Cells for staining
with SRB were fixed to the plate by the addition of 50% (w/v) ice-cold TCA per well
(250pl final volume) and incubated at 4°C for one hour. Wells were washed ten
times with tap water, and air-dried. TCA-fixed cells were then stained with 50pl
0.4% (w/v) SRB solution (in 1% acetic acid (v/v)) at room temperature for 30
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minutes. Unbound dye was then removed by 4 washes with 1% (v/v) acetic acid, and
the plates were air-dried. Cellular-protein-bound SRB dye was then dissolved in
150pl lOmM Tris buffer per well (pH 10.5), and optical density (proportional to the
cellular protein present), was measured at 540nm using a Biohit BP800 microplate
reader. It can be seen from figure 6.1 that SRB staining is linear with cell density
from 1000 to 50000 cells/well when HepG2 is used as an example, however this is
true for all cell lines investigated.
6.3.3 MTT Assay
The MTT assay is based on the ability of viable cells to reduce a yellow tetrazolium
compound to a blue formazan product (Banasiak et al, 1999). This conversion
indicates metabolic activity of mitochondrial dehydrogenases in living cells. In the
wells containing cells for MTT assessment, medium was removed and replaced with
200pl fresh medium. Cells were incubated for 3 hours in the dark with 50pl MTT
solution, at 37°C. Medium was then removed, and formazan crystals were
solubilised in 200pl DMSO and the optical density was measured at 570nm using a
Biohit BP800 microplate reader. The concentration of MTT was optimised and it
can be seen from figure 6.3 that MTT conversion is linear with cell density from 500
to 30000 cells/well when HCT116 is used as an example.
6.3.3.1 Determination of optimal MTT concentration
The HCT116 cell line was seeded over a range of cell densities (500-500000
cells/well) and allowed to attach for 24 hours. MTT was then added over a range of
concentrations (lmg/ml to 6mg/ml), left to incubate for 3 hours in the dark, and the
plate was read at 570nm. An MTT concentration of 2mg/ml was selected for future
cytotoxicity studies with the MTT assay as no increase in OD values was obtained by
increasing the MTT concentration from 2mg to a maximum of 6mg/ml, and
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Figure 6.3: Determination of optimal MTT concentration for cytotoxicity
assays
HCT116 cells were exposed to increasing concentrations of MTT (1mg/ml to




6.3.4 Cytotoxicity Studies with Hepatocytes
6.3.4.1 Fresh hepatocytes
Cells were obtained in suspension and assessed for viability using a trypan blue
exclusion test. Cells (20000 viable/well) were plated in collagen-I pre-coated 96-
well plates in supplemented WEM, and allowed to adhere for 12 hours at 37°C in a
5% CO2 humidified incubator. Cells were then treated with a series of drug dilutions
for 24-hours. At the end of drug exposure, the media was aspirated and the cells
washed with 50pl PBS before adding 200pl/well of fresh complete WEM.
Cytotoxicity studies were performed using the MTT and SRB assays.
6.3.4.1 Cryopreserved hepatocytes
Cryopreserved hepatocytes were thawed and viability was determined, as described.
Cells (20000 viable/well) were plated in collagen-I pre-coated 96-well plates in
supplemented WEM, and allowed to adhere for the minimum number or hours
required for attachment (5 hours) at 37°C in a 5% CO2 humidified incubator. Cells
were then treated with a series of drug dilutions for 24-hours. At the end of drug
exposure, the media was aspirated and the cells washed with 50pl PBS before adding
200pl/well of fresh complete WEM. Cytotoxicity studies were performed using the
MTT and SRB assays.
6.3.5 Analysis of Cytotoxicity Data
After treating cells over a concentration range for each drug it is possible to produce
dose response curves. A sigmoidal dose-response curve with variable slope model
was used to fit the data using GraphPad Prism Software, allowing analysis of data
and determination of the IC50 values. IC50 values were defined as the concentrations
that correspond to a reduction of cellular growth by 50% when compared with values
of untreated control cells, or 50% cell death in the case of non-proliferating cells.
The EC50 defined by GraphPad Prism represents the concentration of drug required
to produce 50% of the maximal drug effect, therefore to determine IC50 it is
necessary to read from the curve created. In this thesis it is the IC50 and not the EC50
concentrations that are considered, as it can be compared between cell lines and is
not influenced by the maximum drug effect.
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6.3.6 Detection of the Mechanism of Cell Death
Cells were plated in luminometer-grade 96-well plates (white polystyrene with clear
bottoms) and allowed to attach to plate (24 hours for cell lines, 12 hours for fresh
hepatocytes, 5 hours for cryopreserved hepatocytes). Cells were drug-treated for
24hours, and after removal of drug the ApoGlow® Assay and the Apo-ONE®
homogeneous caspase-3/7 assay was performed at 24, 48 and 72-hours after the start
of drug treatment.
6.3.6.1 ATP and ADP Assays
The adenylate nucleotide ratio assay (ApoGlow® assay, Cambrex) allows
bioluminescent detection of both ATP and ADP levels in cell in vitro. This method
utilises the enzyme luciferase, which catalyses the formation of light from ATP and
luciferin according to the following reaction:
luciferase
ATP + luciferin + 02 ^ oxyluciferin + AMP + PPj + CCE + liaht
Mg++
Where: ATP= adenosine triphosphate, 02= oxygen, AMP= adenosine
monophosphate, PPj= pyrophosphate, C02= carbon dioxide.
To assess ifATP and ADP content is linearly related to cell number, standard curves
were produced (figure 6.4). Both ATP and ADP are linearly related to cell number
and over the range of 10-50000cell/well ATP had and R2 of 0.999 and ADP had an
R2 of 0.982.
The ApoGlow™ assay comprises three successive measurements, detecting both
ADP and ATP in cells. Firstly, Nucleotide Monitoring Reagent (NMR) and ADP-
Converting Reagent (ADP-CR) were reconstituted in Tris Acetate buffer for a
luminometer with 50pl volume injectors. Briefly, lOOpl/well of nucleotide releasing
reagent was added and after 5 minutes 50pl/well NMR (containing luciferin and
luciferase) was added and an immediate reading taken (reading A) using a
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luminometric plate-reader. The emitted light intensity measured in reading A is
linearly related to ATP concentration in the cells. A second reading is taken after 40
minutes during which time the luminescent signal from the first reading decays
(reading B). The ADP-CR (50pl/well) is then added to convert the ADP present to
ATP and the luminescent signal was measured 5 minutes later (reading C). This
provides ADP levels after subtracting the background reading (reading B). The ratio
of ADP:ATP was calculated as [(reading C - reading B)/reading A)]. The kinetics of
the ApoGlow™ assay can be seen in figure 6.5. The kit was used according to
manufacturer's instructions with the exception of taking the ATP decay reading
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Figure 6.4: ATP and ADP Standard Curve
HCT116 cells were plated at increasing cell densities (10-50000 cells/well).
ApoGlow™ assay was performed as described in section 6.3.6.1 and shows that ATP












Figure 6.5: Kinetics of the ApoGlow™ assay
5000 HepG2 cells/well were plated 24hours before the assay. Cells were incubated
with media to mimic drug treatment for 24hours, followed by the ApoGlow™ assay
performed as described in section 6.3.6.1.
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The use of the ApoGlow™ assay resulted in a large variability between samples and
cell lines (data not shown). This is due to the continuous decay of the luminescent
signal after the first measurement. The ADP measurements were therefore
inaccurate, and resulted in ADP:ATP ratios that were not interpretable using the
ApoGlow™ assay. A second ATP assay was therefore tested (CellTiter-Glo®
Luminescent Assay, Promega). Although the principle of the assay is similar, the
luminescent signal measuring ATP levels was more stable (Figure 6.6). After
addition of the ADP converting reagent, the variability of the ADP measurements
was reduced and both ATP and ADP levels were measured accurately.
It is clear that the half-life of the luminescent signal in the kit from Cambrex is far
shorter (<40minutes) than that of the kit from Promega (greater than 6 hours).
Because of the quick succession in which the readings are taken, CellTiter-Glo®
reagent from Promega was selected to determine ATP levels followed by
measurement of ADP (by conversion of ADP to ATP) using ADP-CR from
Cambrex. Even using this method, reliable ADP measurements were not obtained

































































Figure 6.6: Comparison of Cambrex and Promega kit signal half-life
24-hours after plating (25000 HCT116/well and 13000 HepG2/well), cells were
incubated with media to mimic drug treatment for 24hours, followed by addition of
NRR and NMR (Cambrex), or CellTiter-Glo® reagent (Promega). ATP
measurements were made immediately on the luminometer, and every 10 minutes
thereafter for 1 hour, and then 6hours after the initial reading (A). B, shows the
readings until 30minutes after initial reading as these are within the timeframe of the




6.3.6.2 Caspase-3/7 Activity Assay
The Apo-ONE® homogeneous caspase-3/7 assay allows measurement of caspase-3
and -7 activity, by measuring a fluorescent product produced by caspase-3/7
cleavage of a profluorescent substrate rhodamine 110, bis- (N-CBZ-L-aspatyl-L-
glutamyl-L-valyl-L aspartic acid amide) (Z-DEVD-R110). After cell lysis, using a
buffer that rapidly permeabilises cells, the active caspase-3 and caspase-7 can cleave
the profluorescent substrate. The Z-DEVD-R110 peptide sequence that is cleaved to
elicit a fluorescence signal is recognised by both caspase-3 and caspase-7. Following
excitation at 485nm the rhodamine 110 leaving group becomes intensely fluorescent,
and fluorescence emission is measured using a fluorescence plate-reader. The
amount of fluorescent product generated is proportional to the amount of caspase-3/7
cleavage activity present in the sample. The kit was used according to
manufacturer's instructions with minor alterations. The ratio of substrate to buffer
was maintained at 1:100 but volumes of sample per well in 96-well plate and Apo-
ONE mixed reagent were reduced from lOOpl to 50pl but the ratio of media:reagent
was maintained at 1:1 as recommended.
The caspase-3/7 assay does not discriminate between the two caspases, therefore the
affinity of the substrate for caspases-3 and -7 was investigated. A standard curve
using purified recombinant caspase-3 and caspase-7 and produced a linear increase in






























Figure 6.7: Caspase-3 and Caspase-7 standard curves
A dilution series of purified, active, recombinant, human caspases-3 and -7
(0.1 ng/ml to lOng/ml) was prepared in DMEM media in duplicate in a white-walled
96-well plate. Fluorescence measurements were made 21 hours after addition of the
substrate. Results are expressed as mean and S.D. of duplicates.
6.3.6.3 Data analysis
At the 24-hour timepoint selected, in addition to the ADP:ATP assay and caspase-3/7
assay, an SRB assay was carried out. By normalising the data from ADP:ATP and
caspase assays to the OD from the SRB assay (which is relative to the number of
living cells there) the cells that have already died as a consequence of drug treatment
are accounted for, and only indication of cell death in the cells that are still alive is
determined. Without normalisation of ATP data to SRB values to account for a
reduction in the number of living cells, the ATP assay could be used as another
cytotoxicity assay to determine cell death.
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6.4 METHODS: RNA EXTRACTION AND qRT-PCR
6.4.1 RNA Extraction
Cultured cells (cell lines and hepatocytes for RNA analysis at start of drug treatment)
were approximately 70% confluent in T75 tissue culture flasks. Fresh hepatocytes
(for RNA analysis when they arrived from UKHTB) were centrifuged for 5minutes
at 70g and supernatant discarded. Total RNA was then prepared from cells using Tri
reagent, as per manufacturer's instructions, using 7.5mls Tri reagent per 75cm tissue
culture flask or per hepatocyte cell pellet. Samples in Tri reagent were frozen at -
70°C until processing, which occurred within 1 month.
Frozen samples in tri reagent were removed from -70°C and thawed in a cold-water
bath, before addition of 0.2ml chloroform per ml of Tri reagent used initially.
Samples were shaken vigorously, allowed to stand at RT for 15mins and then spun at
12000g for 15mins at 4°C in SS34 rotor in Sorvall® RC-6 centrifuge. The aqueous
phase was transferred to a fresh tube and 0.5ml isopropanol added per ml of tri
reagent used initially. Samples were allowed to stand for lOmins at RT before
another spin at 12000g at 4°C for lOmins during which RNA precipitate formed a
pellet at the bottom of the tube. The interphase and organic phase were stored at this
stage at 4°C to allow subsequent isolation of protein. The supernatant was removed
from tube and pellet of RNA was washed with 1ml of 75% ethanol per 1ml Tri
reagent used in sample preparation. Samples were vortexed, and re-spun at 12000g
at 4°C for lOmins. Most of the supernatant was removed and pellet was resuspended
in 75% ethanol solution and stored at -20°C for up to 3 months. RNA samples were
later removed from -20°C freezer and centrifuged at 16000g for lOmins at 4°C.
Supernatant was removed and the pellet was air-dried for 15mins, then dissolved in
50pl distilled RNase-free water and heated at 55°C for lOmins in a thermal cycler to
unfold tightly packed RNA.
6.4.2 DNase Treatment of RNA Samples
RNA samples were either treated with DNasel and an RNase inhibitor (HIa to H22d,
Htl to Ht31, and immortalised hepatocytes), or TURBO DNA-free™ (samples Ht32
to Ht49, H23a to H30d and hepatoma cell lines) to ensure that any contaminating
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DNA was eliminated and to protect RNA samples from degradation. RNA
concentration was determined by spectrophotometry on a NanoDrop, and the RNA
was stored at -70°C until required for qRT-PCR.
6.4.3 Quantification of RNA by NanoDrop
1 pi of the stock RNA sample was loaded onto NanoDrop Spectrophotometer and the
NanoDrop Software determined RNA concentrations and O.D. 280 to 260 ratios.
6.4.4 Assessment of RNA Integrity
Many of the RNA samples analysed in these studies are from human tissue, and
therefore an accurate and reproducible measurement of the quality of the RNA
samples to be used for qRT-PCR analysis was required. The RNA 6000 Nano Assay
was used to determine the quality of extracted RNA. 1 pi of each RNA sample to be
analysed was pipetted into one well on a RNA 6000 Nano chip, and following
manufacturer's instructions the chip was loaded and run on an Agilent 2100
Bioanalyser. The samples are separated by electrophoresis and following detection
of fluorescence the Bioanalyser software generates an electrophoretic trace and gel¬
like image (Figure 6.8).
Visual interpretation of the images produced by the Bioanalyser software is user-
dependent. Therefore, to standardise determination of RNA quality, RNA integrity
numbers (RIN) can be calculated by an Agilent software tool. More than 1300 RNA
samples of varying qualities were used to develop the software. The entire
electrophoretic trace is taken into account, and RIN numbers are assigned ranging
from 1 (most degraded) to 10 (most in intact), which gives an indication of the
quality of the RNA. The determination of RIN by the Agilent Bioanalyser is
reported to be one of the most reliable and reproducible ways in which to determine
RNA quality (Imbeaud et al, 2005). RIN numbers of the RNA samples from fresh
human hepatocytes are shown in table 6.6. Sample H24d (from donor 10) was
excluded from qRT-PCR analysis of gene expression, as RIN of 2.5 was too low.
Excluding this sample, RNA from fresh hepatocytes used for qRT-PCR had RINs
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ranging from 6.1 to 9.4, which was found to be of suitable quality for this
application.
nt
Figure 6.8: Agilent Assessment of RNA integrity
RNA ladder and RNA samples were loaded onto a RNA 6000 Nano chip and run on
an Agilent 2100 Bioanalyser according to manufacturer's instructions. A
representative gel-like image is shown with samples of human adult liver (BD
Biosciences, used as qRT-PCR standard), HepG2, Hla and HI la RNA are shown.
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Table 6.6: RNA integrity numbers (RIN) obtained for RNA samples, using an
Agilent 2100 Bioanalyser and Agilent software





























































































6.4.5 Quantitative Reverse Transcription Polymerase Chain Reaction
(qRT-PCR)
qRT-PCR was performed using a real-time cycler Rotor-gene 3000 and
QuantiTect®SYBR® Green RT-PCR Kit, according to manufacturer's instructions.
Primers for each gene (see table 6.7) were designed using Primer3 software
(Whitehead Institute for Biomedical Research, http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi) and produced by either CRUK Oligo Synthesis Lab
or Sigma Genosys. For primer sequences and NCBI accession numbers and product
sizes (bp) of primers used for RT-PCR please refer to table 6.7. A standard curve
was generated using known concentrations (dependent upon gene to be investigated)
of human liver total RNA (BD Biosciences). Reactions were run in triplicate along
with two additional reactions: one in which reverse transcriptase was omitted to
allow assessment of genomic DNA contamination in each RNA sample, and the
other containing no template (water as a substitute) to assess contamination of
reagents during set-up of the reaction and primer dimer. Quantification of all genes
is relative to the geometric mean of two reference genes. Samples were heated for
30minutes at 50°C to allow reverse transcription, followed by PCR initial activation
step for 15minutes at 95°C. Following this, 40 cycles of a 3-step cycling process was
performed: denaturation for 15 seconds at 94°C, annealing for 30 seconds at 57°C,
then extension for 30 seconds at 72°C. All PCR products were checked by melt
curve analysis of the PCR product, by stepwise increase in temperature by 1°C every
5 seconds from 65-99°C in the final step.
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6.4.6 Size of qRT-PCR Products
The size of the products amplified by qRT-PCR (see table 6.7) was verified by UV
visualisation on 2%-agarose gels after ethidium bromide was added in the sample-



















Figure 6.9: Verification of qRT-PCR product sizes
Samples amplified by qRT-PCR were loaded onto a 2% agarose and product sizes
were visualised under UV light.
6.4.7 Analysis of qRT-PCR Data
Each sample was run in triplicate, and unknowns calculated from the standard curve.
The mean of triplicates from the gene of interest was normalised to the geometric
mean of triplicates of two reference genes. To evaluate differences in expression




6.5 METHODS: PROTEIN EXTRACTION AND WESTERN BLOT
ANALYSIS
The technique of protein extraction and Western Blotting was attempted for analysis
of the same proteins for which mRNA levels were measured. Due to the limited
number of hepatocytes available, it was not possible to obtain enough cells
specifically for protein analysis. Protein was therefore extracted from Tri reagent
from these samples however there was little yield and the protein samples generated
in this way were unfortunately unsuitable for Western blot analysis.
6.5.1 Protein Isolation from Tri Reagent
Phenol-ethanol supernatants, saved from RNA extraction of the same samples using
tri reagent, were taken out of storage at 4°C. Protein was precipitated from this
solution with 1.5ml isopropanol per ml of Tri reagent used in the initial sample
preparation. Samples were allowed to stand for lOmins at room temperature, and
then centrifuged at 12000g for 10 mins at 4°C. The supernatant was then discarded
and the pellet washed with 0.3M guanidine hydrochloride/95% ethanol. using 2ml
per lml Tri reagent used in sample preparation. The sample was then incubated in
wash solution for 20 mins at room temperature, before centrifugation at 7500g for
5mins at 4°C. This washing step was repeated 3 times in total. After removal of the
supernatant, 2ml of 100% ethanol was added to the protein pellet, vortexed, and
allowed to stand for 20mins at room temperature. Samples were then centrifuged at
7500g for 5mins at 4°C, and pellets dried using a SpeedyVac for 15mins. The
protein pellet was then dissolved in 1% SDS by repeated pipetting up and down.
Samples were then centrifuged at lOOOOg for lOmins at 4°C, to remove any insoluble
material. The supernatant was then transferred to a new tube, and stored at -20°C.
6.5.2 Bicinchoninic Acid Protein (BCA) Assay
To determine protein concentration a BCA assay was performed according to
manufacturer's instructions. A concentration range of bovine serum albumin was
used to generate a standard curve. Absorbance of the standard curve and protein
lysates was then measured at 570nm on a microplate reader, allowing determination




20pg of total cellular protein was separated by SDS-PAGE on a mini-gel apparatus
and transferred to polyvinylidene fluoride membrane. Aliquots containing equal
concentrations of protein were prepared, and their volumes equalised using lysis
buffer. After addition of loading buffer to samples, they were denatured at 95°C for
5 mins in a heat block. Samples were loaded onto a 10-15% polyacrylamide gel
(determined by MW of protein of interest), along with RPN-800 MW marker in at
least one lane, and run at 80V for 15mins, then at 200V for 45mins-lhr. After
electrophoresis, proteins were transferred to a permeabilised (with methanol)
Immobilon-P membrane in a mini wet-transfer tank at 100V for lhr. Transfer of
protein to membrane was confirmed by staining of membranes with Ponceau S (0.1
%(w/v) in 5% acetic acid (v/v)).
Membranes were blocked using 5%-marvel in tris-buffered saline (TBS) for 1 hour
at room temperature, and then incubated overnight with primary antibody in 2.5%
marvel-TBS solution. For details of primary antibodies and suppliers please refer to
table 6.8. Membranes were then washed 3 times for 5 minutes in TBS-Tween 20
(0.1%), then twice for 5minutes with 5% marvel-TBS-Tween 20, before incubation
with secondary antibody for lhour in 2.5% marvel-TBS. For details of secondary
antibodies and suppliers please refer to table 6.9. Membranes were then washed 5
times for 5 minutes with TBS-Tween 20 and once for 5 minutes with TBS. After
1minute incubation with luminescence substrate solution, light emission was
detected on photographic film in a dark room.
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Table 6.9: Secondary antibodies forWestern Blot detection
SECONDARY
ANTIBODY
DILUTION RAISED IN TYPE
SUPPLIER
DETAILS
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ABSTRACT
Novel ruthenium(II) organo-metallic compounds are active in ovarian cancer models [Aird
RE, Cummings J, Ritchie AA, Muir M, Morris RE, Chen H, et al. In vitro and in vivo activity and
cross resistance profiles of novel ruthenium(II) organometallic arene complexes in human
ovarian cancer. Br J Cancer 2002;86(10):1652-7], [(T)6-C6HsC6H5)Ru(en)Cl]+ (as a PF6 salt, where
en = ethylenediamine (RM175)) has been evaluated in a 13-cell line panel. Particular sensi¬
tivity (~10-fold lower than mean IC50) was noted in breast cancer and non-small cell lung
cancer cell lines. In addition, IC50 in the A549 was 2 h-M and RM175 (25 mg kg"1, days 1 and 5,
i.p.) caused a significant (p = 0.004) growth delay in a xenograft model. HC11 [("n6-tetrahy-
droanthracene)Ru(en)Cl]PF6 was more potent in the A549 cell line (IC50 0.5 |xM). HC11
(25mgkg \ days 1, 8 and 15, i.p.) was also active in vivo. Following RM175 25 mgkg 1,
days 1 and 5, and 15mgkg \ days 1-5, HC11 25 and 40mgkg 1, day 1, elevated alanine
transaminase levels were detected, suggesting hepatotoxicity. No changes were observed in
kidney or haematological parameters. In liver sections, multi-focal hepatic necrosis was
seen, becoming confluent at high doses of HC11. In vitro studies confirmed that HC11 was
more toxic than RM175 to fresh human hepatocytes and equitoxic to mithramycin. Liver
toxicity may be related to the arene ligand and modification may reduce the potential for
hepatic toxicity, while maintaining the anti-tumour activity seen.
( 2005 Elsevier Inc. All rights reserved.
available at www.sciencedirect.cor
/of.
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The metal ruthenium (Ru) possesses several favourable
chemical properties that indicate itmay be a strong candidate
to form a basis for rational anticancer drug design [2,3], Ru11
complexes demonstrate similar ligand exchange kinetics to
those of platinum (Pt11 and PtIV) while displaying only low
toxicity. Ruthenium(III) has the ability to mimic iron in
binding to plasma proteins including transferrin and albumin
[3], Transport and sequestration of Ru into tumour cells may
be mediated via protein transport and receptor mediated
uptake [4,5], Due to differing ligand geometry between their
*
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complexes, some Rum compounds (octahedral) bind to DNA
forming predominately inter-strand crosslinks as opposed to
the intra-strand crosslinks favoured by square-planar Pt11 in
cisplatin [6,7], In addition, non-nuclear targets, such as the
mitochondrion and the cell surface, have also been impli¬
cated in the antineoplastic activity of Ru complexes,
particularly in the case of the clinically investigated Rum
antimetastatic drug trans-[RuCl4(DMS0)(Im)](ImH) (NAMI-A)
[8]. NAMI-A has completed clinical phase I evaluation, and
cutaneous toxicity was dose-limiting. Nausea and vomiting
was also noted. Mild reversible nephrotoxicity was noted
and a pre- and post-hydration regimen was utilised.
Neurotoxicity and hepatic toxicities were not identified.
Stable disease was identified in a patient with non-small cell
lung cancer.
Previous investigators have focused on Rum complexes as
potential anti-tumour agents [9-11], These are thought to be
activated by reduction to Ru" in the body (Clarke et al. [2]). In
contrast, we have developed a series of novel organo-metallic
Ru11 arene complexes [12] including [(m6-C6HBC6H5)Ru(en)Cl]+
(RM175) and [(r)6-tetrahydroanthracene)Ru(en)Cl]"f (HC11). The
presence of the arene ligand stabilises the Ru11 oxidation state
[13], These Ru'1 complexes have been evaluated for activity in
both in vitro and in vivo models of human ovarian cancer, and
cross-resistance profiles established in cisplatin and multi¬
drug resistant (MDR) variants [1]. Issues relevant to the
cytotoxicity of these compounds are their selectivity for
guanine on DNA, leading to the formation of an N7-Ru bond
together with the formation of a strong hydrogen bond
between the C6 carbonyl group of guanine and an NH proton
of the ethylenediamine ligand.
In this paper we report results of studies to assess the anti-
tumour activity in a range of tumour types using an automated
screen approach and subsequent studies focusing on non-
small cell lung cancer models. We also report preliminary
toxicity data, to illustrate the likely therapeutic index of these
compounds.
2. Materials and methods
RM175 and HC11 (Fig. 1) were synthesised and characterised
using the methods reported previously [12,14], A549 and H520
cell lines were obtained from Cancer Research UK Cell
Services. Fresh human hepatocytes were obtained from the
UK Human Tissue Bank after ethical approval from NHS
Lothian.
2.1. In uitro cytotoxicity using propidium iodide
fluorescence assay
Human tumour cells (see Table 1) were plated in 96-well flat-
bottomed microtitre plates (50 (xL cell suspension, 1 x 10s or
5 x 104 cells/mL) and additional 50 jxL of culture medium was
added. After a 24 h recovery, 50 (xL of culture medium
containing 50 fxg/mL gentamycin was added into the six
control wells ormedium containing the test drugwas added to
the wells. Each drug concentration was plated in triplicate.
Following 3-6 days of incubation, depending on cell doubling
time, a modified propidium iodide (PI) assay [15] was
performed. Culture medium was replaced by fresh medium
and 50 ixL of an aqueous propidium iodide solution (25 |xg/mL)
was added to each well. PI does not cross intact cell
membranes and enters only the nucleus of dead cells by
intercalation into DNA and RNA. The fluorescence signal
correlates with the number of dead cells. Fluorescence (FUJ
was measured using a Millipore Cytofluor 2350 microplate
reader (excitation 530 nm, emission 620 nm). Microplates were
then kept at -18 °C for 24 h, yielding in a total cell kill. After
thawing of the plates and a second fluorescence measurement
(FU2) the amount of viable cells was calculated by subtraction
of FU2 from FUi.
Growth inhibition was expressed as treated/control x 100
(%T/C); inhibiting concentrations (IC) were determined by
plotting compound concentration versus cell viability. Mean
IC50, IC70 and IC90 values were calculated for each individual
cell line. From all IC70 values the mean IC70 was calculated
according to the formula:
Mean ICsoyo = 10 (ElIog(IC50.7o)x)
where x is the value of specific tumour cell line and n is the
total number of tumour cell lines studied. If an IC50 or IC70
could not be determined within the examined dose range, the
lowest or highest concentration studied was used for the
calculation.
2.2. In uitro cytotoxicity in A549 and H520 using
sulforhodamine B assay
The cytotoxic activity of the test compounds was assessed
using a cell death assay based on detection of cells by
sulforhodamine B (SRB), a stain specific for proteins, used for
this purpose by the United States National Cancer Institute
[16], Briefly, A549 and H520 were plated out at densities,
,nh2
RIVI175 HC11
Fig. 1 - Chemical structures of HC11 and RM175.
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Table 1 - In vitro growth inhibition in lung cancer cell
lines
A549 H520
IC50 (fxM) Range IC50 (|xM) Range
RM175 3.0 2.9-3.3 3.5 3-3.8
HC11 0.50 0.49-0.51 0.53 0.53-0.54
CDDP 2.6 2.9-4.2 9.5 9.3-9.8
determined by growth curve analysis (data not shown), that
gave the best range of log phase growth after 2-3 days culture
in 96-well plates. After this time the media were removed
from each well by aspiration and fresh media containing drug
at known concentrations were added to each well. Cells were
incubated a further 24 h and the media removed by aspira¬
tion. Wells were washed in warmed PBS (200 |xL) and then
layered with fresh culture media. Cells were then incubated
72 h, at 37 °C/5% C02. To each well was then added
trichloroacetic acid (TCA), 10% final concentration and the
plates were incubated 1 h at 4 °C in order to fix the cells.Wells
were washed gently under running water and allowed to air
dry. SRB, 50 (xL, was then added to each well and the plates
incubated 30 min at room temperature. The excess SRB was
then washed off with four washes of 1% acetic acid and the
plates allowed to completely air dry. To each well was then
added Tris-HCl, pH 10.5, 150 |xL/well and the plates were
incubated 1 h at room temperature and then very gently
mixed by shaking. Absorbance was read at 540 nm on a
96-well microplate reader.
2.3. In uitro cytotoxicity in fresh human hepatocytes using
the MTT assay
Fresh human hepatocytes (20,000 viable cells) were plated in
collagen-I pre-coated 96-well plates (BD Biosciences, Oxford,
UK), in William's E medium (WEM) (Cambrex, Wokingham,
UK) supplemented with 10% FCS, L-glutamine, penicillin
(100 U/mL), streptomycin (100 (xg/mL), 10 nM insulin and
30 nM dexamethasone and allowed to adhere for 12 h at
37 °C/5% C02 in a humidified atmosphere. Stock solutions of
HC11 and RM175 were prepared with 5% (v/v) dimethylsulf-
oxide (DMSO) so that the final concentration of DMSO the
hepatocytes were exposed to was never greater then 0.5%. A
stock solution of mithramycin (Sigma) was prepared using
sterile water. Cells were treated with 50 (xL ofRM175 (1-50 fxM),
HC11 (0.07-13.5 (xM) or mithramycin (0.1-10 (xM) for 24 h. At
the end of drug exposure, the media were aspirated and the
cells washed with 50 (xL PBS before adding 200 (xL/well of fresh
completeWEM. Cytotoxicity studies were performed using the
3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bro¬
mide (MTT) assay 24 h after the end of drug treatment. Cells
were incubated in 200 fxL fresh 37 °C WEM containing 0.4 mg/
mL MTT (Sigma, Gillingham, UK) for 3 h in the dark at 37 °C.
Medium was then removed, and formazan crystals were
solubilised in 200 |xL DMSO. The optical density was measured
at 570 nm using a Biohit BP800 microplate reader. A compar¬
ison between the MTT and SRB assays was also undertaken
(data not shown) to ensure relevant and valid comparison of
IC50 values obtained using both assays.
2.4. In vivo toxicity of RM175 and HC11
These studies were performed in C57/B1 6 mice 6-weeks old.
Treatment schedules for RM175 administration were: RM175
schedule 1—25mgkg~1 administered i.p. days 1 and 5
(50mgkg 1 total); RM175 schedule 2—15 mg kg 1 adminis¬
tered i.p. days 1-4 (60 mgkg"1 total). For HC11, the following
schedules were used: HC11 schedule 1—25 mg kg-1 adminis¬
tered i.p. on day 1; HC11 schedule 2—40 mg kg-1 administered
i.p. on day 1. The following parameters were measured in
plasma: haematology (RBC, WBC and platelets) and biochem¬
istry (ALT, ALP, total bilirubin, creatinine and urea) and the
liver, spleen, lungs, kidneys and peritoneum were collected
for subsequent evaluation. Three animals were to be culled at
each of the following time-points: RM175 schedule 1—days 3,
5,8 and 10; RM175 schedule 2—days 2-5; HC11 schedules 1 and
2—days 2-5.
2.5. Pathology studies
Liver and spleen from experimental and control animals were
removed immediately after sacrifice and fixed by immersion
in 10% buffered formalin. Liver lobes were embedded in
paraffin wax and sectioned at 5 (xm for histopathological
assessment. All sections were stained with haematoxylin and
eosin (H&E) using standard techniques. Sections were scanned
and assessed for significant changes on two occasions.
Selected liver sections were examined for fatty change using
oil-red-0 stain.
2.6. In uiuo efficacy 0/RM175 in LXFL xenografts
RM175 was tested for in vivo activity in the large cell lung
cancer model LXFL 529 growing subcutanously in serial
passage in NMRI-nude mice. LXFL 529 was derived from a
patient with untreated large cell lung cancer. Master stocks
were frozen down at passage 7 in between liquid nitrogen and
these experiments were performed in passage 24. The chara¬
cteristics of the models have been described previously [17],
Nu/nu athymic mice ofNMRI background from an in-house
breeding facility were used for all experiments. Tumours were
implanted s.c. in both flanks of 6-week-old nude mice.
Treatment commenced when tumours reached diameters of
5-6 mm. Animals were randomly assigned into treatment
groups. Food and water were provided ad libitum. Tumour
growth was followed by serial two-dimensional caliper
measurements and body weight documented concomitantly
twice a week. Tumour volumes were calculated according to
the formula (length x width2)/2 and mean as well as median
relative tumour volume (vol. day x/day 0 x 100) were used for
analyses. Data were presented as mean relative tumour
volumes ± S.E., optimal T/C values of the test divided by the
control relative tumour volumes were calculated.
2.7. In vivo efficacy of RM175 and HC11 in A549
xenografts
Xenografts were established from the A549 cell lines by
subcutaneous implantation of 107 cells in serum free media in
the flank of animals. All animal experiments were carried out
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according to UKCCCR guidelines [18]. Female nu/nu mice
were implanted on both flanks with 2-3 mm3 fragments of
viable tumour and randomised when tumour volumes
reached 30-100 mm3. Animals were randomised into control
and drug treated groups (5 animals/group). Ru" complexes
were administered as 10% DMSO solutions in sterile saline at
a volume of 0.1 mL/10 g of body weight i.p. HC11 was
administered at a dose of 25mgkg~1 on days 1, 8 and 15.
RM175 was administered at a dose of 25 mg kg-1 on days 1 and
5. Tumour xenografts were measured three times a week
in perpendicular diameters and tumour volume calculated
as (length x width2)/2.
3. Results
3.1. In uitro testing of RM175 in the 14 cell line panel
RM175, [(T)6-C6H5C6H5)Ru(en)Cl]+ (as a PF6 salt), was shown to
have a mean IC70 of 3.9 pg/mL (-8 pM) and the IC50 value was
3 pM, confirming the level of activity we have reported
previously (Aird et al. [1]) and demonstrating it has a broad
spectrum of activity (Fig. 2). Particular sensitivity (~10-fold
lower than mean IC50) was noted in a breast cancer cell line
(401NL) and a non-small cell lung cancer (NSCLC) cell line
(LXFL 529L). Comparative analyses were performed to ascer¬
tain whether the pattern of sensitivity correlated with other
known agents. The strongest correlation was with mitoxan-
trone (0.61), but this was not thought to be significant,
considering the number of cell lines tested (13).
The cytotoxicity of both compounds was also determined
in two other non-small cell lung cancer cell lines, H520 and
A549 (Table 1). HC11 [(in6-tetrahydroanthracene)Ru(en)Cl]PF6
was highly cytotoxic in both cell lines with IC50's of 0.53 and
0.5 pM, respectively. RM175 was less active than HC11 with
IC50's of 3 and 3.5 pM in A549 and H520, respectively, but
similar to cisplatin (IC50 = 2.6 and 9.5 pM for A549 and H520,
respectively).
3.2. In uiuo toxicity of RM175 and HC11
In order to evaluate the activity of both compounds, the
determination of a non-toxic dose was necessary. For RM175,
the previously determined active dose of 25 mg kg-1 on days 1
and 5 and a more dose intense schedule of 15mgkg_1
day 1 x 5 were evaluated. Two dose levels, 25 and 40 mg kg \
1, were tested for HC11, administered on day 1 only.
Weight loss of 10% was observed after administration of
15 mgkg-1 day-1 of RM175 on day 5 but this did not have a
significant impact on the animals. In contrast, HC11 adminis¬
tered at a dose of 40 mgkg^1 induced significant weight loss
with all animals losing 10% body weight by day 3 (range 5-
16%). Animals were unwell and were culled earlier than the
proposed days 5 and 8 time-points.
The evaluation of blood biochemistry parameters showed
a rise in alanine transaminase (ALT), noted following the
administration ofHC11, in particular (Fig. 3). Following a single
dose of 25 mgkg-1, i.p., the elevation of ALT was maximal at
48 h (mean 418 U L"1 in the treated group, mean 97 U L_1 in the
control groups) and had resolved by day 8. Following
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Fig. 2 - In vitro data from the 13 cell lines in the Freiburg screen. IC70 data (pg/mL) are expressed relative to the mean IC7
(3.921 pg/mL).
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Fig. 3 - Changes in alanine transaminase (ALT)
plasma levels in animals following administration
of HC11 at the dose of 25 mg kg"1 (white bars) or
40 mg kg-1 (black bars) as a single injection i.p.
on day 1. Results are mean ± S.D. of three
animals at each time-point.
40mgkg 1, there was a marked elevation of ALT by 72 h
(mean 3907 U L"1) compared to untreated animals (mean
97 U L"1). These changes were associated with histopatholo-
gical changes (Fig. 4): following treatment with HC11
(25 mgkg"1), on day 2, no major differences were identified
between treated and control animals, although there was a
low level of fatty-like vacuolar change around large blood
vessels (portal tracts) in the treated group. However, on days 3
and 5 the oeeunence uf multiple small and larger foci of
necrosis of hepatocellular parenchyma accompanied by
infiltrations of polymorphs (neutrophils) and macrophages
was noted. In the animals sacrificed on day 8, a similar lesion
was identified in 1/3 animals and showed features sugg¬
estive of scarring. At all time-points, in animals receiving
40 mg kg \ there was a variable but often severe focal or more
diffuse/lobar necrotising reaction with polymorph and
macrophage presence. These infiltrations were either par¬
enchymal or, more often, perivascular. Individual apoptotic
hepatocytes in the adjacent hepatocellular parenchyma were
also seen in many of these livers Where lobar lesions were
present the adjacent lobes were usually unaffected, how¬
ever. The lesions were more marked in the animals culled
on days 4 and 5.
Following administration of RM175, elevation of ALT
was seen in the group receiving 15 mg kg"1 on days 1-5 after
95 h (mean 355 U L"1) compared to control animals
(62 U L -1). No elevation of ALT was seen in the group
receiving 25 mgkg"1 on days 1 and 5. The histopathology
showed only minor changes such as small polymorph and
macrophage inflammatory foci adjacent to the hilar region
in 2/3 animals on day 4. The significance of this is unclear, as
low-level inflammatory cells were present in the extra-
hepatic omental hilar tissue in many of the sections in the
series, but were not seen in control animals. A solitary
peripherally located small necrotic focus with a few
associated polymorphs was seen in 1/3 animals on day 5.
The cause of this was not apparent, but it is similar, but less
severe than the changes associated with HC11.
Fig. 4 - Microscopic evidence of liver toxicity after
HC11 administration. Animals were treated with
HC11 i.p. on day 1. Livers were collected on day 3
and pathology examination was carried out after
H&E staining. (A) HC11 40 mg kg-1 showing extensive
necrosis; (B) HC11 25 mg kg"1 showing vacuolar change,
consistent with fatty degeneration; (C) control.
No changes were noted in urea or creatinine over the
course of the experiment. A single animal in the high dose
(40 mg kg ^ HC11 study was noted to be thrombocytopenic,
but this occurred on day 5 when the animal was profoundly
unwell.
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Fig. 5 - In vitro cytotoxicity of RM175 (■), HC11 (▼) and
mithramycin (O) in fresh human hepatocytes. Cells
were treated over a range of concentrations with RM175,
HC11 ormithramycin for 24 h. Twenty-four hours after the
end of drug treatment, the MTT assay was performed as
described. Results are expressed as percentage of survival
as compared to untreated cells and are the mean ± S.E.M
of triplicate samples.
3.3. In uitro cytotoxicity o/HCll and RM 175 in fresh
human hepatocytes
To ascertain whether the changes noted in the in vivo
experiments in rodents might be relevant in patients, we
evaluated the cytotoxicity of RM175 and HC11 in vitro in fresh
human hepatocytes, using the known hepatotoxic drug,
mithramycin, as a positive control. Both ruthenium com¬
pounds induced a rapid cytotoxic effect (Fig. 5), detectable at
the end of drug exposure (24 h). IC50 values for the two
ruthenium compounds were markedly different, with HC11
being 40-fold more toxic (RM175 ICS0 24 pM, HC11IC50 0.6 pM).
In comparison, the IC50 for mithramycin was 0.7 pM.
3.4. In uiuo anti-tumour activity of RM175 and HC11
The anti-tumour activity of RM175 and HC11 was evaluated
using 25 mg kg-1, days 1 and 5 of RM175 and 25 mg kg-1 of
HC11 on days 1, 8 and 15. RM175 was also evaluated at two
dose levels in the LXFL 529L xenografts, in Freiburg. Both
RM175 and HC11 were evaluated in the A549 model.
Significant growth delay was noted in the A549 model
(Fig. 6A) on day 46 for both RM175 (Vt/V0 = 5.3 ± 1.9,
p = 0.004) and HC11 (Vt/V0 = 4.7 ± 0.7, p = 0.001) compared to
controls (9.8 ± 1.1). However, anti-tumour activity was not
seen in the LXFL 529Lmodel (Fig. 6B), although this study was
performed in the NMRI mouse strain and only 4% bodyweight
loss was noted (data not shown), so possibly below the
maximally tolerated dose.
4. Discussion
This paper presents the anti-tumour activity and safety
profiles of two Ru" arene complexes, RM175 and HC11, in
(A) Time (days)
(B) Time(Days)
Fig. 6 - In vivo efficacy of RM175 and HC11 on A549 (A)
and LXFL lung cancer xenografts (B). (A) Animals bearing
A549 xenografts were treated with RM175 25 mg kg-1, i.p.,
on days 1 and 5 (#), HC11 25 mg kg-1 on days 1, 8 and 15
(A) or vehicle (■). (B) Animals bearing LXFL xenografts
received vehicle (■) or RM175 i.p. on days 1, 5 and 13 at
the dose of 15 mg kg-1 (O) or 25 mg kg"1 (□). Results are
expressed as the average growth rate (V/Vo) of each
group ± S.E.
vitro and in vivo. In vitro assessment of RM175, [(ni6-
C6HsC6H5)Ru(en)Cl]+ (as a PF6 salt) using the Freiburg screen,
demonstrated a mean IC50 of 3 pM, confirming the level of
activity we have reported previously and demonstrating
RM175 has a broad spectrum of activity. Particular sensitivity
(~10-fold lower than mean IC50) was noted in breast cancer
(401NL) and non-small cell lung cancer (529L) cell lines. Using
the data from the Freiburg screen, it was not possible to
identify compounds with a similar spectrum of activity, or to
identify a particular mechanism of action, i.e. RM175 was
"compare-negative" in this screen.
The particular activity (RM175 ICB0 < 0.5 pM) noted in the
large cell lung cancer model, in vitro, in the Freiburg screen,
led us to undertake further in vitro studies in two additional
non-small cell lung cancer cell lines, A549 and H520. The
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ICS0 values were similar to those obtained in the Freiburg
screen for RM175 which confirmed the activity seen in lung
cell lines. Moreover, HC11 was more active than RM175 and
cisplatin in these two cell lines. HC11 has been shown
previously to be 10-fold more active than RM175 in the
ovarian cancer cell line, A2780 [1], These results are in
contrast with the lack of cytotoxicity of NAMI-A observed in
vitro against breast and colon cancer cell lines [19] and
suggest a different cellular target for these two classes of
compounds. These Ru" arene compounds have been shown
to interact strongly with guanine bases in DNA [14],
To provide a preliminary assessment of the potential
therapeutic index for these agents, we evaluated myelosup-
pression, liver and renal toxicity, as possible sequelae of the
use of a heavy metal containing anti-proliferative complex.
Previous pharmacokinetic studies using NAMI-A reported
high concentrations of ruthenium in the kidneys after a single
i.v. administration [20]. When NAMI-A was administered daily
i.p., the highest concentrations of ruthenium were observed in
the liver and kidneys [21]. In this study, no clear evidence of
either bone marrow or kidney toxicity was identified. How¬
ever, liver toxicity was observed with both RM175 and HC11. It
was mild and reversible in animals receiving RM175 and HC11
at low doses (25 mg kg-1) but became severe in animals treated
with HC11 at a dose of 40mgkg~1, suggesting a low
therapeutic index for this particular compound.
Fresh hepatocyte models have been used previously to
investigate liver toxicity and are considered to be one of the
best in vitro models for this purpose [22]. Mithramycin is a
known hepatotoxic anti-cancer drug [23] and has been
included as a positive control in this study with fresh
hepatocytes. All three compounds (HC11, RM175 and mithra¬
mycin) caused hepatocyte toxicity after drug treatment.
However, HC11 was 40-fold more cytotoxic (IC50 0.6 p.M) than
RM175 (IC50 24 (j,M) and equitoxic to the known hepatotoxin,
mithramycin (IC50 0.7 p.M). Moreover, the IC50 for RM175 was
approximately 10-fold higher in fresh hepatocytes, when
compared to the IC50 observed for A549 and H520 (see Table 1),
suggesting a log difference between drug concentrations
active in tumour cells and concentrations toxic for normal
cells. However, HC11 displayed similar IC50 values in fresh
hepatocytes and in NSCLC cell lines, suggesting a low (~1)
therapeutic index. It is unlikely that the cytotoxic effect
observed in vitro is due to the opening of the arene ring in the
tissue culture medium since previous studies have shown the
stability of these ruthenium complexes in presence of amino
acids, peptides, proteins and nucleotides [24-26],
The anti-tumour activity of both RM175 and HC11 was
evaluated in animals bearing A549 xenograft and RM175 was
also evaluated in Freiburg in the LXFL lung model. Both RM175
and HC11 were active in the A549 model, but RM175 did not
show activity in the LXFL model. Pharmacokinetic studies of
NAMI-A have reported an excellent distribution in the lungs
[21]. This was associated with an antimetastatic effect of this
compound against Lewis lung carcinoma in mice. A prefer¬
ential uptake of ruthenium by lung cells may also be suggested
considering the anti-tumour activity of NAMI-A against Lewis
lung carcinoma grown as xenografts [21],
Hepatotoxicity is not a recognised side effect following the
administration of platinum containing drugs, at standard
dosages, and was not a feature of the NAMI-A phase I trial. In a
study of the administration of high-dose carboplatin, rever¬
sible biochemical hepatotoxicity was identified, but doses six
times higher than the standard dosage regimen were being
used [27], Titanocene dichloride is also an organo-metallic
compound containing cyclic aromatic hydrocarbons (cyclo-
pentadienyl). It was associated with reversible liver and GI
tract damage, observed for 4-8 days after administration at 40-
60 mgkg-1 in pre-clinical studies [28]. In subsequent phase I
trials, renal toxicity was the major dose-limiting event,
although hepatotoxicity was dose-limiting in one patient
[29,30], It is known that cyclic aromatic hydrocarbons can be
hydroxylated and conjugated in the liver leading to the
generation of potentially toxic species. Therefore, studies to
evaluate the role of cytochrome P450s in induction of liver
toxicity are being performed and these will be incorporated
into screening protocols, if appropriate. The present study
suggests that fresh human hepatocytes can be used to
evaluate the potential hepatotoxicity of this class of agents
and that indeed HC11 may be potentially hepatotoxic.
However, further chemical synthesis is ongoing to "design
out" this toxicity and improve the therapeutic index of this
series of compounds.
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Capecitabine is converted into 5'-deoxy-5-fluorocytidine (5'DFCR), 5'-deoxy-5-fluorouridine
(5'DFUR) and 5-fluorouracil (5-FU) by CES1 and 2, CDD, and TP, in both liver and tumour. 5-
FU is catabolised by DPD. Gene expression analysis of these enzymes was undertaken in
fresh human hepatocytes, mouse liver, colorectal cancer cell lines and xenografts. Cell
lines with low CDD expression (<1.5) had 5'DFCR/5'DFUR cytotoxicity ratios >2 and cell
lines with TP/DPD < 0.6 had 5'DFUR IC50> 50 pM (SRB assay). A pharmacokinetic/pharma¬
codynamic study in nude mice bearing HCT 116 xenografts and treated with capecitabine
by oral gavage assessed pharmacokinetic, gene expression and antitumour activity. Low
liver CDD correlated with high 5'DFCR plasma concentrations in mice. CDD expression
was -100-fold higher in fresh human hepatocytes than mouse liver, explaining the higher
plasma 5'DFUR concentrations reported previously in humans. Himour 5-FU concentration
correlated with TP/DPD and with tumour response. These studies identify the potential
utility of gene expression analysis and drug monitoring in tumour in patients.
© 2007 Elsevier Ltd. All rights reserved.
1. Introduction
Capecitabine (Xeloda*; Hoffmann La Roche) is an oral fluoro-
pyrimidine which mimics a continuous infusion of 5-fluoro¬
uracil (5-FU).1"3 Capecitabine is metabolised in the liver and
tumour by carboxylesterases (CES1 and CES2)4 and cytidine
deaminase (CDD) to 5'-deoxy-5-fluorocytidine (5'DFCR) and
5'-deoxy-5-fluorouridine (5'DFUR), respectively. 5'DFUR is
subsequently activated by pyrimidine phosphorylases (thy¬
midine phosphorylase (TP) and possibly uridine phosphory-
lase (UP)) by metabolism to 5-FU.5,6 Dihydropyrimidine
dehydrogenase (DPD), highly expressed in liver, metabolises
5-FU to dihydro 5-FU, inactivating it. In tumour cells, 5-FU
interacts with its pharmacological target, thymidylate syn¬
thase (TS).
During capecitabine development, a physiologically-based
pre-clinical model was built to predict the pharmacokinetics
of capecitabine in patients.7 This complex mathematical
model was based on enzymatic activities of capecitabine met¬
abolising enzymes determined in vitro in mouse tissues, lim¬
ited pharmacokinetic data over 24 h after the administration
of a single dose of capecitabine and physiological parameters
(blood flow rate, volume of individual organs) based on the lit¬
erature data. The model was shown to predict tumour expo¬
sure to 5-FU and integrated the interspecies differences
between humans and mice. However, the population
*
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pharmacokinetics studies carried out in patients including
pharmacodynamic data (toxicity) did not show any clear rela¬
tionship between systemic metabolite exposure in patients
and toxicity, suggesting that drug and metabolite concentra¬
tions in plasma do not accurately reflect the tissues' exposure
to the drug.8,9 In another study, drug concentrations and en¬
zyme activity in tumour, liver and plasma were determined
in patients treated with capecitabine.10 The study confirmed
high concentrations of 5-FU in tumour tissue, but failed to
establish a correlation between drug concentrations and en¬
zyme activity.
Pre-clinical models using human cancer xenografts can
address these issues. Due to the extensive metabolism of
capecitabine, the levels of expression of the enzymes in¬
volved in its activation, both in liver and tumour, are likely
to play a role in its antitumour effect. Indeed, overexpression
of CDD in the T24 human bladder cancer cell line sensitised
cells to 5'DFCR.11 In xenograft tumours with high TP expres¬
sion, higher tumour 5-FU concentrations were demonstrated
after the administration of capecitabine than 5-FU suggesting
tumour-specific activation of capecitabine by TP.12"14 How¬
ever, in uitro, similar 5'DFUR- and 5-FU-mediated cytotoxicity
were observed in COLO320 cells (TP negative) and in WiDr
cells (high TP), suggesting that UP might also metabolise
5'DFUR in the absence of TP.15 Finally, to date, the expression
of TS in tumours is the best predictive marker of response to
5-FU systemic therapy, but this has not been demonstrated
for capecitabine.16
To develop a comprehensive view of the contribution of
each enzyme to the metabolism of capecitabine, an
in vitro study using 6 colon cancer cell lines was combined
with a gene expression analysis of capecitabine-metabolis-
ing enzymes to identify key parameters for optimal cytotox¬
icity. A similar approach was also used in vivo in nude mice
bearing the human colon cancer xenograft HCT 116. Cape-
citabine-metabolising enzymes gene expression was deter¬
mined in xenograft tissue and mouse liver over a 3-week
treatment period, using capecitabine at 2 dose levels. A
similar gene expression analysis was carried out in human
hepatocytes to identify interspecies differences in drug
metabolism. Capecitabine and metabolite concentrations
were also determined in liver, plasma and tumour
xenografts.
2. Materials and methods
2.1. Cell lines and human hepatocytes
HCT 116, HCT8, HCT15, HT29, SW620 and COLO205 human
colon cancer cells were obtained from the European Collec¬
tion of Cell Cultures ECACC (Salisbury, UK). Fresh human
hepatocytes from eight individual donors were obtained
from the UK Human Tissue bank (Leicester, UK) after ethical
approval from NHS Lothian (LREC/2003/8/42). Cells were re¬
ceived approximately 8 h after isolation. Only hepatocytes
with viability greater than 80%, as determined by trypan
blue exclusion at the time of collection, were used in the
study. At the time of arrival, cells were centrifuged, resus-
pended in Tri-reagent® and stored at -80 °C until RNA
extraction.
2.2. Gene expression analysis of capecitabine-
metabolising enzymes by qRT-PCR
For cell lines, cells were collected in Tri-reagent® (SIGMA). For
xenografts and liver samples, tissues were homogenised in
Tri-reagent® (SIGMA) using a Mikro dismembrator (Sartorius,
Epsom UK). Total RNA was prepared according to manufac¬
turer's instructions followed by DNAse-treatment with Hirbo-
Free® DNAse (Ambion, Huntingdon UK). The quality of RNA
was evaluated by electrophoretic analysis on a 2100 Agilent
Bioanalyser. All qRT-PCR experiments were carried out with
RNA integrity number >9. RNA concentrations were deter¬
mined using a Nanodrop ND-1000. The transcripts of interest
were amplified according to a previously published method.17
Results were normalised by p-2-microglobulin (B2M) expres¬
sion in both mouse liver and fresh hepatocytes, and by RNA
polymerase II large subunit (POLR2) in HCT 116 xenografts
(HCT 116 has a very similar expression for B2M and POLR2)
and colon cancer cell lines. To compare gene expression in
mouse and human tissues, a conversion factor was calculated
between mouse and human standards used for quantification
after verifying that all reaction efficiencies were close to 100%
for all genes investigated. Three livers and six xenograft sam¬
ples were analysed per time-point in each group unless the
amount of RNA recovered from the tissue was insufficient
for qRT-PCR. Gene expression is expressed as the ratios be¬
tween the gene of interest (GOI) and the reference gene (REF).
2.3. In vitro cytotoxicity of capecitabine, 5'DFCR, 5'DFUR
and 5-FU in human colon cancer cell lines
Drug concentrations that inhibited 50% of cell growth (IC50)
were determined using the sulforhodamine B technique.18
Cells were plated on day 1 in 96-well plates at a density of
2500 cells/well for HCT 116, 3500 cells/well for HCT8 and
HT29, 5000 cells/well for HCT15, 6000 cells/well for SW620
and 7000 cells/wells for COLO205 in a volume of 150 pl/well.
All cell lines were treated on day 2 with increasing concentra¬
tions of capecitabine (0.1-10 mM), 5'DFCR (10 nM-100 pM),
5'DFUR (2.5-500 jiM) or 5-FU (0.5-250 jiM) for 24 h. After drug
exposure, cells were washed once with cold PBS and placed
in 200 jil of drug-free medium for 72 h after the end of drug
exposure. The cells were then fixed with trichloroacetic acid
and stained with sulforhodamine B. Optical densities were
measured at 540 nm with a Biohit BP-800 (Bio-Hit, Helsinki,
Finland). The results are based on three independent experi¬
ments performed in triplicate.
2.4. Pharmacokinetic/pharmacodynamic studies
Six-week-old C57/B16 Nu/Nu mice were obtained from Cancer
Research UK (London, UK) and quarantined for 2 weeks before
the start of experiments. Animal experiments were carried
out under a project licence issued by the UK Home Office,
and UKCCCR guidelines19 were followed rigorously.
Bilateral HCT 116 xenografts were obtained by subcutane¬
ous injection of 107 cells/flank. Animals bearing HCT 116
xenografts were treated with vehicle or capecitabine 0.52 or
2.1 mmol/kg (563 and 2250 mg/m2, respectively) given once
daily for 5 consecutive days/week by oral gavage for 3 weeks
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(days 0-4, 7-11, 14-18). Animals were culled on day 0 at 15,
30 min, 1, 2, 4, 8 and 24 h, and prior to planned treatment
on days 7 and 14 after the start of treatment. Three animals
per time-point were analysed. At the time of collection, blood
was collected in heparin, and plasma isolated and stored at
-80 °C. The liver was removed immediately and stored in
RNAlater® solution (SIGMA, Gillingham, UK). Tumours were
macro-dissected to remove fibrotic tissue and blood vessels
and snap-frozen in liquid nitrogen.
TUmour response was assessed during the course of treat¬
mentby calipermeasurements ofxenografts taken three times
aweek in perpendicular diameters from the start of treatment.
Honour volume was calculated as (length»width2)/2. Results
were expressed as mean ± SEM of tumour growth rate (ratio be¬
tween volume on the day of measurements and tumour vol¬
ume on the first day of drug treatment) of 16 and 10
xenografts for controls and treated animals, respectively.
2.5. Determination of capecitabine and metabolite
concentrations in plasma, liver and tumour xenografts
Capecitabine and metabolite concentrations were determined
both in plasma and tissues according to our previously pub¬
lished method.20 Briefly, 50 mg of tissue was homogenised
with 250 jil of 50 mM ammonium acetate:acetonitrile (1:3 v/
v). After centrifugation at 3500 g for 10 min at 4 °C, the super¬
natant was transferred into a 200 jil tapered well 96-well
microplate and evaporated to dryness. The dried extract
was resuspended in 100 jil water and 10 pi was analysed by
HPLC. For plasma samples, 50 pi of plasma was mixed with
150 pi of acetonitrile and processed similarly. Compounds
were separated on a Develosil ODS-UG-3 column
(4.6 x 150 mm, 3 pm) (Nomura Chemical) and mass spectrom¬
etry analysis was carried out on a Finnigan TSQ Quantum Dis¬
covery mass spectrometer using specific SRM transitions for
each compound. Results were expressed as means ± SD val¬
ues for three samples for each tissue.
2.6. Statistical analysis
sion into its active metabolites and therefore which metabo¬
lite is delivered to the tumour. A gene expression analysis of
capecitabine metabolising enzymes was carried out in mouse
liver, HCT 116 colon cancer xenografts and fresh human
hepatocytes by qRT-PCR according to a previously published
method.17
There was a significantly different pattern in gene expres¬
sion between mouse liver and HCT 116 xenografts (Fig. 1).
CES1 and DPD were the most prominent enzymes expressed
in mouse liver tissue compared to HCT 116 xenografts (CES1
was not expressed in HCT 116 xenografts). Conversely, the le¬
vel of CDD gene expression was ~100-fold lower in mouse li¬
ver compared to HCT 116 xenografts (GOI/REF = 0.02 and 3.05,
respectively). UP expression was similar in mouse liver and
HCT 116 xenografts (GOI/REF = 0.45 and 0.62, respectively).
TP expression was higher in tumour xenografts (mean GOI/
REF = 1.65) than in the mouse liver (mean GOI/REF = 0.6) while
DPD expression was ~100 times greater in mouse liver than in
HCT 116 xenografts. Overall, the TP/DPD ratios ranged from
0.005 to 0.03 in liver and 5.02-5.36 in HCT 116 xenografts.
To identify potential interspecies differences in drug
metabolism, the gene expression was compared between
mouse liver and human hepatocytes. The variability between
donors was relatively limited with the coefficient of variation
ranging from 26% for DPD to 58% for CES1. The major differ¬
ences in gene expression were observed for CES2 and CDD:
CES2 expression was ~100-fold higher in human liver than
in mouse liver tissues (GOI/REF = 17 and 0.1, respectively). A
similar difference was observed for the expression of CDD
(GOI/REF = 2.5 and 0.02, respectively). The consequence of
these differences is potentially a greater conversion of cape¬
citabine to 5'DFCR and subsequently to 5'DFUR in human li¬
ver, in comparison to mouse liver.
3.2. CDD, TP and DPD expressions influence both 5'DFCR
and 5'DFUR cytotoxicities
The growth inhibitory effect of capecitabine and metabolites
is linked in part to the metabolism of the drug in cancer cells.
For the cytotoxicity assays, growth inhibition curves were
plotted as a percentage of control cells and IC50 estimates
were determined by Graphpad Prism 3 Software (Graphpad
Software, San Diego, CA) using a sigmoidal curve fitting with
variable slope. The goodness of fit determined by r2 was great¬
er than 0.9 and the Hill coefficient <-1.
The gene expression data analysis of xenograft samples
used a one-way ANOVA and Bonferroni multiple comparisons
between controls and treated samples. The normality of the
distributions was verified prior to the ANOVA.
3. Results
3.1. Gene expression profiles of capecitabine-metabolising
enzymes differ in tumour xenografts, mouse liver and human
Iiuer
In vivo, the initial metabolism of capecitabine takes place in
the liver. The level of expression of capecitabine-metabolising
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Fig. 1 - Gene expression of capecitabine metabolising
enzymes in mouse liver and HCT 116 xenografts. Norma¬
lised gene expression was determined by quantitative RT-
PCR for CES1, CES2, CDD, TP and DPD in mouse liver (O), HCT
116 xenografts (A) and human hepatocytes (*). Note that
CES1 was not expressed in HCT 116 xenografts.
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Table 1 - Cytotoxicity of capecitabine and metabolites in colon cancer cell lines
IC50 values (pM)
CAPE 5'-Deoxy-5-fluorocytidine 5'--Deoxy-5 -fluorouridine 5-Fluorouracil
(mean ± SD) (5'DFCR mean ± SD) (5'DFUR, mean ± SD) (5-FU, mean ± SD)
HCT 116 2850 995 57.5 4.80 35.2 2.00 7.70 0.700
HT29 1590 219 186 40.8 57.5 6.10 6.70 0.800
SW620 4190 1150 217 36.0 57.5 6.60 22.3 2.70
HCT8 5970 4200 121 20.0 66.8 11.2 6.70 0.70
HCT15 5840 3970 586 82.0 86.0 12.0 9.90 1.30
COLO205 863 165 59.9 10.0 32.2 7.00 4.90 0.60
The cytotoxic effect of 24-h exposure to capecitabine, 5'DFCR, 5'DFUR and 5-FU was determined by SRB assay. Results are mean ± SD of 3-5
experiments performed in triplicate.
To identify potentially limiting steps in capecitabine metabo¬
lism in cells, the cytotoxicity of capecitabine and its metabo¬
lites was determined in six colon cancer cell lines using the
SRB assay and compared with the gene expression profile of
capecitabine-metabolising enzymes in the same cell lines
determined by qRT-PCR.
Capecitabine induced a significant cytotoxic effect in vitro
only at high concentrations (Table 1). Mean IC50 values varied
from 860 pM in COLO205 cells to 6000 pM in HCT8 cells. Both
5'DFCR and 5'DFUR were significantly more cytotoxic than
capecitabine: IC50 values ranged from 58 to 590 pM for 5'DFCR
and 32 to 86 pM for 5'DFUR. The distribution of IC50 estimates
for 5'DFCR was greater across the six cell lines (10-fold range)
than for 5'DFUR (<3-fold range). Finally, 5-FU IC50s varied 4.5-
fold between the most sensitive (COLO205) and least sensitive
(SW620) cell lines.
Gene expression analysis of capecitabine-metabolising en¬
zymes, i.e. CES1 and 2, CDD, TP, DPD was also carried out
using qRT-PCR (Table 2). CES1 was significantly expressed
only in HCT8 and COLO205 cells (normalised CES1 = 1.29
and 1.24, respectively). CDD expression varied 10-fold across
the cell lines, COLO205 expressing the highest levels (norma¬
lised CDD = 2.54) and HCT-15 the lowest (normalised
CDD = 0.22). TP was expressed significantly only in HCT 116
and HT29 cells (normalised TP = 0.38 and 0.33, respectively).
Finally, both HT29 and HCT-15 cells express high levels of
DPD (normalised DPD = 0.93 and 1.19, respectively). Overall,
only HCT 116 and HT29 cell lines expressed significant levels
Table 2 - Gene expression analysis of capecitabine
metabolising enzymes in colon cancer cell lines
CES1 CES2 CDD TP DPD
HCT 116 <LOQ 0.30 1.05 0.38 0.13
HT29 <LOQ 0.53 0.25 0.33 0.93
SW620 0.02 1.27 0.28 <LOQ <LOQ
HCT8 1.29 0.89 1.78 <LOQ 0.01
HCT15 <LOQ 0.61 0.22 <LOQ 1.19
COLO205 1.24 0.31 2.54 0.05 <LOQ
CES1, CES2, CDD, TP and DPD mRNA expressions were determined
by qRT-PCR as previously published [Macpherson, 2006 #178]. Gene
expressions are normalised by the geometric mean of 18S, B2M,
GAPDH and POLR2 reference genes. Results are mean ± SD of 2
independent experiments performed in triplicate. <LOQ: values
lower than limit of quantification.
of all the enzymes involved in the metabolic pathway of
capecitabine.
When the ratios of 5'DFCR and 5'DFUR IC50 estimates were
plotted against the mRNA expression of CDD, cell lines which
displayed low expression (<1.5) had a high ratio (>2) suggest¬
ing that conversion of 5'DFCR within the tumour cells was a
major factor determining 5'DFCR cytotoxic effect (Fig. 2A).
Moreover, the difference in 5'DFUR IC50 estimates between
cell lines was unrelated to TP expression. However, the ratio
of TP and DPD expressions did correlate with 5'DFUR IC50
(Fig. 2B): Four cell lines expressing TP/DPD ratios lower than
0.6 displayed significantly higher 5'DFUR IC50 values
(>50 pM) than the two cell lines presenting ratios greater than
3. However, the IC50 values for these two cell lines were very
similar (~33 pM) despite a ~6-fold difference in the ratios.
No correlation was observed between UP or UP/DPD and
5'DFUR cytotoxicity.
3.3. Difference in gene expression is consistent tuith
pharmacokinetic profiles in plasma, liver and tumour
xenografts
To establish whether the differences in gene expression
would impact on metabolism in vivo, a pharmacokinetic/phar¬
macodynamic study was carried out in mice bearing HCT 116
xenografts receiving 0.52 and 2.1 mmol/kg/d of capecitabine
by oral gavage. Capecitabine administered at 0.52 mmol/kg/
day induced partial control of HCT 116 xenografts tumour
growth: growth rate = 7.5 ±0.5 on day 21 (Fig. 3A). Capecita¬
bine 2.1 mmol/kg/day achieved complete control of tumour
growth during the treatment period: growth rate = 1 ± 0.2 on
day 21 (this dose of capecitabine is similar to the dose used
in patients).
The pharmacokinetic study showed that 5'DFCR was the
most abundant metabolite in both plasma (Fig. 3B) and liver
(Fig. 3C): Cmax = 110 ± 10 pM in plasma and 590 ± 140 pM in li¬
ver. When considering the concentrations 0-8 h after admin¬
istration, there was a significant correlation between liver and
plasma concentrations of 5'DFCR at both dose levels (r2 = 0.91,
n - 18 and r2 = 0.95, n = 18 at 0.52 and 2.1 mmol/kg/day of
capecitabine, respectively). The low CDD expression observed
in mouse liver could therefore be a limiting factor to the con¬
version of 5'DFCR in the liver.
The residual concentrations determined in liver and tu¬
mour tissues on day 7 (Fig. 3D), 72 h after the previous oral






















Fig. 2 - Impact of CDD and TP/DPD on capecitabine metabolites cytotoxicity. (A) The ratio of ICS0 values for 5'DFCR and 5'DFUR
is plotted against CDD mRNA expression in six colon cancer cell lines. (B) Correlation between TP/DPD ratios and cytotoxicity
of 5'DFUR.
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Fig. 3 - Pharmacokinetic/pharmacodynamic study with capecitabine. (A) capecitabine efficacy in HCT 116 xenografts. HCT
116 cells were implanted subcutaneously in nude mice. Animals received either capecitabine 0.52 or 2.1 mmol/kg once daily
by oral gavage for consecutive 5 days/week for 3 weeks (days 0-4, 7-11, 14-18). The growth rate is presented for each
individual xenograft. (B) Capecitabine and metabolite concentrations in plasma. (C) Liver tissue after the first dose of
capecitabine (2.1 mmol/kg); capecitabine (A), 5'DFCR (■), 5'DFUR (•). (D) Concentrations of capecitabine (CAP), 5'DFCR, 5'DFUR
and 5-FU in liver tissue (white bars) and HCT 116 xenografts (black bars) on day 7 of treatment.
dose of capecitabine (2.1 mmol/kg/day) administered on day
4, were unexpected, demonstrating high concentrations of
5'DFCR in the liver (790 nM). 5'DFCR was also demonstrable
in the tumour, albeit at a lower concentration (120 nM) than
in the liver. Also, surprisingly high concentrations of 5-FU
were present in the tumour (mean 6600 nM) at this time-
point, whilst 5-FU was undetectable in either the liver or the
plasma. 5-FU was also detectable in the tumours of animals
treated with capecitabine 0.52 mmol/kg/day: 2200, 4000 and
4800 nM (mean values on days 7, 14 and 21, respectively (data
not shown)).
A gene expression analysis was carried out in tumour
xenografts during the course of the treatment. TP/DPD in¬
creased over time in xenografts exposed to 2.1 mmol/kg/day
of capecitabine: From 6.6 on day 7 to 10 on day 21 while xeno¬
grafts exposed to 0.52 mmol/kg/day of capecitabine increased
slightly from 3.1 on day 7 to 5.3 on day 21. There was a signif¬
icant correlation between tumour 5-FU concentrations (days
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Fig. 4 - Pharmacokinetic/pharmacodynamic relationships after administration of 0.52 mmol/kg/d (open symbols) and
2.1 mmol/kg/d (close symbols) of capecitabine. Samples were collected on day 7 (V, T), day 14 (□, ■) and day 21 (O, •) after
administration. (A) Correlation between 5-FU concentrations in xenograft tumours and TP/DPD ratios. The correlation line
and 95% confidence intervals are presented. (B) 5-FU concentrations in xenograft tumours and tumour response. Individual
xenografts data are presented.
7, 14 and 21 at both dose levels) and TP/DPD gene expression
(r2 = 0.37, p = 0.01, n = 16) (Fig. 4A). No other correlations were
observed with 5'DFCR, 5'DFUR or capecitabine. In addition, no
correlation was observed between TP or UP expression and
either capecitabine or metabolite concentrations.
Moreover, 5-FU concentrations were significantly related
to tumour response (Fig. 4B): Xenografts exposed to
2.1 mmol/kg/d of capecitabine leading to 5-FU concentra¬
tions >4000 nM showed constant control of tumour growth
(growth rate <2 at all time). Conversely, xenografts exposed
to 0.52 mmol/kg/d of capecitabine with lower tumour 5-FU
concentrations showed a progressive increase in growth
rate over time. Even when 5-FU concentrations reached
4000 nM on day 21, the growth rate was high. This sug¬
gests that early control of tumour growth with high con¬
centrations of 5-FU in the tumour is necessary for growth
control.
4. Discussion
Capecitabine undergoes extensive metabolism in both liver
and tumour. The studies presented here were undertaken to
test the hypothesis that gene expression analysis between
different target tissues could help to predict interspecies dif¬
ferences, potential variability between patients and tumour
response.
The gene expression data presented in this study are consis¬
tentwith enzymatic activities previously reported by Tsukam-
oto et al., in particular the low expression ofCDD in mouse liver
and its greater enzymatic activity in human compared to
mouse liver.21 Similar correlations were previously shown for
DPD, TS and TP, allowing the use of quantitative RT-PCR (qRT-
PCR) as an indirect measure of enzyme activities.22
In in vitro studies determining the growth inhibition of
capecitabine and metabolites in six colon cancer cell lines,
CDD expression correlated with 5'DFCR cytotoxicity, consis¬
tent with previously published data.11 Cell lines demonstrat¬
ing high TP/DPD ratios also showed greater sensitivity to
5'DFUR.
Differential gene expression between mouse liver and HCT
116 xenografts was able to explain the different pharmacoki¬
netic profiles for capecitabine and metabolites in plasma, li¬
ver and xenografts: high carboxylesterase expression in the
liver facilitated the efficient conversion of capecitabine to
5'DFCR, consistent with low capecitabine concentrations in
the liver compared to 5'DFCR concentrations. However, the
very low level of hepatic CDD in the mouse liver became a
limiting factor in 5'DFCR conversion, resulting in higher con¬
centrations of 5'DFCR than 5'DFUR in the plasma. High DPD
expression in mouse liver in conjunction with relatively low
TP expression explained the absence of 5-FU in the liver, as
any 5-FU which was formed would have been rapidly con¬
verted to dihydro-5-FU and other metabolites. In HCT 116
xenografts, the absence of CES led to significant concentra¬
tions of capecitabine in the tumour tissue. Concentrations
of 5'DFUR were higher than 5'DFCR due to high CDD expres¬
sion. As previously observed by Ishikawa et al., 5-FU was the
predominant metabolite in tumour.12 In contrast to the situa¬
tion in liver, high TP expression associated with low DPD
expression favoured 5-FU formation over its detoxification
in this particular xenograft model.
The low efficiency of 5'DFUR conversion in mouse liver by
both UP and TP observed in this study was first identified by
El-Kouni et al.23 The same study showed that human hepatic
TP and not UP was the main enzyme converting 5'DFUR in li¬
ver. More recently, UP knock-out mice, which present high
plasma and tissue uridine concentrations, were shown to tol¬
erate 5-FU (85 mg/kg) better than wild type animals, suggest¬
ing that UP plays an important role in the anabolism of 5-
FU.24 However, neither 5'DFUR nor capecitabine was tested
in that study. In tumours and cell lines, a large body of litera¬
ture focuses on TP as a determinant for tumour-specific
formation of 5-FU after capecitabine administration."-"How¬
ever, uridine phosphorylase can convert 5'DFUR into 5-FU in
human and mouse tumour cell lines.25 In this study, TP
expression was ~3-fold higher than UP in HCT 116 xenografts
but no correlation was observed between TP or UP expression
and 5'DFUR cytotoxicity. However, in vitro, cell lines present¬
ing high TP/DPD ratios showed a greater sensitivity to 5'DFUR.
Moreover, in vivo, 5-FU concentrations in the tumour also
correlated with TP/DPD expression. This is consistent with
results from previous pre-clinical studies using human cancer
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xenografts and correlating TP/DPD ratios with the efficacy of
capecitabine and 5'DFUR.26
The gene expression analysis identifies CDD as an impor¬
tant factor for the delivery of 5'DFUR to the tumour. The
greater CDD expression observed in fresh human hepatocytes
as compared to mouse liver predicts the greater conversion of
5'DFCR into 5'DFUR. Higher concentrations of 5'DFUR were
indeed reported by Mader et al. in human plasma.27 This con¬
firmed the potential role of CDD in clinical outcome following
capecitabine administration. CDD polymorphisms induce dif¬
ferent metabolic activity and their potential importance in
relation to capecitabine therapy merits further study.28
These studies have confirmed the importance of the
expression of drug metabolising enzymes in the pharmacoki¬
netics and activity of this commonly used agent. TP/DPD is a
predictive marker of sensitivity and its variations over time,
although important, are related to tumour 5-FU concentra¬
tions. Whilst the invasive assessment of gene expression
and fluoropyrimidine PK in normal liver and metastatic can¬
cer tissue using sequential biopsies in patients is not feasible,
advances in non-invasive imaging using 19F imaging using
magnetic resonance spectroscopy might allow a more de¬
tailed monitoring of capecitabine PK in individual patients.
A recent study by Klomp et al.29 has demonstrated the feasi¬
bility of such an approach.
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